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Abstract 
 
A cocktail of human pharmaceuticals contaminate surface waters worldwide in the ng-
µgl
-1
 range. Adverse effects on non target organisms including endocrine disruption and 
alterations in behaviour and growth have been reported. All new pharmaceuticals require an 
environmental risk assessment (ERA) prior to market authorisation. The aims for this research 
were to (1) assess the limitations of the current ERA by comparing crude and refined predicted 
environmental concentrations (PECs) used in ERAs with measured environmental concentrations 
(MECs) from the literature; (2) interview key people working in the field of risk assessment and 
ecotoxicology of pharmaceuticals in order to establish expert opinion in the area; (3) to establish 
whether bioinformatics databases can be used as a potential tool to aid ecotoxicological tests for 
use in ERAs.  
The scientific literature was data mined for environmental concentration data and 
compared with calculated PECs for ten pharmaceuticals carbamazepine, diclofenac, 17α ethinyl 
estradiol, fluoxetine, gemfibrozil, ibuprofen, paracetamol, propranolol, tamoxifen and 
Trimethoprim. An engagement exercise through questionnaire based interviews with 
representatives of regulatory bodies, water companies and pharmaceutical companies as well as 
academics involved in ecotoxicology was undertaken to establish experts’ views on 
pharmaceutical risk assessment and management. A genomic search for human drug target 
homologues in aquatic species for the ten selected pharmaceuticals was undertaken. Molecular 
docking experiments on two pharmaceuticals, diclofenac and ibuprofen were carried out for 
human drug target homologues in Daphnia pulex, (water flea) Oncorhynchus mykiss (rainbow 
trout), Salmo salar (Atlantic salmon) and Danio rerio (zebra fish).  
The current environmental risk assessment may be insufficient to protect the aquatic 
environment. PECs can underestimate MECs due to the simplicity of the calculations and the 
assumptions underpinning them. The interviewees regarded the exposure assessment of the ERA 
including the PEC calculation as inaccurate and recommended using exposure modelling 
computer software as a potential solution. The bulk of the scientific literature had substantial 
deficiencies in the reporting of environmental data; setting reporting standards for peer reviewed 
journals may make such data more useful for regulators and policy makers.  Interviewees felt 
that the current ecotoxicity tests would benefit from a more intelligent approach incorporating 
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the mode of action of the drug. The bioinformatics results show that protein drug targets are 
highly conserved in some aquatic organisms but not others. The molecular docking results 
indicate that the cyclooxygenase (COX 2) primary drug target homologues are probably 
functional in O.mykiss, S.salar and D.rerio but not D.pulex. It appears from this data that 
bioinformatics and molecular docking indeed may be a useful tool to aid ecotoxicology tests by 
informing choice on relevant chronic test endpoints and directing sensitive species selection. 
Such techniques might contribute to more appropriately targeted ecotoxicity testing. 
Interviewees felt that the 10 ngl
-1
 action limit was an inappropriate mechanism to trigger 
ecotoxicological tests. The pharmaceuticals data analysis shows that many existing 
pharmaceuticals regularly exceed the 10 ngl
-1
 action limit for ecotoxicological assessment. A 
system of prioritisation is required to assess the need for retrospective risk assessment of these 
medicines. 
This thesis provides an original analysis of the current environmental risk assessment of 
human pharmaceuticals and makes recommendations for improvements. A novel application of 
molecular docking utilizing the mode of action of the pharmaceutical has the potential to aid and 
direct ecotoxicological tests.  
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1.1 Background 
Human pharmaceuticals have been suspected to be pollutants of the aquatic environment 
since the 1970’s (Hignite & Azarnoff, 1977; Kummerer, 2010). It is only over the last 20 years 
that advances in analytical chemistry techniques have confirmed this and led to a wealth of 
information and data on pharmaceuticals in water courses. A substantial number of publications 
have reported concentrations of some 180 different human drugs in surface waters worldwide in 
the ng-µgl
-1
 range (Sadezky et al., 2010).  These pharmaceuticals, however, still only represent a 
small proportion of medicines currently licensed in the UK, which is thought to be over 3000 
(Redshaw et al., 2008). Pharmaceuticals have also been reported in sewage influent and effluent, 
sewage sludge, agricultural land, groundwater, estuarine and marine waters, reservoirs, drinking 
water and landfill leachate (Roberts & Thomas, 2006; Kasprzyk-Hordern et al, 2009; Mompelat 
et al., 2009; Lapworth et al., 2012; Eggen et al., 2010).  
1.2 Sources of exposure 
Routes of entry of drugs into water courses include disposal of unused medicines down 
the sink or toilet, pharmaceutical manufacture, hospital effluent, landfill leachate, land run off 
from agricultural sewage sludge application and veterinary use (Kummerer, 2009). There is no 
accurate quantitative data on the contribution from each of these sources to contaminant levels in 
aquatic environments (Roig & Touraud, 2010). However, the main source is thought to be 
human usage (Cunningham et al., 2006; Sanderson et al., 2003). Pharmaceuticals are designed to 
avoid degradation by the body in order to have the desired therapeutic effect (Fent et al., 2006). 
They are excreted in urine and faeces as parent compound, conjugates and metabolites (Carlsson 
et al., 2006, Herberer, 2002). These are not fully removed by sewage treatment facilities and are 
discharged into water courses, where they persist (Calisto & Esteves, 2009) and may accumulate. 
In fact as much as 80% of the total load of pharmaceuticals entering sewage treatment plants 
(STPs) may be discharged into surface waters (Zabczynski et al., 2010).  
1.3 Ecotoxicological effects 
Aquatic organisms are exposed to a continuous cocktail of human pharmaceuticals. At 
least a dozen different pharmaceuticals have been measured in a single surface water sample 
(Daughton & Brooks, 2011).  This is highly likely to be a substantial underestimate because of 
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limitations in analysis. Human pharmaceuticals are designed to have a specific biological effect 
(Schmitt et al., 2010). This effect can often disrupt key biological functions in aquatic organisms 
such as reproduction and growth (Fent et al., 2006). Despite the high toxicity and high potency 
of some pharmaceuticals, only one major effect on aquatic organisms has come to light. The 
presence of the synthetic hormone contraceptive 17α ethinylestradiol (EE2) in sewage effluent 
and surface waters has been clearly linked with the endocrine disruption of fish and frogs 
(Gyllenhammar, 2009; Caldwell et al., 2008). The presence of intersex fish was discovered as far 
back as 1976 within STP settlement lagoons in the UK (Sumpter & Johnson, 2008). It is still 
unknown exactly to what extent synthetic hormones such as EE2 effect feminisation of male fish 
compared with naturally occurring oestrogens such as oestrone; however, it is thought to play a 
major role (Sumpter, 2010). Fish are particularly sensitive to EE2, the predicted no effect 
concentration (PNEC) for EE2 is <1 ngl
-1 
(Lange et al., 2001; Caldwell et al., 2008).  This 
detrimental effect on aquatic organisms was not foreseen. However, it is important to highlight 
that the mode of action (MoA) for EE2 is via the oestrogen receptor which is highly conserved in 
other vertebrates i.e. other than human, such as fish (Christen et al., 2010).   
Veterinary medicines have also been the cause of a dramatic detrimental effect on non 
target organisms. The use of diclofenac in cattle has caused a major decline in vultures in India 
and Pakistan. The Gyps genus of vulture were surprisingly sensitive to residues of diclofenac in 
deceased carrion on which they fed, leading to acute renal failure and visceral gout (Oaks et al., 
2004). Diclofenac has since been withdrawn as a veterinary medicine (Kumar, 2006). However it 
is still used widely as an analgesic in human medicine; it is persistent through sewage treatment 
and is regularly detected in effluent and surface waters around the world (Hoeger et al., 2005).  
Despite the longevity of exposure of aquatic organisms to a wide variety of human drugs, 
notable adverse effects are surprisingly rare. The reason for this may be that the concentrations in 
aquatic ecosystems are far too low to show acute toxic effects. Acute effects data show that 
generally, an effect concentration of over 1 mgl
-1
 is required to induce mortality in aquatic 
organisms (Crane et al., 2006; Fent et al., 2006). It is now widely accepted that the route of 
exposure is of a continuous chronic nature and this is beginning to be reflected in the 
ecotoxicological publications in the literature.  
A number of reviews have been published which summarise ecotoxicological effects of 
human pharmaceuticals, for example, Santos et al., (2009) and  Fent et al., (2006). There are 
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several examples of chronic effects on aquatic organisms at environmentally relevant 
concentrations. The antidepressant fluoxetine (Prozac) has been shown to effect innate 
behavioural responses of fish at environmentally relevant concentrations (Painter et al., 2009; 
Schultz et al., 2011).  Alterations in reproduction patterns have also been observed (Brooks et al., 
2003). The beta blocker propranolol has been shown to inhibit egg laying in fish at 
environmentally relevant concentrations (Huggett et al., 2002). The anti-convulsive 
carbamazepine has been shown to effect antioxidant defence systems in fish brains (Li et al., 
2010). However Fent et al., (2006) concluded that for most pharmaceuticals, chronic lowest 
effect concentrations (LOECs) were two orders of magnitude higher than maximal reported STP 
effluent concentrations.  
These examples of potential adverse effects on non target organisms highlight the 
uncertainties regarding the effects of pharmaceuticals in the aquatic environment. Environmental 
policy is based on the precautionary principle and prevention principles (Kampa et al., 2010). 
Prevention principles are more complicated for pharmaceuticals than for other chemical 
pollutants, such as pesticides, because they are required for human health benefits. This means 
that unlike veterinary use of diclofenac, sales and usage of human medicines cannot be restricted 
on environmental grounds. This means that end of pipe solutions, i.e. wastewater treatment, must 
be considered as a control measure. The precautionary principle emphasises that, where evidence 
of a threat to the health of the environment exists, scientific uncertainty must not be allowed to 
delay reasonable forms of management action (Kampa et al., 2010). The detrimental effects of 
human pharmaceuticals such as EE2 on aquatic organisms and mounting evidence of other subtle 
chronic effects on behaviour, health and reproduction may soon be sufficient to require 
precautionary action to manage the effects in the environment, despite scientific uncertainty over 
impacts. This potential for effects has led to the development of an environmental risk 
assessment (ERA) of human pharmaceuticals as part of the licensing procedure. 
1.4 Environmental risk assessment 
Environmental risk assessment (ERA) of human medicines appeared as part of the 
marketing authorisation process in the 1990s, however, detailed risk assessment was only carried 
out in exceptional cases prior to 2004 (Holzmann, 2005). The current environmental regulation 
of human pharmaceutical products in Europe is laid out by Directive 2004/27/EC. This states 
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that an ERA should accompany any application for marketing authorisation of a medicinal 
product for human use. The guidelines for the ERA procedure in the European Union are set by 
the European Agency for the Evaluation of Medicinal Products (EMEA) and contained in 
EMEA//CHMP/SWP/4447/00, which came into force December 2006. It is a tiered process 
beginning with an initial prediction of environmental concentration (PEC) with an action limit 
for further ecotoxicological risk assessment of 10 ngl
-1
. If the PEC exceeds this action limit, 
phase II of the ERA is invoked. This involves the calculation of a risk quotient (RQ), the ratio 
between the PEC and a predicted no effect concentration (PNEC). The PNEC is derived from 
ecotoxicological tests which should include acute and chronic data from organisms of at least 
three trophic levels; usually algae, Daphnia and fish.  
Since the introduction of the ERA in Europe several papers have been published 
assessing its usefulness/ fitness for purpose and level of protection for aquatic organisms (Ferrari 
et al., 2004; Bound & Voulvoulis, 2004; Kuster et al., 2009). This has led to certain amount of 
identification of its limitations and recommendations for its improvement. These include aspects 
related to the overall procedure, effects assessments and exposure assessments. 
1.4.1  General limitations of the ERA 
One of the limitations with the ERA is that authorisation of a new medicine cannot be 
turned down on an environmental basis. Even if a substantial risk to the environment is perceived, 
it is assumed that the benefit to human health far outweighs any environmental damage. There 
are no guidelines for mitigation of a perceived environmental problem in the current 
authorisation process aside from a statement on the package leaflet which should read: 
 
“Medicines should not be disposed of via wastewater or household waste. Ask 
your pharmacist how to dispose of medicines no longer required. These measures 
will help to protect the environment.” 
 
Since the main source of pharmaceuticals is thought to be from human usage and not disposal, 
this control measure does not adequately address the problem.  
Another key shortfall of the current ERA requirements is that it only applies to new 
medicines requiring authorisation. A large proportion of medicines were authorised prior to 2006 
and have therefore not undergone an ERA. It has been recommended that in accordance with 
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other environmental legislation for industrial chemicals, (Registration, Evaluation Authorisation 
and Restriction of Chemicals, REACH) and pesticides (The Pesticides Framework Directive 
2009/128/EC) that retrospective ERA for human medicines should be performed using a system 
of prioritisation (SRU, 2007). Sweden has embarked on a fairly comprehensive prioritisation 
strategy for pharmaceuticals (Wennmalm & Gunnarsson, 2009). However, no such system of 
ranking and prioritisation for retrospective risk analysis of pharmaceuticals has been applied in 
the UK. The Environment Agency attempted to prioritise pharmaceuticals of environmental 
concern and undertook a monitoring study in 2003 (EA, 2003). Unfortunately a lack of effects 
data, especially chronic effects data, and a lack of analytical chemistry techniques for measuring 
the compounds of highest concern restricted its effectiveness. 
It is known that pharmaceuticals occur as mixtures in the environment. In human 
medicine the potential for synergistic, additive and antagonistic effects of combinations of drugs 
is considered of high importance, however this is not the case with the ERA. Several compounds 
in the aquatic environment may affect the same metabolic pathway or process in non target 
organisms. This could lead to effects in aquatic organisms that would not occur if exposed to a 
compound in isolation. The current ERA does not take into account mixture effects of different 
pharmaceuticals. For many therapeutic classes of pharmaceuticals more than one product 
available with the same mode of action (MoA). Examples include non steroidal anti 
inflammatory drugs (NSAIDs) and antidepressants such as selective serotonin reuptake inhibitors 
(SSRIs). These drugs have been shown to have combined effects that are much higher than the 
individual drug in isolation would show. These classes of drugs have been shown to follow a 
concentration addition model (Christensen et al., 2007; Cleuvers, 2004).   
The action limit of 10 ngl
-1 
has also come under some scrutiny on its level and as a 
mechanism for risk assessment. The level was set using mainly acute effects data with an 
assessment factor applied (Schmitt et al., 2009). The application of assessment factors to account 
for acute to chronic effects has been shown to be flawed (Roig, 2010). The use of an action limit 
that terminates risk assessment for compounds which have a PEC of less than 10 ngl
-1
 may lead 
to potentially toxic substances being overlooked. This is not wholly unlikely considering the case 
of EE2 and the lack of scientific knowledge about the effects of and exposure to, many human 
pharmaceuticals. Although 10 ngl
-1
 is considered to be at least two orders of magnitude below 
the therapeutic dose for most medicines, the effects of active compounds cannot be excluded. 
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Impacts with pesticides have been shown in the low ngl
-1
 range (Steur-Laurisden et al., 2000; 
Kampa et al., 2010). 
1.4.2  Limitations of the ERA for exposure assessment 
On the exposure assessments side of the ERA several problems have been identified. 
These include some of the assumptions that are made in calculation of the PEC. These include 
the dilution factor default value of 10 and the wastewater production per person per day default 
of 200L (Tarazona et al., 2009). PECs are based on an assumption that 1% of the population will 
consume the drug and is termed the market penetration factor (Fpen). This does not reflect the 
actual level of consumption after market authorisation. The PEC calculation also assumes the 
same market penetration across all the countries in Europe and that consumption is equal across 
a country and over the course of the whole year. The PEC calculation also neglects to account for 
degradation processes in the environment such as photolysis and microbial degradation 
(Mompelat et al., 2010). The potential inaccuracies of the PEC calculation has led to some 
comparison of PECs with measured environmental concentrations (MECs) with mixed results 
(Coetsier et al, 2009; Liebig et al., 2006; Bound & Voulvoulis, 2006; Carballa et al., 2008). 
Refinements can be made to the initial crude PEC if it is over the 10 ngl
-1
 action limit. These 
include removal by sewage treatment and metabolism by the body. The reliability of estimating 
these is problematic (Tauxe-Wuersch et al., 2005; Santos et al., 2009; Carballa et al., 2008). The 
EMEA guidelines recommend using the SimpleTreat computer package to estimate removal by 
STPs however this package is mainly based on the octanol-water partition coefficient (log Kow) 
which has been shown to be a poor indicator of actual adsorption of pharmaceuticals to sewage 
sludge (Besse & Garric, 2010; Fent et al., 2006). 
1.4.3  Limitations of the ERA for ecotoxicological effects assessment  
The ecotoxicological effects calculation, i.e. the PNEC has also come under criticism for 
its lack of incorporation of the MoA of the drug (Boxall & Greenwood, 2010; Poynton et al., 
2008; Sanderson & Thomsen, 2009) and the limited number of species used for its derived level 
(Besse & Garric, 2010). It has been recommended that some pharmaceuticals should undergo 
effects tests even if the PEC was below the action limit of 10 ngl
-1
. Reasons for this include: 
potential for persistence, bioaccumulation, carcinogenic, mutagenic or reproductive effects, high 
potency or low therapeutic margin, known toxic effects of structurally similar compounds and 
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new classes of therapeutics which may have unknown ecotoxicological effects (Schmitt et al., 
2009).  
1.5  Integration of expert knowledge into ERA 
In the EU precautionary management for the release of pharmaceuticals into the aquatic 
environment is governed by an ERA. Since the new guidelines for this ERA were introduced in 
2006, six years ago, it is considered prudent to assess its efficiency and effectiveness for the 
protection of the aquatic environment. In order to gain useful insights into issues related to 
human pharmaceuticals in the aquatic environment and the associated ERA, expert knowledge 
(i.e. scientific knowledge) holder engagement is a useful tool. It provides a technique to gather 
valuable information and opinion from different standpoints in an area of high scientific 
uncertainty such as pharmaceutical impact on aquatic systems.  
Stakeholder consultations, including communication with experts, are an essential 
component of risk management and are important for developing policies (Daughton, 2003a & b). 
Expert knowledge can often provide valuable information for assessing environmental problems 
beyond that contained in the peer reviewed literature (Reed, 2008). In a stakeholder engagement 
exercise in 2006, a key finding was that engagement by multiple levels of government and 
multiple stakeholders, including experts, holds much promise as a tool to improve management 
of pharmaceuticals in the environment (Doerr-MacEwen & Haight, 2006).  
Over the last 10 years the UK Government has strongly promoted the more effective use 
of science to inform policy-making and regulation (Holmes & Clark, 2008). The Cabinet Office 
(1999) consider that a core competency of good policy-making is using the “best available 
evidence from a wide range of sources” including evidence from “expert knowledge and the 
critical evidence held in the minds of front line staff in departments, agencies and local 
authorities and those to whom the policy is directed’’. Effective access to information and 
expertise is a necessary precursor to the use of science to inform policy-making and regulation 
(Holmes & Clark, 2008). External experts (including researchers, consultants and experts in 
other Government departments and agencies) are an important source of scientific advice 
(Holmes & Clark, 2008). These experts synthesise and interpret information for policymakers 
and their involvement may lend credibility to ensuing policy decisions. The involvement of 
diverse experts can also lead to a more comprehensive understanding of ecological hazards and 
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can improve problem formulation by generating an ecologically robust set of information on 
which to base the subsequent, more technical ERA (Dana et al., 2012). The participatory ERA 
process can also increase the transparency of the ERA by exposing the logic and rationale for 
decisions made at each step (Dana et al., 2012).  
 One of the aims of this research was to interview relevant individuals who can provide 
expert knowledge and valuable information on the successes and failings of the current ERA. 
The individuals that were targeted were involved directly with the ERA procedure including 
academics, water company managers, government agency staff and pharmaceutical company 
employees. Engagement with these experts may provide novel insights into the performance of 
the ERA and provide new knowledge on how it could be improved in a practical and applicable 
way. It is considered that it would be largely unhelpful to engage with a range of other 
stakeholders such as shareholders, pharmacists, doctors and the general public as they would 
have little knowledge or understanding of the complex guidelines which comprise the ERA. 
 
1.6 Bioinformatics 
Pharmaceuticals are different to some chemical pollutants in that they are designed to 
have a specific biological effect (Christen et al., 2010; Dorne et al., 2007; Kar & Roy, 2010). 
This means that traditional ecotoxicity tests using mortality as an end point might underestimate 
potential chronic effects in the environment and therefore give an underestimate of effects 
concentrations (Crane et al., 2006). Standard tests even when using chronic end points such as 
reproduction still do not incorporate, in most cases, the mechanism or mode of action (MoA) of a 
pharmaceutical compound. Many chronic ecotoxicological studies using MoA related end points 
have revealed NOEC concentrations that are substantially lower than traditional studies (Crane et 
al., 2006; Boxall & Greenwood, 2010). Another potential shortfall is that a relatively narrow 
variety of species are used in the ecotoxicological tests recommended by OECD guidelines and 
the EMEA guidelines. These may not incorporate the most sensitive species that could be 
exposed in water courses. This fact is supported by chronic effects studies on species that are not 
currently included in the guidelines. For example, a study by Meredith-Williams et al., (2012) 
showed a substantial difference in the uptake and bioconcentration of pharmaceuticals across 
three species of aquatic invertebrates. Mussels, not currently considered in ERAs have also been 
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shown to be surprisingly sensitive to some drugs such as fluoxetine (Bringolf et al., 2010). 
Serotoninergic antidepressants have been shown to have effect concentrations that ranged over 
several orders of magnitude in crustaceans and algae (Henry et al., 2004; Johnson et al., 2007). 
This has also been highlighted by the unexpected and surprisingly high sensitivity of vultures in 
Asia to diclofenac (Oaks et al., 2004). 
These problems have led many authors to propose an intelligent testing strategy for 
pharmaceuticals. This would incorporate MoA based chronic tests and endpoints. The use of 
‘omics’ based approaches using extrapolation of human and mammalian data has been suggested 
as a method for predicting environmental effects for risk assessment (Gunnarsson et al., 2008; 
Christen et al., 2010; Berninger & Brooks, 2010; Boxall & Greenwood, 2010). Schmitt et al., 
(2009) recommended that chronic test end points should reflect the MoA of the drug or known 
side effects and also that effects testing should be carried out regardless of the PEC when drug 
target structures are conserved across species. 
Human pharmaceuticals target specific proteins and metabolic pathways that might be 
highly conserved in other species. Evolutionary conservation of drug targets could prove a useful 
method for guiding the ERA by identifying sensitive species and interpreting the relevance of 
existing toxicological data (Besse & Garric, 2010). If a drug has a specific MoA in a human then 
this same MoA may also be occurring in other organisms. For example the beta blocker 
propranolol may cause cardiovascular effects in fish (Owen et al., 2007, 2009) and drugs such as 
statins may also break down cholesterol in fish as well as humans (Ellesat et al., 2010).  
Sequence conservation in drug targets has been proposed as a potential guide for selecting end 
points for toxicity studies and also to select a range of species that may be sensitive (Christen et 
al., 2010; Gunnarsson et al., 2008; Kostich & Lazorchak, 2008).  
It is important to note that the existence of a similar protein sequence in an organism does 
not automatically mean that the human MoA of the drug will occur. In a study by Gunnarsson et 
al., (2008), a high number of conserved drug targets were identified in other species. In order to 
make this information relevant to ecotoxicological tests and ERAs further work on the 3D 
structure of the proteins was needed to predict drug protein interactions. Besse & Garric, (2010) 
identified four ways that bioinformatics information could aid and direct ecotoxicological tests 
for ERA: 
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1. Identification of drugs with the most potential to elicit adverse effects on non-
target organisms. 
2. Interpretation and assessment of ecotoxicological and pharmacological data. 
3. Improvement of the possibilities to identify which pharmaceuticals may pose a 
risk to a certain type of species (or identification of specific sensitive species to 
certain compounds). 
4. Selection of relevant species and/or end points for ecotoxicological studies. 
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1.7  Hypothesis 
1. The environmental risk assessment (ERA) for human pharmaceuticals and use of 
predicted environmental concentrations may be inadequate to protect the aquatic 
environment.  
2. Bioinformatics and molecular docking may be a potential tool to aid and direct the ERA 
of human pharmaceuticals through a focus on mode of action. 
 
1.8  Aims 
1.8.1 Overarching aim  
Assess the current effectiveness of the environmental risk assessment of pharmaceuticals 
(ERA) and make recommendations for improvements. 
1.8.2 Specific objectives 
1. Assess the reliability of the predicted environmental concentration (PEC) used for 
environmental risk assessments (ERA) in relation to reported pharmaceutical 
environmental concentration data.  
2. Investigate reporting standards in peer reviewed literature for data on pharmaceuticals in 
aquatic systems and their potential use in monitoring and ERA.  
3. Establish whether currently available bioinformatics databases are a potential tool to aid 
ecotoxicological testing as part of risk assessment.  
4. Examine expert opinion, obtained through interviews, on risk assessment and risk 
management of pharmaceuticals. 
 
1.9 Thesis structure 
Section 1: Introduction 
Introduction, Aims, Hypothesis and Thesis Outline 
 
Section 2: Pharmaceutical Data Analysis 
Addresses Specific objectives 1 & 2 of this thesis by providing an analysis of:  
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1. The environmental concentration data for pharmaceuticals in aquatic environments and 
STPs including the efficiency of sewage treatment on removal of pharmaceuticals and the 
effect population size on sewage effluent concentrations.  
2. The reliability and robustness of predicted environmental concentrations (PECs) in the 
context of reported measured environmental concentrations (MECs) and the limitations 
of current methods for calculating crude and refined PECs for human pharmaceuticals in 
water bodies.  
3. The scientific literature for its utility in making environmental concentration data 
reported in scientific journals useful to environmental risk assessors and regulators. 
 
 The rationale for this section was to investigate the effectiveness of the first stage of the 
ERA relating to the initial calculation for exposure of pharmaceuticals in the aquatic 
environment. This initial stage currently dictates whether further environmental risk assessment 
including ecotoxicological tests should be performed. This is the pivotal point at which it is 
decided if there is the possibility of an environmental risk and therefore it is essential to ascertain 
if this is a reliable and robust mechanism to protect the environment.  
  Environmental risk assessment should be seen as an ongoing process and therefore it is 
necessary to periodically review its effectiveness. Therefore it is important that the reporting of 
environmental concentration data in the scientific peer reviewed literature is made useable to 
environmental risk assessors and policy makers. 
 
Section 3: Interviews  
 This section addresses Specific objective 3 by presenting the results and analysis of 
eleven in depth interviews with representatives of regulatory bodies, academics, the 
pharmaceutical industry and water industry. The results provide views, opinions and 
recommendations on the successes, failings, limitations of and future improvements to the 
current environmental risk assessment of pharmaceuticals in the environment. This section links 
both the work performed in Section 2 on exposure concentrations, predicted and measured (i.e. 
the initial stage of the ERA) and Section 4, the potential for bioinformatics to aid and direct 
ecotoxicological risk assessment (the second stage of the ERA) thereby addressing on the 
overarching aim of the thesis.  
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Section 4: Bioinformatics 
 Section 4 addresses Specific objectives 4 by assessing the potential application of 
current bioinformatics databases and molecular docking to direct ecotoxicity tests. A BLAST 
search for drug target homologues in aquatic organisms is included. Two drugs diclofenac and 
ibuprofen were used to investigate the ability of the molecular docking package AutoDock to 
predict interactions with drug target homologues in aquatic species. The rationale for this section 
and aim 4 was to address the lack of incorporation of the mode of action (MoA) of 
pharmaceuticals when ecotoxicological effects are assessed as part of the ERA. Bioinformatics 
may provide a useful improvement that could be made to the ERA to protect the aquatic 
environment. 
 
Section 5: Conclusion 
 Tests the central hypotheses and overarching aim of the thesis by assessing the 
effectiveness of the ERA and concludes by making recommendations for improvements to the 
ERA for human pharmaceuticals in freshwater systems.  
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Section 2 
Pharmaceutical Data 
Analysis 
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2.1  Aim of Section 2 
This chapter will collate and analyse data on concentrations of ten selected 
pharmaceuticals in the aquatic environment including surface waters, sewage effluent, 
groundwater, marine and estuarine water and drinking water. The efficiency of sewage treatment 
for removal of pharmaceuticals and the effect population size has on sewage effluent 
concentrations is investigated. The reliability and robustness of predicted environmental 
concentrations (PECs) in the context of reported measured environmental concentrations (MECs) 
will be examined and the limitations of current methods for calculating crude and refined PECs 
for human pharmaceuticals in water bodies will be assessed. 
 
2.2  Novelty of work performed in Section 2 
There is disagreement in the scientific peer reviewed literature on the reliability of PECs 
for human pharmaceuticals. In this section the direct PEC and MEC comparisons for human 
pharmaceuticals in surface waters from the literature in Europe were evaluated. Prescription data 
was also used to calculate a PEC for England which was compared to all the MEC data 
published to date. Rather than comparing a crude or refined PEC to measurements taken in a 
single water body, this work aims to compare crude PECs to more than a decade of published 
environmental data not previously considered as a single body of work. This section also 
provides a novel analysis of the relationship between population size and sewage effluent 
concentrations of human pharmaceuticals. This work concludes that the current PEC calculation 
in the EMEA ERA guidelines is not always precautionary and conservative. 
Unfortunately a novel meta analysis of MECs was not possible due to a lack of reporting 
standards in the peer reviewed scientific literature. The environmental concentration data 
gathered during this work leads to a novel set of recommendations for reporting environmental 
concentration data in peer reviewed scientific journals. 
 
2.3  Introduction 
Despite a considerable amount of published data on environmental concentrations of 
human pharmaceuticals the fate and effects of these micro pollutants is still largely unknown. 
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Routes of entry of human drugs into water courses include disposal of unused medicines via the 
sink or toilet, pharmaceutical manufacture, hospital effluent, landfill leachate and land run off 
from agricultural sewage sludge application. However, the main route of entry of 
pharmaceuticals into water bodies is thought to be through incomplete metabolism by the body 
(Ellis, 2006; Cunningham et al., 2006; Sanderson et al., 2003) and subsequent discharge in 
sewage effluent. 
Factors that have a major effect on drug concentrations in surface waters, therefore, relate 
predominantly to this source. Thus the amount of pharmaceutical consumed by local populations 
is significant, as is the percentage excreted as parent compound or conjugates in urine and faeces 
and the pharmaceutical removal efficiency of the STP (Jones et al., 2005). Other influences on 
final concentration include the volume of the receiving water body and degradation processes in 
the environment (Fatta-Kassinos et al., 2011; Loffler et al., 2005).  
In the EU any application to licence a new medicine must be accompanied by an ERA. In 
2006 the European Agency for the Evaluation of Medicinal Products (EMEA) published a 
revised guideline for ERA of human pharmaceuticals (EMEA/CHMP/SWP/4447/00). It is 
general practice for an ERA of any substance to begin with a conservative predicted 
environmental concentration (PEC). The calculation for the initial PEC for human 
pharmaceuticals often termed the crude PEC is specified in EMEA guidelines. If the PEC 
exceeds the action limit of 10 ngl
-1
 then a second phase of the ERA is triggered and the PEC is 
refined with consideration of relevant data on metabolism, excretion, degradability and 
persistence. This refined PEC value is compared to the predicted no effect concentration (PNEC), 
which is derived from existing ecotoxicological data. If the ratio termed the risk quotient, is 
greater than 1 the PEC and PNEC are further refined using substance and compartment specific 
tests.  
The crude PEC calculation assumes that: 1% of the population consume the maximum 
daily dose of a drug; 100% of pharmaceuticals prescribed are consumed evenly across the 
population; and that over the year, 100% of the parent compound is excreted and no removal 
occurs during sewage treatment. Despite the apparent simplistic and uncertain nature of this 
method there are two reasons why it is necessary. The first is that the actual consumption data is 
not available until a drug has been licensed so an estimate of usage must be made. The second is 
that it is impractical to measure the environmental concentrations of all the pharmaceuticals that 
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are marketed annually in all the water bodies that may be affected. Given these limitations it is 
necessary to estimate the exposure concentrations (Besse & Garric, 2008; Kostich et al., 2010).  
Several studies on the accuracy of the PEC calculation have been performed and the 
evidence is somewhat contradictory, some have found PEC and measured environmental 
concentrations (MEC) values to be in good agreement (Besse & Garric, 2008) while others have 
shown this not to be the case (Coetsier et al., 2009). Liebig et al., 2006 demonstrated that PECs 
calculated on the basis of human metabolic removal and removal by sewage treatment were very 
close to measured environmental values, but noted that exposure assessments should always 
result in PECs that are higher than environmental concentrations. Refined PECs have, in fact, 
also been found to underestimate MECs for several pharmaceuticals (Bound & Voulvoulis, 
2006).  Indeed, Morasch et al., (2010) found some MEC/PEC ratios to be greater than 10. The 
uncertainty over PEC leaves the EMEA ERA open to criticism and some workers have suggested 
that the ERAs are insufficiently robust to protect aquatic environments (Ferrari et al., 2004). 
Undoubtedly, the PEC calculation must be conservative and precautionary to protect the 
environment. If a pharmaceuticals environmental concentration is underestimated then 
unforeseen adverse effects on non target organisms may occur and remain un-investigated.   
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2.4  Methods 
2.4.1  Data collection 
A comprehensive and systematic search of peer reviewed literature; books, UK 
government (e.g. Department for the Environment, Food and Rural Affairs, DEFRA), EU 
Commission reports and Environment Agency (EA) reports was undertaken. Online databases 
‘National Centre for Biotechnology Information’ (www.ncbi.nlm.nih.gov) and ‘Science Direct’ 
(www.sciencedirect.com) were used initially with search terms such as ‘pharmaceutical AND 
environment’, ‘pharmaceutical AND pollution’ followed by specific searches relating to each of 
the selected pharmaceuticals. The matrixes included in the initial search were: Surface waters 
including rivers, streams, lakes, reservoirs, coastal waters, sea water, ground water, soil, landfill 
leachate, soil, drinking water, sewage effluent, influent and sludge. The initial search included all 
pharmaceuticals from all therapeutic classes. This resulted in approximately 500 relevant articles. 
The references provided in each publication were also examined.   
The information and data extracted from relevant publications were: pharmaceutical, 
therapeutic class, matrix (surface water, effluent etc), mean (and standard deviation), median, 
minimum, maximum, single reported pharmaceutical concentrations, sample size, country and 
location of the detection, analytical method used and the detection limit of that method, sewage 
treatment employed, date of sampling, flow of the receiving waters, population size served by 
STP or population base of surrounding area, flow/ quantity of effluent discharge and any 
reported weather conditions. 
Data on pharmaceuticals chemical structure, physical and chemical data and consumption 
data were found using: Drug Bank (www.drugbank.ca); Centre for Coastal Environmental 
Health and Bimolecular Research, pharmaceuticals in the environment database (PEIAR) 
(www.chbr.noaa.gov/peiar); RxList (www.rxlist.com); and UK Department of Health 
Prescriptions cost analysis 2008 
(www.ic.nhs.uk/webfiles/publications/PCA%202008/PCA%202008v2.pdf).  
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2.4.2 Data analysis 
2.4.2.1 Concentrations in surface waters and sewage effluent 
Ten pharmaceuticals were selected for potential meta analysis on the basis of being 
representative of each major therapeutic class, population usage (highly prescribed) (Department 
of Health prescription cost analysis, 2008), wealth of environmental concentration data from the 
literature search (see appendix 1), high concentrations detected in the environment and known or 
potential (suspected) ecotoxicological impacts. The ten pharmaceuticals were: carbamazepine 
(anticonvulsive), diclofenac (non steroidal anti-inflammatory), 17α-ethinylestradiol (EE2) 
(contraceptive), fluoxetine (Prozac) (antidepressant), gemfibrozil (lipid regulator), ibuprofen 
(non steroidal anti-inflammatory), paracetamol (analgesic), propranolol (ß-blocker), tamoxifen 
(cancer drug) and trimethoprim (antibiotic). Measurements were included regardless of their 
collection method (grab sample or 24 hour composite) and analytical method used, in order to 
increase the amount of data available for analysis.  
Originally, it was hoped that a meta analysis of the ten selected pharmaceuticals could be 
performed using the guidelines in the Cochrane Systematic Reviews of Interventions (2008). 
This is an accepted protocol for meta analysis data on medical health practices. The Cochrane 
Review can be used to analyse results from different studies. The method involves collection of 
mean values, standard deviation (SD) and sample size of data collected in each study.  The 
intention was to compare the data collected on environmental concentrations of the ten selected 
pharmaceuticals to assess the effect of different parameters such as weather (season), river flow, 
sewage treatment type and population size.  
The mean concentration values from the literature were extracted from the complete 
MEC data set (see appendix 1). Where the mean value was not supplied, some authors, on 
request, also supplied raw data for mean calculations (see acknowledgements). If enough raw 
data was available in the original publication (or supplied by email), the mean and SD were 
calculated. Where positive detections were found below the limit of quantification for that 
method, a figure of half the detection limit was used as in methods used in Ashton et al., (2004). 
Unfortunately the data available in the literature was not generally appropriate for use 
with the Cochrane Review computer package (see Section 2.4.5 on reporting standards). 
Sufficient data was available to compare the mean (reported or calculated from the data) reported 
concentrations in surface water and sewage effluent for four of the selected pharmaceuticals: 
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carbamazepine, diclofenac, gemfibrozil and ibuprofen. These were selected for further study. 
Mean of means calculations on these pharmaceuticals included all the reported concentrations. 
For non detections (ND) a value of zero was included in the calculation. For the other six 
pharmaceuticals; paracetamol, trimethoprim, tamoxifen, EE2, fluoxetine and propranolol all 
MEC measurements were used for analysis including; single reported measurements, mean, 
median, max and minimum concentrations. 
2.4.2.2 Sewage treatment efficiency  
The efficiencies of different sewage treatment technologies including: primary 
sedimentation, secondary biological, activated sludge, biological trickling filter, tertiary 
treatments, settlement lagoons, chlorination and UV for removal of pharmaceuticals was 
assessed. Four pharmaceuticals were selected for this study because there was the greatest 
amount of data available on their removal by sewage treatment. The efficiency of sewage 
treatment for carbamazepine, diclofenac, ibuprofen and gemfibrozil was determined by 
calculating the change in concentration between sewage influent and effluent at individual 
sewage treatment plants (STP) or pilot plants, using the equation:  
[Cinfluent - Ceffluent]/Cinfluent x 100. 
2.4.2.3  Pharmaceutical dilution in receiving waters 
The dilution effect of pharmaceutical concentration from sewage effluent outfall to 
receiving waters was investigated. Measurements from final effluent and downstream/upstream 
receiving water concentrations for carbamazepine, diclofenac, gemfibrozil and ibuprofen were 
analysed. The dilution in pharmaceutical concentration from sewage effluent outfall to the 
receiving waters was calculated using the equation: 
[Ceffluent - Csurface water]/Ceffluent x 100. 
2.4.2.4 Population size and effluent concentration correlations 
Microsoft Office Excel was used to calculate statistical correlations between population 
size and concentration of pharmaceutical in sewage effluent for four pharmaceuticals: 
carbamazepine, diclofenac, ibuprofen and gemfibrozil using a 95% confidence limit of the mean 
(n varies with dataset). These were performed first using all data without separation of sewage 
treatments and then between broad categories of sewage treatment (see above). 
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2.4.3  Action limit for environmental risk assessment 
The frequency that nine of the selected pharmaceuticals were reported as present in 
surface waters above the 10 ngl
-1
 action limit for risk assessment set by the EMEA guidelines 
was assessed using mean MECs (see above). EE2 was not included in this assessment as 
concentrations are rarely detected at this level. 
 
2.4.4  Calculation of PECs for comparison with MECs 
Two surface water PECs were calculated using the Committee on Medicinal Products for 
Human Use (CHMP), 2006 guidelines for each of the selected pharmaceuticals. The first PEC 
calculations were performed using all the default values including the default market penetration 
factor (Fpen) set out in the guidelines (Eq 1). The second set of PEC calculations involved the 
substitution of the Fpen of 1% for actual prescription data for England in 2008.  
 
2.4.4.1  Crude PEC using default market penetration factor (Fpen) 
The first equation (Eq 1) was used to calculate a crude PEC (PEC 1). The only variable 
between different pharmaceuticals when using Eq1 is the maximum daily dose. This data was 
obtained from RxList. The default Fpen of 1% is based on a wide range of individual market 
penetration factors from German consumption data in 2001 (EMEA CHMP, 2006). 
 
[Eq 1] Crude PEC (EMEA guidelines, 2006) 
DOSEai * Fpen  
PEC
SURFACEWATER 
= ------------------------------------------------------------------------------  
WASTEWinhab * Dilution 
 
DOSEai: Maximum daily dose consumed per inhabitant (mg.hab
-1
.day
-1
) 
Fpen: Percentage of market penetration (default value = 1%) 
WASTEWinhab: Amount of wastewater per inhabitant per day (l.hab
-1
.day
-1
; default value = 200L) 
Dilution: dilution factor from STP to surface water (default value = 10) 
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2.4.4.2 Crude PEC calculations using prescription data 
The EMEA guidelines advise that if marketing or consumption data is available then PEC 
calculations can be performed using this data. Consumption data for England were collected for 
the majority of pharmaceuticals in this study from the Department of Health cost analysis 2008 
(NHS, 2008). The IMS™ sales data from 2004, obtained from DEFRA, (2007), were used for 
paracetamol and ibuprofen. The latter provides the total amounts of active ingredient sold, which 
are generally more realistic than prescription data for these two pharmaceuticals because of their 
high over the counter sales (DEFRA, 2007). The population of England in 2008 was 51.5 million 
(UK National Statistics, 2008).  
 
 
[Eq 2] Crude PEC using consumption data  
 
                     Consumption [mg*year
-1
]  
PEC surface water = --------------------------------------------------------------------------------------------   
          WASTEWinhab [l/inh*d] * Dilution * 365 d*year
-1
* inhabitants [inhab]  
 
(See equation above for definition of terms) 
 
2.4.5  Critical analysis of reporting methods and standards in the literature 
The quality of reporting environmental concentration data in peer reviewed scientific 
journals was too poor to perform a meta analysis on amalgamated data from articles. This led to 
a novel analysis of reporting methods and standards of human pharmaceuticals.  Proposed 
reporting criteria (see below) were selected on the basis of information that was regularly 
missing from publications which was critical for performing a meta analysis of environmental 
concentration data. Missing information related to population size, sewage treatment, flow rates, 
season, and pharmaceutical persistence in water bodies. Meta analysis is a recognised and 
valuable tool in medical interventions and could be an equally useful tool in environmental 
protection.  
Reporting standards for peer reviewed publications on the selected ten pharmaceuticals 
were assessed. In total 128 articles were analysed for the presence or absence of the following 
information as an indication of reporting standard: 
 
1. Date, month or season for sampling. 
37 
 
In order to assess how seasonal changes may affect environmental concentrations of 
pharmaceuticals it is necessary to know the date that samples were collected. Date of sampling is 
especially important for assessing the reliability of predicted concentrations (PECs) as 
sales/prescription data may vary season to season or year to year. 
 
2. Sample size or number of samples. (Frequency of detection was not counted if the 
overall sample size was not provided.) 
It was intended that the “The Cochrane Review” would be used as the method for performing a 
meta analysis of environmental concentration data. This method uses the statistical mean in order 
to compare data sets from different studies. The sample size for each mean is required in order to 
apply weighting according to the size of the study and the contribution each study makes to the 
overall finding. For example a mean of 3 samples is not as statistically significant as a mean of 
40 samples. The sample size is therefore important for assessing the weight of evidence that a 
study provides. 
 
3. Statistics including median, mean, standard deviation, 90th percentile, minimum, 
maximum or a range of concentrations for the selected pharmaceuticals. 
In order to perform a meta analysis of data from different studies, statistical uniformity is needed. 
The Cochrane Review uses the mean and standard deviation for this purpose. The statistical 
method used in each publication was recorded during data collection. 
 
4. Replicate samples either taken on a different date or time at the same location, at a 
different sewage treatment plant (STP), different location on the river or more than one 
river in the same location. Composite samples were also included as a repeat.  
A single measurement does not provide robust information with which to draw conclusions 
about the concentrations of pharmaceuticals in a water body. 
 
5. Location of sampling site for surface water e.g. upstream or downstream from sewage 
outfall.  
When examining the effects that sources of pharmaceuticals have on concentrations in water 
bodies it is necessary to know the location of the sampling site. In theory concentrations of 
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pharmaceuticals should be lower upstream of the sewage effluent outfall, highest at the sewage 
discharge point and then decrease downstream of the discharge point. In order to ascertain if this 
is the case it is necessary to know the location of sewage effluent discharge points and hence the 
location of the sampling site. 
 
6.  Distance from a sewage outfall and position of the sampling location.  
Changes in pharmaceutical with distance from the sewage outfall location might provide 
information on persistence of pharmaceuticals in water bodies. It is desirable to know what 
downstream dilution effects are taking place on sewage effluent discharge points downstream. 
This is important for examination of the dilution default of 10 used in PEC calculations. 
 
7. Population served or capacity of the STP relevant to the sample location. 
In order to calculate a predicted concentration for a pharmaceutical in the environment the total 
amount of the pharmaceutical consumed over the year is divided by the size of population. It is 
therefore important to determine if the size of population served by an STP affected the 
concentration of the pharmaceutical in the final sewage effluent.  
 
8. Specification of sewage treatment process.  
In order to assess the efficiency of different sewage treatments for the removal of 
pharmaceuticals and hence the affect on concentrations in receiving water bodies it is necessary 
to know the type of sewage treatment employed. 
 
9. Average discharge of effluent or the quantity of sewage treated.  
If the average discharge of effluent is provided it is possible to calculate the environmental load 
using the concentration of pharmaceutical in sewage effluent. 
 
10. For surface waters the average river flow rate or flow rate at the time of sampling. 
Changes in pharmaceutical concentration may be directly related to the flow rate of the river. 
This data is useful for calculation of average and maximal loads based on high and low flow data. 
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11. Limit of detection (LOD) for the analytical method. (A limit of quantification (LOQ) 
was considered valid.)  
This information is required to assess the limitations of the analytical chemistry method used and 
ascertain the reliability and robustness of the results. 
 
The articles were scored against the criteria and the percentage of articles providing each 
category of information calculated.  
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2.5  Results 
2.5.1 Physical, chemical and sales data for selected pharmaceuticals  
Structure, physical and chemical information, octanol-water partition coefficient (log 
Kow), water solubility and prescription amounts in England, (2008) in numbers and weight (kg) 
were collected for each of the ten selected pharmaceuticals; carbamazepine, diclofenac, EE2, 
fluoxetine, gemfibrozil, ibuprofen, paracetamol, propranolol, tamoxifen and trimethoprim (Table 
2.1 & Table 2.2). 
 
Table 2.1 Physical, chemical and prescription data  
(
a
: www.chbr.noaa.gov/peiar/; 
b
: www.drugbank.com; 
c
: IMS data DEFRA, 2004; 
d
: Oakes et al., 2010; 
e
: Mompleat et al., 2010; OTC: over the counter sales) 
 
Pharmaceutical Therapeutic 
use 
Log 
kow 
 
Water 
solubility  
(mg ml
-1
) 
Consumption data, England, 2008 
(prescriptions 
in 1000’s) 
(kg) 
Carbamazepine 
CAS -298-46-4 
anti-convulsive 
anti-neuralgic 
anti-manic 
anti-diuretic 
anti-psychotic 
2.25
e 
0.0177
a 
24,025 45,705kg 
Diclofenac 
CAS -15307-86-5 
analgesic 4.51
e 
2.43
a 
71,935 26,442.7 
Ethinylestradiol 
CAS -57-63-6 
contraceptive 3.67 11.3
ab 
- 0.08 
Fluoxetine 
CAS-54910-89-3 
anti-depressant 
anti-obsessional 
3.82
-
4.67
d 
14
a 
5,034.5 4435.4 
Gemfibrozil 
CAS-2581-30-0 
anti-
hyperlipidemic 
3.9
e 
10
a 
20.6 755.3 
Ibuprofen 
CAS-15687-27-1 
analgesic 3.97
e 
0.021
a 
OTC 330,292
c 
 
Paracetamol 
CAS-103-90-2 
analgesic 0.46
e 
14
a 
OTC 3,534,737
c 
Propranolol 
CAS-318-98-9 
anti-
hypertensive/diu
retic 
beta-adrenergic 
blocking agent 
-
0.45
e 
0.07
a 
2,732.1 7,784.5 
Tamoxifen 
CAS-10540-29-1 
anti-estrogen 
cancer drug 
6.3
e 
0.0002
b 
641.1 521.4 
Trimethoprim 
CAS – 738-70-5 
antibiotic 0.91
e 
0.3-0.4
a 
12.1
b 
3,203.4 9736.6 
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Table 2.2 Chemical structure of selected pharmaceuticals 
 
 
 
Carbamazepine 
 
 
 
 
Ethinylestradiol 
 
 
 
Gemfibrozil 
 
 
 
Ibuprofen 
 
 
 
Tamoxifen 
 
 
 
Diclofenac 
 
 
 
Fluoxetine 
 
Paracetamol 
 
 
 
Propranolol 
 
 
Trimethoprim 
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2.5.2 Surface water concentrations in freshwater systems  
Mean surface water concentrations were collected or calculated for four 
pharmaceuticals, diclofenac, carbamazepine, ibuprofen and gemfibrozil. The 
concentrations varied with pharmaceutical but all were in the ng – μgl-1 range (Fig 2.1-
2.5). A summary of the data for all four of these pharmaceuticals separated between 
Europe and outside of Europe is also provided (Fig 2.1). Mean measurements of these 
four pharmaceuticals regularly differed more than an order of magnitude (Fig 2.5). The 
variation between measured concentrations was to a degree that meant the results could 
only be shown on a logarithmic scale. The standard deviations of total means were too 
large to be shown graphically when calculating the total mean (Fig 2.1). Mean reported 
concentrations for these pharmaceuticals ranged from 0.1 ngl
-1
 to 2.1 μgl-1. All four 
pharmaceuticals had total mean of means concentrations between 10 and 100 ngl
-1
 and all 
had some mean detections over 100 ngl
-1
.  Mean ibuprofen concentrations exceeded 1 
μgl-1 on more than one occasion (Fig 2.4). Measured surface water concentrations for all 
four pharmaceuticals in Europe (Austria, Finland, France, Germany, Romania, Spain, 
Switzerland, UK) appeared representative of the situation outside of Europe (data from 
USA, Canada, China and Brazil) (Fig 2.1).  
In studies of surface water, where a mean concentration was obtained 
carbamazepine was almost always present. The highest mean concentration reported for 
this pharmaceutical was 675 ngl
-1
 in France (Coetsier et al., 2009) and the overall mean 
of all mean reported concentrations worldwide using all the mean data was 54 ngl
-1
 with 
a standard deviation of 106.3 ngl
-1
 (Fig 2.2). The mean outside of Europe was 31 ngl
-1
 
and inside Europe was 68 ngl
-
1 (Fig 2.1). Only twice, in Romania, was the mean 
calculated as less than the limit of detection for that method (see appendix 2 for raw data). 
A mean concentration of carbamazepine in surface waters in England was not found in 
the literature although maximum concentrations have been reported between 7 ngl
-1 
(Kasprzyk-Hordern et al., 2008) and 647 ngl
-1 
(Kaspryk-Horndern et al., 2009) in Wales. 
The mean concentration value for carbamazepine appears to exceed 10 ngl
-1
 (ERA action 
limit) in 69.5% of sampling campaigns for surface waters worldwide and 73% within 
Europe (see appendix 2 for raw data).  
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Pharmaceutical and location of sampling 
25th percentile min total mean max 75th percentile
EMEA trigger limit 
Fig 2.1 Summary of reported and calculated mean measured environmental concencentrations (MECs) in surface 
waters from the literature. For a breakdown of this data see Figs 2.2-2.5. (European data includes measurements taken in: 
Austria, Finland, France, Germany, Romania, Spain, Switzerland, UK. Outside Europe data includes measurements taken in 
Canada, China, Brazil, USA). For raw data see appendix 1.  
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Diclofenac had a total mean surface water concentration in Europe of 47.2 ngl
-1
 
and 28.2 ngl
-1
 for the rest of the world (Fig 2.1). The highest mean concentration of 
diclofenac was 272 ngl
-1 
measured in Berlin in 2003 (Quintana & Reemtsma, 2004) (Fig 
2.3).  The mean concentrations of diclofenac fell below the detection limit in 14.3% of 
surface water sampling events (see appendix 3 for raw data). The average of all mean 
concentrations calculated was 40 ngl
-1 
four times the ERA action limit. The standard 
deviation about the total mean was 53 ngl
-1 
(Fig 2.3). 
Ibuprofen showed the largest variation in concentration and the highest mean 
concentration in surface waters of the four drugs (Fig 2.4). Its highest mean concentration 
was 2.1µgl
-1
 (Fig 2.4) was measured in the UK in 2006 (Bound & Voulvoulis, 2006). 
Non detections (or detections below the method’s detection limit) (see appendix 4 for raw 
data) occurred in 10% of published mean results and was incorporated into the mean of 
mean surface water concentration, which was 186 ngl
-1
 (SD 385 ngl
-1
) (Fig 2.4), nearly 
19 times the ERA action limit.  
The total mean surface water concentration in Europe for gemfibrozil was 24.9 
ngl
-1
 and 49.5 ngl
-1
 for outside of Europe (Fig 2.1). The overall total mean was 35.3 ngl
-1
 
with a standard deviation of 45.6 ngl
-1
 (Fig 2.5). A highest mean concentration of 
gemfibrozil was measured in an urban waterway in the USA of 170 ngl
-1
 (Vanderford & 
Snyder, 2006) (see appendix 5 for raw data). The mean concentration of gemfibrozil 
exceeded 10 ngl
-1
 in over 50% of the published literature. Overall there was much less 
data for gemfibrozil. A published mean concentration was not available and insufficient 
raw data has been measured in order to calculate one for the UK.  
 The ranges of concentrations of trimethoprim (Fig 2.6), paracetamol (Fig 2.7), 
propranolol (Fig 2.8) and tamoxifen (Fig 2.9) were all quite variable. There was much 
less data for tamoxifen with only two countries, France and the UK investigating the 
environmental concentration of this pharmaceutical. Trimethoprim, paracetamol and 
propranolol were regularly detected in water courses worldwide often exceeding 10 ngl
-1
, 
the trigger limit for risk assessment. Paracetamol concentrations exceeded 1µgl
-1
, 100 
times the trigger limit in several countries (UK, Canada, USA) (Fig 2.7).  Maximum 
concentrations of 2.4µgl
-1
 in the River Taff, UK, 1km upstream from the STP (Kasprzyk-
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Hordern et al., 2008) and 10µgl
-1
 in the USA (Kolpin et al., 2002) have been reported for 
this analgesic.  
There was limited data for concentrations of fluoxetine (Table 2.3) and EE2 
(Table 2.4) in surface waters but reported concentrations were always in the ngl
-1
 range. 
The highest reported concentration of fluoxetine was a mean of 20 ngl
-1
 in the USA 
(Shultz & Furlong, 2008) however a measurement 3 ngl
-1
 also in the U.S.A (Benotti et al., 
2009) is more representative of general findings (Table 2.3). EE2 surface water 
concentrations have been measured, in a reconnaissance exercise studying over 90 rivers 
and streams in the USA, at a maximum of 831 ngl
-1
 and a median of 73 ngl
-1
 (Kolpin et 
al., 2002) (Table 2.4). However reported concentrations in other published literature were 
usually below the detection limit of the method or around 0.5- 4 ngl
-1
.  
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Fig 2.6 Measured environmental concentrations (MECs) of trimethoprim in surface water. Individual points 
represent MECs reported in the literature. Only positive detections are shown due to logarithmic scale. Data set 
includes 74 measurements below the limit of detection or quantification (LOD/LOQ). For raw data and references see 
appendix 1.  
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Fig 2.7 Measured environmental concentrations (MECs) of paracetamol in surface water. Individual points 
represent MECs reported in the literature. Only positive detections are shown due to logarithmic scale. Data set 
includes 18 non detections (ND) and 54 detections below the limit of quantification (LOQ). For raw data and 
references see appendix 1.  
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Fig 2.8 Measured environmental concentrations (MECs) of  propranolol in surface water. Individual points represent 
MECs reported in the literature. Only positive detections are shown due to logarithmic scale. Data set includes 4 non 
detections (ND) and 31 measurements below the limit of quantification (LOQ). For raw data and references see appendix 1.  
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Fig 2.9 Measured environmental concentrations (MECs) of tamoxifen in surface water. Individual points 
represent MECs reported in the literature. Only positive detections are shown due to logarithmic scale. Data set 
includes 31 measurements below the limit of detection or quantification (LOD/LOQ). For raw data and references 
see appendix 1.  
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Table 2.3 Measured environmental concentrations of fluoxetine in surface water 
(ngl
-1
) (ND: non detection; bld: below detection limit) 
 
  
Table 2.4 Measured environmental concentrations of EE2 in surface water (ngl
-1
) 
(ND: non detection) 
 
Despite the wide variation in surface water concentration data for all 9 of the 
pharmaceuticals investigated from the published literature frequently had a mean 
measured concentration above the 10 ngl
-1
 action limit set by the EMEA for further 
environmental risk assessment (Table 2.5). 
 
 
Mean Median Minimum Maximum Reference 
ND       Kim et al., 2007 
bld bld bld bld Gros et al., 2006 
  0.8   3 Benotti et al., 2009 
<18 <18 <18 <18 Alvarez et al.,  2005 
ND ND ND ND Batt et al., 2008 
2.6       Vanderford & Snyder, 2006 
<0.50       Vanderford & Snyder, 2006 
12       Schultz & Furlong, 2008 
20       Schultz & Furlong, 2008 
12       Schultz & Furlong, 2008 
5.5       Vanderford et al., 2003 
ND ND ND   Vanderford et al., 2003 
  14 bld 44 Gonzalez-Alonso et al., 2010 
Mean Median Minimum Maximum Reference 
ND 
   
Kim et al., 2007 
 
73 
 
831 Kolpin et al., 2002 
ND ND ND ND Zhang et al., 2007 
 
1.4 
 
1.4 Benotti et al., 2008 
ND 
  
1 Peng et al., 2008 
<1.0 
   
Vanderford et al., 2003 
   
ND Zuccato et al., 2005 
ND 
   
Zuehlke et al., 2004 
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Table 2.5 Percentage of mean surface water concentrations greater than the 10 ngl
-1
 
environmental risk assessment action limit.  Only mean measurements used for 
comparison. (a: Brazil, Canada, China, Korea, Taiwan and the USA. b: Austria, France, Finland, 
Germany, Greece, Hungary, Italy, Netherlands, Norway, Poland, Romania, Slovenia, Spain, Sweden, 
Switzerland, and UK.) 
 
Pharmaceutical Worldwidea+ b Europeb 
 
Total  mean 
reported or 
calculated 
concentrations  
Percentage 
>10 ng/L 
Total mean 
reported or 
calculated 
concentrations 
Percentage 
>10 ng/L 
carbamazepine 59 69.5 37 73 
diclofenac 49 77.6 33 78.8 
fluoxetine 14 21.4 1 0 
gemfibrozil 44 38.6 18 44.4 
ibuprofen 79 74.7 47 79.7 
paracetamol 16 87.5 13 100 
propranolol 18 61.1 24 54.2 
trimethoprim 26 46.2 12 75 
tamoxifen 6 33.3 6 33.3 
 
Mean concentrations of carbamazepine, diclofenac, gemfibrozil, ibuprofen, 
paracetamol, propranolol and trimethoprim were all above the trigger limit in more than 
50% of samplings in Europe. Mean concentrations of tamoxifen were over 10 ngl
-1
 in 
Europe in 33% of the studies. Fluoxetine was not measured above 10 ngl
-1
 in Europe but 
has exceeded this limit elsewhere in the world. Insufficient data was available for EE2, 
but findings show that generally concentrations of this drug were small.  
 
2.5.3 Sewage effluent concentrations 
Mean concentrations of carbamazepine, diclofenac, ibuprofen and gemfibrozil in 
sewage effluent were very varied (Fig 2.10-2.15). A summary graph of mean MEC data 
for these four pharmaceuticals is also provided with European data separated from data 
outside of Europe (Fig 2.10). Again a logarithmic scale had to be used to display the data 
graphically. The total means for these pharmaceuticals ranged from 34 ngl
-1
 (gemfibrozil) 
and 3.5 µgl
-1
 (ibuprofen) (Fig 2.10). The maximum mean across the four pharmaceuticals 
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was for ibuprofen at 16.5µgl
-1
 (Fig 2.10) and the lowest was below the detection limits or 
not detected (see appendix 6-9). Apart from concentrations of gemfibrozil outside of 
Europe, the 75
th
 percentile of the means for all four drugs was above 100 ngl
-1
 and 
concentrations regularly exceed 1 µgl
-1
(Fig 2.10).  
Carbamazepine is ubiquitously detected in sewage effluent worldwide. Mean 
reported concentrations ranged from 7 ngl
-1
 (Canada) (Metcalfe et al., 2003) to 2.5 µgl
-1
 
(France) (Togola & Budzinski, 2007) with a total mean of all mean concentrations 
measured of 544.6 ngl
-1
 (standard deviation, 524.2 ngl
-1
) (Fig 2.11).  A mean effluent 
concentration of carbamazepine has not been measured in sewage effluent in the UK 
although a maximum of 4.6µgl
-1
 has been reported in Wales (Kasprzyk-Hordern et al., 
2009) (Fig 2.11) (see appendix 6 for raw data). Total mean concentrations inside and 
outside Europe were over 100 ngl
-1 
(Fig 2.11)
 
exceeding the ERA trigger limit when the 
dilution factor of 10 (see PEC Eq 1) from sewage effluent to sewage outfall was applied. 
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Fig 2.10 Summary of reported and calculated mean sewage effluent concentrations from the literature. For a 
breakdown of this data see Figs 2.11-2.14. (European data includes measurements taken in: Austria, Finland, France, 
Germany, Romania, Spain, Switzerland, UK. Outside Europe data includes measurements taken in Canada, China, Brazil, 
USA). For raw data see appendix 1.  
58 
 
 
 
1
1
0
1
0
0
1
0
0
0
1
0
0
0
0
V
an
d
er
fo
rd
 &
 S
n
y
d
er
 2
0
0
6
C
la
ra
 e
t 
al
 2
0
0
5
C
o
et
si
er
 e
t 
al
 2
0
0
9
H
u
a 
2
0
0
6
L
ec
le
rc
q
 e
t 
al
 2
0
0
8
M
ia
o
 e
t 
al
 2
0
0
5
M
o
ld
o
v
an
 e
t 
al
 2
0
0
7
P
ed
ro
u
zo
 e
t 
al
 2
0
0
7
S
an
to
s 
et
 a
l 
2
0
0
5
S
an
to
s 
et
 a
l 
2
0
0
9
T
o
g
o
la
 &
 B
u
d
zi
n
sk
i 
2
0
0
7
M
et
ca
lf
e 
et
 a
l 
2
0
0
3
C
o
n
ce
n
tr
a
ti
o
n
 (
n
g
l-
1
) 
R
ef
er
en
ce
 
F
ig
 2
.1
1
 M
ea
n
 c
o
n
ce
n
tr
a
ti
o
n
s 
o
f 
ca
rb
a
m
a
z
ep
in
e 
in
 s
ew
a
g
e 
ef
fl
u
en
t 
re
p
o
rt
ed
 i
n
 t
h
e 
li
te
ra
tu
re
. 
D
at
as
et
 d
id
 n
o
t 
co
n
ta
in
 a
n
y
 m
ea
n
 m
ea
su
re
m
en
ts
 b
el
o
w
 t
h
e 
li
m
it
 o
f 
d
et
ec
ti
o
n
 o
r 
q
u
an
ti
fi
ca
ti
o
n
 (
L
O
D
/L
O
Q
).
 M
u
lt
ip
le
 p
o
in
ts
 f
o
r 
th
e 
sa
m
e 
re
fe
re
n
ce
 a
p
p
ly
 t
o
 d
if
fe
re
n
t 
se
w
ag
e 
tr
ea
tm
en
t 
p
la
n
ts
 (
S
T
P
s)
 S
ee
 a
p
p
en
d
ix
 6
 f
o
r 
ra
w
 d
at
a.
 
T
o
ta
l 
m
ea
n
 5
4
4
 ±
 5
2
4
.2
 n
g
l-
1
  
59 
 
Diclofenac had a maximum mean concentration of 3.5µgl
-1
 (Austria) (Clara et al., 
2005), a minimum mean concentration of 5 ngl
-1
 (Canada) (Metcalfe et al., 2003), and an 
overall mean of mean concentrations reported or calculated of 505 ngl
-1 
(standard 
deviation, 640.8 ngl
-1
 in sewage effluent (Fig 2.12.) The European total mean 
concentration was 577 ngl
-1
 in Europe and 230 ngl
-1
 outside of Europe (Fig 2.10). In the 
UK the mean concentration of diclofenac in sewage effluent ranged between 382.7 ngl
-1
 
(Roberts & Thomas, 2006) and 714 ngl
-1
 (Hilton & Thomas, 2003) (Fig 2.12) (see 
appendix 7 for raw data).  
Ibuprofen had a detection frequency of 92% in sewage effluent (see appendix 8 
for raw data). The mean concentration ranges from ND (Togola & Budzinski, 2007) (not 
shown on graph due to logarithmic scale) to 16.5 µgl
-1
 (Canada) (Metcalfe et al., 2003) 
with a total average mean of 1.47 µgl
-1
 (SD 3.2µgl
-1
) (Fig 2.13). In the UK reported mean 
concentrations range from 213 ngl
-1
 (Bound & Voulvoulis, 2006) to 12.8 µgl
-1
 (Roberts 
& Thomas, 2006) (Fig 2.13 & appendix 8). In Europe the total mean was 1 µgl
-1 
but was 
higher outside of Europe at 2.8 µgl
-1 
(Fig 2.10). 
Much less data exists in the literature for gemfibrozil than carbamazepine, 
ibuprofen and diclofenac. Only four studies were found where a mean concentration was 
presented or could be calculated from raw data and none of these were in the UK (see 
appendix 9 for raw data). The range of means was 4.3 ngl
-1
 to 1.1 µgl
-1
 in sewage effluent 
with an overall average of 233.4 ngl
-1
 (SD 329.3 ngl
-1
) (Fig 2.14). The total mean in 
Europe was 34 ngl
-1
 (Fig 2.10) and is based on only one study in France (Togola & 
Budzinski, 2007). The total mean for MECs outside of Europe of was 402.4 ngl
-1
 based 
on 3 studies, 2 from Canada (Brun et al., 2006; Hua, 2006) and 1 from the USA 
(Vanderford & Snyder, 2006) (Fig 2.10).  
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Paracetamol ranged in concentration from ND (not detected) to 24.5µgl
-1
 within 
sewage effluent (Fig 2.15). Non detections cannot be seen on the graph due to the 
logarithmic scale (see appendix 1 for raw data). The highest concentration was reported 
in the UK (Kasprzyk-Hordern et al., 2009) (Fig 2.15).  The mean reported concentrations 
ranged from 9.5 ngl
-1
 to 11.7 µgl
-1
 and approximately half of all measurements reported 
for paracetamol in final sewage effluent worldwide were zero or below the detection limit 
(see appendix 1 for raw data).  
The range of reported mean concentrations in sewage effluent for propranolol was 
between zero (Pedrouzo et al., 2007) (Spain) and 560 ngl
-1
 (France) (Coetsier et al., 2009) 
(Fig 2.16). The latter was also the highest mean concentration of propranolol in sewage 
effluent found in the literature. The majority of detections fell between 10 and 1000 ngl
-1
. 
Non detections of propranolol were reported four times in 90 sampling events worldwide.  
Trimethoprim concentrations in sewage effluent ranged from zero or below 
detection limit in 16% of sampling events (see appendix 1 for raw data).  The highest 
reported concentration was 7.9 µgl
-1
 (Fig 2.17) which was a mean measurement from the 
USA in 2007 (Batt et al., 2007). The maximum recorded concentration was not published 
in this article. Concentrations of trimethoprim exceeded 1µgl
-1
 regularly across of variety 
of countries worldwide (Fig 2.17) (see appendix 1 for raw data).  
There is a lack of data for measurements of the anti-cancer drug tamoxifen in sewage 
effluents. Tamoxifen has been measured in sewage effluent in just 3 studies, one in 
France (Coetsier et al., 2009) and two in the UK (Hilton et al., 2003; Roberts & Thomas, 
2006). The maximum reported concentration was 740 ngl
-1
 (Roberts & Thomas, 2006) 
(Fig 2.18) and non detections accounted for 78% of sampling events (see appendix 1 for 
raw data). 
 There is also lack of data for measured concentrations of EE2 and fluoxetine in 
sewage effluent. A maximum concentration of 43 ngl
-1
 of EE2 (Soliman et al., 2004) and 
a mean of 7 ngl
-1
 (Desbrow et al., 1998) has been reported (Table 2.6).  For fluoxetine, a 
mean concentration of 560 ngl
-1
 was reported in sewage effluent in the USA (Benotti et 
al., 2007) and a maximum of 73 ngl
-1
 in the U.S.A (Batt et al., 2006) (Table 2.7). 
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Fig 2.15 Measured environmental concentrations of paracetamol in sewage effluent. Individual points represent 
reported concentrations in sewage effluent from the literature. Only positive detections are shown on the graph due to 
the logarithmic scale. Dataset includes 33 non detections (ND) or detections below the limit of quantification (LOQ). 
For raw data and references see appendix 1. 
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Fig 2.16 Measured environmental concentrations of propranolol in sewage effluent. Individual points represent 
reported concentrations in sewage effluent from the literature. Only positive detections are shown on the graph due to 
the logarithmic scale. Dataset includes 4 non detections (ND) or detections below the limit of quantification (LOQ). 
For raw data and references see appendix 1. 
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Fig 2.17 Measured environmental concentrations of trimethoprim in sewage effluent. Individual points represent 
reported concentrations in sewage effluent from the literature. Only positive detections are shown on the graph due to the 
logarithmic scale. Dataset includes 20 non detections (ND) or detections below the limit of quantification (LOQ). For raw 
data and references see appendix 1. 
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Fig 2.18 Measured environmental concentrations of tamoxifen in sewage effluent. Individual points 
represent reported concentrations in sewage effluent from the literature. Only positive detections are shown on 
the graph due to the logarithmic scale. Dataset includes 33 non detections (ND) or detections below the limit 
of quantification (LOQ). For raw data and references see appendix 1.  
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Table 2.6 Reported concentrations of 17 α ethinylestradiol (EE2) in sewage 
effluent (ngl
-1
) (ND: non detections) 
 
Table 2.7 Reported concentrations of fluoxetine in sewage effluent (ngl
-1
) (ND: 
non detection; bld: below detection limit) 
 
Mean Median Minimum Maximum Reference 
7 
   
Desbrow et al., 1998 
ND 
   
Desbrow et al., 1998 
4.3 
   
Desbrow et al., 1998 
0.6 
   
Desbrow et al., 1998 
1.9 
   
Desbrow et al., 1998 
0.2 
   
Desbrow et al., 1998 
0.6 
   
Desbrow et al., 1998 
0.8 
   
Desbrow et al., 1998 
1.3 
   
Kim et al., 2007 
   
43 Soliman et al., 2004 
   
31 Soliman et al., 2004 
   
40 Soliman et al., 2004 
<0.3 <0.3 <0.3 <0.3 Thomas, 2007 
ND 
   
Trenholm et al., 2006 
ND 
  
1 Peng et al., 2008 
    
Zuccato et al., 2005 
2 
   
Zuehlke et al., 2004 
0.4 
   
Zuehlke et al., 2004 
Mean Median Minimum Maximum Reference 
    0 64 Hua et al., 2006 
<60       Hua et al., 2006 
bld bld bld bld Gros et al., 2006 
      1.7 Kim et al., 2007 
  ND ND ND Trenholm et al., 2006 
      1.7 Trenholm et al., 2006 
  ND ND ND Trenholm et al., 2006 
      bld Vasskog et al., 2006 
      1.2 Vasskog et al., 2006 
      1.3 Vasskog et al., 2006 
    40 73 Batt et al., 2008 
560       Benotti & Brownawell, 2007 
25       Vanderford & Snyder 2006 
ND       Jones-Lepp et al., 2004 
58       Schultz & Furlong, 2008 
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2.5.4  Removal of pharmaceuticals by sewage treatment 
The efficiency of sewage treatment plants in the removal of four pharmaceuticals 
carbamazepine, diclofenac, ibuprofen and gemfibrozil was assessed. Differences in 
removal efficiency were striking (Table 2.8). The percent removal of these four drugs 
varied not only between different sewage treatments, but also between different STPs 
employing similar treatments (see appendix 10 for raw data). In fact removal efficiency 
varied day to day at the same STP. The results show that pharmaceuticals both increased 
as well as decreased in concentration after sewage treatment (Table 2.8).  
The removal efficiency for diclofenac was quite varied between sewage treatment 
plants and their practices. Removal efficiencies varied from 4.7% (secondary treatment) 
to 99.8% (tertiary treatment with chlorination). Increases in concentration have also been 
reported. Even when treatments were similar at different STPs the removal efficiency 
varied, a range of 7.1 - 77% removal to a 143% increase was found for diclofenac 
concentration in final effluent after conventional activated sludge treatment (Table 2.8).  
Carbamazepine was very persistent in all sewage treatments and regularly 
increased in concentration. Carbamazepine seemed highly resistant to removal with STPs 
achieving removal efficiency of between 0 to 30% and a maximal reported increase in 
concentration of 43.1%. 
Ibuprofen removal ranged from 0 to 100%. Several increases in concentration of 
ibuprofen have been reported (Table 2.8).  There was a lack of data for gemfibrozil but 
available figures suggest its removal can vary from 0 to 100% An increase in 
concentration for gemfibrozil after sewage treatment in a lagoon has also been reported 
(Lishman et al., 2006) (See appendix 10 for raw data). 
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Table 2.8 Sewage treatment efficiencies 
(Percent removal or increase calculated by [Cinfluent - Ceffluent]/Cinfluent x 100).  
References: Lishman et al., 2006; Clara et al., 2005; Gomez et al., 2007; Kasprzyk-Hordern et al., 2009; 
Radjenovic et al., 2009; Bendz et al., 2005; Stumpf et al., 1999; Ternes et al., 1998; Buser et al., 1998; 
Sebok et al., 2008; Thomas et al., 2007; Spongberg & Witter 2008; Kasprzyk-Hordern et al.,2008; 
Quintana et al., 2007; Vanderford & Snyder 2006; Kimura et al., 2007; Santos et al., 2005; Santos et al., 
2007; Santos et al., 2009; Carballa et al., 2004; Buser 1999; Roberts & Thomas 2006; Sebok et al., 2008; 
Metcalfe et al., 2003; Weigel et al., 2004; Benotti & Brownawell 2007; Leclerq et al., 2008; Miao et al., 
2005; Vieno et al., 2006; Zhou et al., 2009) 
Pharmaceutical Sewage Treatment Removal (%) Increase (%) 
diclofenac activated sludge                                                                                                          7.1-77 143 
  activated sludge & trickling filter 9   
  trickling filter  9 75.7 
  secondary (not specified) 4.7-51.6 128.1 
  Tertiary 55.1   
  tertiary and chlorination 99.8   
  membrane bioreactor 32.9-50.6 6.6 
ibuprofen Primary 0 13.3 
  activated sludge  75-100 4.4 
  biological trickling filter  22-93.9   
  secondary (not specified) 64.6-80.7 52.8 
  secondary & disinfection 51.5-100 100 
  activated sludge & biological trickling filter  44.6   
  activated sludge & biological trickling filter & UV 86.8   
  membrane bioreactor  90-99.2   
  Tertiary 96.5-100 104.1 
  Lagoon 98.7-100   
carbamazepine activated sludge  0-30 43.1 
  activated sludge + UV 29.5   
gemfibrozil activated sludge 0-74.6   
  Lagoon   127 
  tertiary and chlorination 99.8   
  biological trickling filter 16   
  secondary (not specified) 81-96   
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2.5.5 Population size and pharmaceutical concentration 
Sewage effluent is thought to be the main source of pharmaceuticals in the aquatic 
environment. The concentrations of four pharmaceuticals in sewage effluent were 
examined in regard to the number of people served by an STP. There was no significant 
correlation (95% confidence limits) between concentrations of ibuprofen (n=56), 
gemfibrozil (n=25), diclofenac (n=53) and carbamazepine (n=65) in final sewage effluent 
and the size of population served by the STP when all sewage treatment technologies 
were pooled (Fig 2.19 – 2.21). When the data was broken down between four broad 
categories of sewage treatment; secondary biological, tertiary, ultra violet disinfection 
and final chlorination, there was still no positive correlation at 90% confidence limits 
between population size and levels of carbamazepine, diclofenac and ibuprofen in final 
effluent. Gemfibrozil was the only pharmaceutical to show a positive correlation, (95% 
confidence limit), between increasing population size and increasing pharmaceutical 
concentration in secondary biological (25 degrees of freedom) and activated sludge 
sewage effluent (Fig 2.2) (11 degrees of freedom) (See appendix 11 for raw data). 
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Fig 2.19 Reported concentrations of carbamazepine in sewage effluent and capacity of sewage treatment plant.  
Correlation between the size of population serviced by the sewage treatment plant and carbamazepine concentration was 
not significant at 95% (n=65). (for raw data see appendix 11). A logarithmic scale used to incorporate wide ranging data. 
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Fig 2.20. Reported concentrations of diclofenac in sewage effluent and capacity of sewage treatment plant. 
Correlation between the size of population serviced by the sewage treatment plant and diclofenac concentration was not 
significant at 95% (n=53). (for raw data see appendix 11).  
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Fig 2.21 Reported concentrations of  ibuprofen in sewage effluent and capacity of sewage treatment plant. 
Correlation between the size of population serviced by the sewage treatment plant and ibuprofen concentration was not 
significant at 95% (n=56). (for raw data see appendix 11). A logarithmic scale used to incorporate wide ranging data. 
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Fig 2.22 Reported concentrations of gemfibrozil in sewage effluent and capacity of sewage treatment plant. 
Correlation between concentrations of gemfibrozil and the size of the poulation served by the Sewage treatment plant was 
significant at 95% (n= 25) (for raw data see appendix 11).  
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2.5.6  Comparison of sewage effluent and receiving waters pharmaceutical 
concentrations 
The results of this study show that the concentration of the four investigated 
pharmaceuticals, carbamazepine (Fig 2.23a), diclofenac (Fig 2.23b), ibuprofen (Fig 2.23c) 
and gemfibrozil (Fig 2.23d) increased as well as decreased in receiving waters 
downstream from the sewage outfall in comparison to final sewage effluent concentration.  
Despite this finding, on the whole results indicated that the majority of surface water 
concentrations were less than the sewage outfall. However the results also show that the 
concentration was not reduced by 90% of the original concentration in all cases and 
therefore surface water dilution was less than the default factor of ten specified in the 
EMEA guidelines for calculation of predicted surface water concentrations.  
Interestingly, when comparing the total mean concentrations calculated for 
surface water (Fig 2.2-2.5) with the total mean concentrations calculated for sewage 
effluent (Fig 2.11-2.14), the difference was approximately an order of magnitude. This 
indicates that overall that sewage outfall dilution was probably around a factor 10. 
However, this does not account for variations in dilution in different water bodies. 
It was not possible to assess the effect of distance downstream from sewage 
outfall due to the lack of data in the published literature. The distance from sewage 
outfall downstream was not always specified and analysis of a range of distances 
downstream and upstream was rarely performed. 
The data available in the published literature was too varied and inconsistent to 
compare the effect of season on surface water concentration. Data was often provided 
over a long monitoring period for example a mean of 12 samplings over a 6 month period. 
Data about other sewage discharges, river flow, rainfall, temperature and pH was not 
usually stated.  
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Fig 2.23 a-2.23d Surface water dilution, shown as percent change in concentration from sewage outfall to receiving surface 
water 
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Fig 2.23a Carbamazepine 
increase in concentration decrease in concentration 
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Fig 2.23b Diclofenac 
decrease in concentration increase  in concentration 
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Fig 2.23c Ibuprofen 
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Fig 2.23d Gemfibrozil 
decrease in concentration increase in concentration 
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2.5.7 Comparison of predicted and measured pharmaceutical concentrations 
Accurately predicting concentrations of pharmaceuticals in the environment is an integral 
part of any environmental risk assessment. To assess the validity of the current calculation used 
to predict surface water concentrations several investigations were performed.  
Firstly the published literature was searched for studies where the predicted 
environmental concentration (PEC) for surface water of one of the ten selected pharmaceuticals 
selected for investigation was compared to a measured environmental concentration (MEC). 
Only 6, out of over 500 articles reporting concentrations of human pharmaceuticals in surface 
waters, directly compared surface water PECs and MECs in Europe for carbamazepine, 
diclofenac, ibuprofen, paracetamol, propranolol, tamoxifen and trimethoprim (Table 2.9). No 
data comparisons were found for gemfibrozil or fluoxetine. Two of these six studies found the 
MEC never exceeded the PEC (Ashton et al., 2004; Letzel et al., 2009). However Letzel et al., 
(2009) reported a PEC that had not been refined for metabolism, removal during sewage 
treatment or environmental degradation, equal to the MEC.  
Overall, nearly 40% of MECs (9 out of 24) exceeded the related PECs.  Paracetamol 
(Bound & Voulvoulis, 2006), ibuprofen (Bound & Vouvoulis, 2006; Castiglioni et al., 2004), 
diclofenac (Coetsier et al., 2009), propranolol (Ferrari et al., 2004), tamoxifen (Coetsier et al., 
2009) and carbamazepine (Coetsier et al., 2009 and Ferrari et al., 2004) were all detected above 
the PEC at least once (Table 2.9).  
The crude calculation of the PEC, however, in general was predominantly above or 
aligned to the MEC calculation. When the MEC exceeded the PEC it was regularly only by the 
maximum recorded concentration. In the case of ibuprofen, paracetamol and tamoxifen PECs 
refined for loss due to metabolism in the body, sewage treatment or environmental degradation 
tended to be underestimates of MECs (Table 2.9). 
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Table 2.9 Predicted (PECs) and Measured (MECs) concentrations from the literature (ngl
-1
) 
(N = no; Y = yes; ND = not detected; STP: sewage treatment plant) 
 
Pharmaceutical Country Reference PEC 
MEC 
(mean) 
MEC 
(Max) 
MEC 
(median) MEC>PEC Refinements 
paracetamol UK Ashton et al., 2004 76400 nd nd   N   
  UK Bound & Voulvoulis, 2006 210 100 550 
 
Y Phase 11B EMEA 
  UK Bound & Voulvoulis, 2006 20,000 100 550 
 
N Phase 1 EMEA 
  UK Bound & Voulvoulis,2006 64,690 100 550   N Phase 11A EMEA 
ibuprofen UK Ashton et al., 2004 10800 1105 5044 
 
N   
  UK Bound & Voulvoulis, 2006 65 370 3080 
 
Y Phase 11B EMEA 
  UK Bound & Voulvoulis, 2006 6000 370 3080 
 
N Phase 1 EMEA 
  UK Bound & Voulvoulis, 2006 4310 370 3080 
 
N Phase 11A EMEA 
  France Coetsier et al., 2009 101 
 
26 13 N excretion & removal in STP 
  Italy Castigliglioni, 2004 45 7 9.8 
 
N   
  Italy Castigliglioni, 2004 3 7 9.8   Y excretion and half life 
diclofenac UK Ashton et al., 2004 1090 154 568 
 
N   
  France Coetsier et al., 2009 72 
 
107 67 Y excretion & removal in STP 
  Germany Ferrari et al., 2004 1810 
 
1200 
 
N   
  Germany Letzel et al., 2008 140 10.4 140   N 
 
propranolol UK Ashton et al., 2004 365 41 215 
 
N   
  UK Bound & Voulvoulis 2006 <2 <4 <4 
 
Y Phase 11B EMEA 
  France Coetsier et al., 2009 121 
 
113 89 N excretion & removal in STP 
  Germany Ferrari et al., 2004 120   590   Y   
tamoxifen UK Ashton et al., 2004 63 ND ND 
 
N   
  France Coetsier et al., 2009 7   25 11 Y excretion & removal in STP 
trimethoprim UK Ashton et al., 2004 289 12 42   N   
carbamazepine France Coetsier et al., 2009 156   675 346 Y excretion & removal in STP 
  Germany Ferrari et al., 2004 1930   2100   Y   
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The relationship between PECs and MECs was investigated further by applying 
the equations in the EMEAs guidelines to the ten investigated pharmaceuticals using first 
Eq 1 and then Eq 2 (see methods Section 2.4.4.1). These equations gave substantially 
different PEC values (Table 2.10).  Equation 1 was set out in the EMEA CHMP 
guidelines (2006) and despite the assumptions and crude nature of the calculation, the 
resultant PECs were predominantly above or in line with MECs found in the literature 
(Table 2.11). There were some exceptions, however. Several MECs for diclofenac 
exceeded the calculated 1 μgl-1 PEC, including MECs of 15 μgl-1 (Jux et al., 2002) and 
1.2 μgl-1 (Ternes et al., 1998). Carbamazepine exceeded the PEC of 4 μgl-1 once, with a 
maximum concentration of 7.1 μgl-1 reported in Germany (Weigel et al., 2004).   
There were no reports of trimethoprim exceeding the PEC of 1 μgl-1 but MECs 
fell in the same range e.g. 0.7 μgl-1  (Kolpin et al., 2002) and 0.5 μg/L (Batt et al., 2008). 
These two measurements were made in the USA but are still relevant to consider in 
respect of Eq 1 since the only variable is maximum daily dose with no location specific 
data incorporated. Default data for the other parameters is specified in the guidelines. The 
calculated PEC 1 of 0.2 μgl-1 for tamoxifen matched two measurements in a UK study by 
Roberts and Thomas, (2006). No MECs were found in the literature above the calculated 
PEC 1 for gemfibrozil, fluoxetine, propranolol, ibuprofen or paracetamol.  
 
Table 2.10 Predicted environmental concentrations (PECs) for England  
PEC 1 calculated using the default market penetration factor of 1%, PEC 2 calculated using prescription 
data in England (2008) (
a
Dose ai = maximum daily dose). 
 
 
 
 
 
 
 
 
 
Pharmaceutical 
Dose ai
a
 
(mg) 
PEC 1 
(μgl-1) 
Consumption 
(Kg) 
PEC 2 
(μgl-1) 
carbamazepine 800 4 45705 1.22 
diclofenac 200 1 26442.7 0.70 
gemfibrozil 1200 6 755.3 0.02 
fluoxetine 80 0.4 4435.4 0.12 
trimethoprim 200 1 9736.6 0.26 
tamoxifen 40 0.2 521.4 0.01 
propranolol 640 3.2 7784.5 0.21 
ibuprofen 3200 16 330292 8.79 
paracetamol 3900 19.5 3534737 94.02 
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Table 2.11 Measured environmental concentrations (MECs) for England (ngl
-1
) 
(E = effluent; SW = surface water; - = not analysed; MECs exceeding PEC 2 are highlighted in bold). 
Reference Matrix carbamazepine diclofenac trimethoprim tamoxifen propranolol ibuprofen paracetamol 
Hilton et al., 2003 E – 2350 1290 42 284 27,300 – 
Roberts & Thomas, 2006 E – 598 414 740 414 15,778 <20 
Hilton & Thomas 2003 E – 460 270 <10 180 3,800 <50 
Bound & Voulvoulis, 2006 E – – – – – 391 281 
Zhou et al., 2009 E 1061 176 – – 135 – – 
Zhang et al., 2008 E 652 85     72     
Hilton et al., 2003 SW – 568 42 <10 215 5,040 – 
Roberts & Thomas, 2006 SW –   19 198 107 2370 <20 
Bound & Voulvoulis, 2006 SW – – – – <4 3080 555 
Hilton & Thomas, 2003 SW – 91 39 <10 37 <20 <50 
Zhou et al., 2009 SW >350 <50 – – >50 – – 
Zhang et al., 2008 SW >200 25     <25     
Thomas & Hilton, 2004 SW – 195 569 71 56 928 – 
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When Eq 2 (consumption/prescription data) was used to calculate the PEC, a 
much smaller value was obtained than for Eq 1 PEC 1, except in the case of paracetamol 
(Table 2.10). This is a reflection of Paracetamol having a higher market penetration 
factor than the default 1%. The PECs derived from Eq 2 were calculated using actual 
consumption data for 2008 in England and then compared with the maximum 
concentrations reported in the literature between 2000 and 2011. A total of 8 studies from 
2003-2011 were found (Table 2.11). It should be noted that sales of drugs differ year to 
year and the prescription data collected for 2008 may differ from precise prescription 
amounts in each of the years in which data was reported. However this was the most 
recent prescription data available.  
Maximum surface water concentrations have been reported above the PECs 
generated in Eq 2 (PEC 2) for tamoxifen, trimethoprim and propranolol (Table 2.11).  No 
MEC data was available for either gemfibrozil or fluoxetine representing a substantial 
knowledge gap. Both had PECs greater than 10 ngl
-1
 the action limit for further risk 
assessment.  
 
2.5.7.1 Site specific MEC and PEC comparison 
In order to provide a more robust comparison of the PECs and MECs, it was 
desirable to assess information on the specific locations used to sample for surface water 
pharmaceutical concentrations. However, in general the articles containing concentration 
data lacked the information necessary (see Table 2.12). The dilution of effluent to 
receiving water was not specified in any of the publications despite common analysis of 
effluent and receiving water pharmaceutical concentrations. The capacity of the STP was 
however, often supplied. According to the EMEA guidelines PECs for local surface water 
concentration can be refined by the following equation: as: 
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[Eq  3] 
Elocalwater * Fstp water 
PECSURFACEWATER = -------------------------------------------------------------------------------- 
WASTEWinhab * CAPACITYstp * Factor * Dilution 
 
 
Where: 
Elocalwater = DOSEai * Fexcreta * Fpen * CAPACITYstp 
Fstp water = Fraction of emission directed to surface water (calculated by simple Treat)  
WASTEWinhab = wastewater production per person per day (default 200L) 
CAPACITYstp = capacity of local sewage treatment plant 
Dilution = dilution factor (default 10) 
Factor  = Factor taking the adsorption to suspended matter into account 
 
 
The information required to carry out further refinements of the PECs for local water 
using the equation was not available in the majority of publications (Table 2.12). In 
particular the Fstp water (Fraction of emission directed to surface water) and Factor 
(Factor taking the adsorption to suspended matter into account) data was not included in 
any of the articles examined. It appears imperative that the standards of reporting for 
environmental concentration data in peer reviewed journals is improved in order to make 
data usable for environmental risk assessments and policy development (see Section 
2.5.9). 
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Table 2.12 Information availability in published literature for measured concentrations of pharmaceuticals in surface waters 
(MECS). Fstp water = Fraction of emission directed to surface water and Factor (Factor taking the adsorption to suspended matter 
into account) was not included in any of the articles examined. (LOD; limit of detection; NP: not provided, POCIS: polar organic 
integrative passive sampler, PE: population equivalents). 
Reference Pharmaceutical LOD Location Dilution CAPACITYstp Date Sample 
Size 
Sampling 
Method 
Roberts & 
Thomas, 2006 
propranolol 
tamoxifen 
ibuprofen 
trimethoprim 
10 
10 
10 
10 
River Tyne 
(6 sites) 
NP NP 14
th
 June Triplicate 
(2.7L) 
12hr 
composite 
Thomas & 
Hilton, 2004 
Diclofenac 
Ibuprofen 
Paracetamol 
propranolol 
Tamoxifen 
trimethoprim 
8 
8 
20 
4 
4 
4 
River Tyne 
River Tees 
River Mersey 
River Thames 
NP NP October & 
November 
2002 
2.7L grab 
Bound & 
Voulvoulis, 
2006 
Ibuprofen 
Paracetamol 
propranolol 
2-4 River Thames 
& a small 
unnamed  river 
in the South 
East 
NP 1.8million & 
150,000 
2003-2004 
(12 week 
period) 
47 samples 
& 13 
samples (1L) 
Composite 
and grab 
Zhang et al., 
2008 
Propranolol 
Carbamazepine 
Diclofenac 
6-487 pg/L (not 
specified for each 
pharmaceutical or 
method) 
River Ouse, 
West Sussex 
NP NP 23-27 
October 
NP POCIS & 
spot 
samples 
Hilton et al., 
2003 
Trimethoprim 
Paracetamol 
Ibuprofen 
Diclofenac 
Propranolol 
Tamoxifen  
10 
50 
20 
20 
10 
10 
Corby 
Great Billing 
East Hyde 
Harpenden 
Ryemeads 
NP 150,000 
296,100 
143,801 
31,905 
365,071 
May-July 
2002 
Sampled 
once each 
month 
(2.7L) 
Grab 
Zhou et al., 
2009 
Carbamazepine 
Diclofenac 
propranolol 
1-288 pg/L (not 
specified for 
individual 
pharmaceuticals 
River Ouse, 
West Sussex 
NP 162,619 November 
2006 
NP NP 
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2.5.8 Reported concentrations of pharmaceuticals in other matrixes 
Carbamazepine, diclofenac, ibuprofen and gemfibrozil have been detected in 
coastal and marine waters and drinking water (Table 2.13).  
 
Table 2.13 Range of concentrations of pharmaceuticals reported in drinking water, 
groundwater and marine water (ngl
-1
) 
 
Generally there was a lack of data for measured concentrations of 
pharmaceuticals in drinking water, groundwater and marine waters. The maximum 
concentration for carbamazepine detected in drinking water was 43.2 ngl
-1
 in the 
Mediterranean, France (Togola & Budzinski, 2008). In the same study a range of 
concentrations for the coastal waters in the Mediterranean was ND-56.3 ngl
-1
 (Table 
2.13). This is the only report of carbamazepine in marine or coastal waters. However, in a 
more comprehensive study of drinking water in the USA, including 18 different locations, 
carbamazepine was detected at a median level of 6 ngl
-1
 and a maximum of 18 ngl
-1
 
(Benotti et al., 2009). The maximum concentration of carbamazepine measured in 
groundwater after infiltration with treated sewage effluent was 1260 ngl
-1
 (Kreuzinger et 
al., 2004). Although this was the highest reported figure it was representative of general 
findings (Drewes et al., 2003, Sacher et al., 2001).  
Diclofenac has been detected at a maximal concentration of 900 ngl
-1 
in 
groundwater (Kreuzinger et al., 2004). However, it was not detected in this matrix in over 
half ofsamples analysed. Diclofenac has been detected in drinking water at maximal 
concentrations of 2.5 ngl
-1 
in the USA and 6 ngl
-1 
in Germany (Jones et al., 2005). The 
highest marine and coastal measurement of diclofenac was 195 ngl
-1 
in the Mersey 
estuary in the UK (Thomas & Hilton, 2004). This study sampled 22 UK estuaries, 15 of 
which were below the detection limit of 8 ng l
-1 
for diclofenac. A similarly high 
 Carbamazepine Diclofenac Gemfibrozil Ibuprofen 
Coastal & marine water 0 - 56.3 0 - 195 0 - 53 0 - 928 
Ground water <5 – 1260 0 - 900 0 - <20 0 - 200 
Drinking water 43.2 2.5 0 - 70 0 - 1350 
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concentration of 191 ngl
-1
 was also found in the Tees. Another study of coastal waters in 
Norway did not find concentrations of diclofenac above 0.7 ngl
-1 
(Weigel et al., 2004). In 
Canada the maximum concentration was 6 ngl
-1
 (Comeau et al., 2008). 
Maximum concentrations of ibuprofen have been detected in estuarine water of 
the Thames, UK at 928 ngl
-1 (Thomas & Hilton, 2004), in Canada’s coastal waters at 230 
ngl
-1
 (Comeau et al., 2008) and in Norway at 0.7 ngl
-1 
(Weigel et al., 2004). Ibuprofen 
has been rarely detected in groundwater although a maximum detection of 200 ngl
-1 
was 
recorded in Berlin (Herberer et al., 1998). Ibuprofen has been detected in drinking water 
at a concentration of 1.35 µg l
-1 
(Loraine & Pettigrove, 2006). 
Gemfibrozil was detected in drinking water in 7 of 18 samples at a median 
concentration of 0.48 ngl
-1 
and a maximum of 2.1 ngl
-1 
in the USA (Benotti et al., 2009). 
There were four other studies of gemfibrozil in drinking water, two non detections, a 
maximum detection of 0.8 ngl
-1 
 (Loo’s et al., 2007) and a highest reported concentration 
of 70 ngl
-1 
 (Tauber, 2003). There has been no analysis of gemfibrozil in the UK. Only 
one sea water analysis of gemfibrozil has been undertaken, in the coastal waters of 
Canada. Here gemfibrozil was detected 3 times out of 31 samples at a maximum 
concentration of 53 ngl
-1
 (Comeau et al., 2008). Gemfibrozil has not been detected above 
the detection limit in groundwater. 
 
2.5.9 Critical analysis of reporting methods and standards for pharmaceuticals in 
surface waters and sewage. 
Meaningful interpretation of data from peer reviewed literature for 
pharmaceuticals in the aquatic environment was severely hampered by poor reporting 
standards. Generally all reports had important information missing. Only 4 out of 128 
articles (3%) published in peer reviewed literature met the criteria to allow useful 
analysis of environmental fate, mobility and longevity of pharmaceuticals (Table 2.13). 
Even then 3 of these articles only examined sewage effluent and not the receiving waters. 
Distance from sewage outfall and direction of water flow criteria therefore were not 
applicable in these cases. 
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The articles always adequately described the detection methods and generally a 
detection limit or quantification limit for that method was provided. The main difference 
between sample collections was grab or composite samples. Some publications used both, 
some did not state which approach was used. Statistical analysis of results varied with 
publication. The mean was most commonly used statistical analysis accounting for 38% 
of publications, 63% of these calculated a standard deviation about the mean. Many other 
publications reported the maximum, minimum, range or median concentration found. 
There were, however, a large number of publications which reported a single grab sample 
measurement. The sample size was specified in less than half of articles examined. The 
method of sewage treatment was stated in 66% of cases however the detail in which it 
was presented varied considerably. Some articles examined concentrations of 
pharmaceuticals in sewage effluent without ever mentioning the treatment type. One fifth 
of publications did not include a date or season for their sampling. Other criteria and 
parameters which were rarely included in articles were biological oxygen demand, 
sewage retention times, hydraulic retention times, age of sewage, temperature, pH and 
time of day samples were taken.  
Table 2.14 Publications meeting the sound science criteria 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Criteria Publications (%) 
Date 80 
Mean 38 
Standard deviation 24 
Sample size  46 
Replicates performed 18 
Direction of water flow 50 
Distance from sewage outfall 57 
Population size 74 
Sewage treatment 66 
Flow rate of effluent or surface water 47 
All criteria met 3 
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2.6 Discussion 
The data mining exercise performed for environmental occurrence and fate data 
for the ten pharmaceuticals investigated revealed that they are frequent pollutants of the 
aquatic environment. They have all been detected in the ng - µgl
-1 
range in surface waters 
and sewage effluents worldwide. 
 
2.6.1 Surface water concentrations in freshwater systems 
Concentrations of pharmaceuticals in surface waters vary considerably from non 
detections to several micrograms per litre (Fig 2.1-2.5). Although data is not available for 
every one of the 3000 or so licensed pharmaceuticals, the results indicate that they will be 
present in parts per trillion to parts per billion range in surface waters wherever they are 
being consumed. The findings show that data can vary by an order of magnitude from 
one sample to another (Fig 2.1-2.5). This was not only the case between MECs from 
different water bodies but also when the same water body was sampled at different times 
of day, e.g. the measurements taken in a study by Zhou et al., (2009). MECs were 
compiled from over 15 countries in 3 continents and therefore it is fair to conclude that 
this situation is congruous worldwide. The variation in concentrations of pharmaceuticals 
in surface waters is best highlighted by the fact that, when mean  MECs for 
carbamazepine, diclofenac, ibuprofen and gemfibrozil were analysed, the standard 
deviation for these results was so large that it could not be shown on the graph (Fig 2.1). 
This finding brings into question the applicability of using a default PEC to represent the 
concentration of a pharmaceutical in any water body in Europe (see Section 2.6.4). 
Carbamazepine (Fig 2.2), diclofenac (Fig 2.3), ibuprofen (Fig 2.4), gemfibrozil 
(Fig 2.5), trimethoprim (Fig 2.6), paracetamol (Fig 2.7) and propranolol (Fig 2.8.) are 
regularly detected in surface waters worldwide. Considerably less data is available for 
tamoxifen but it was detected in studies where it has been measured (Fig 2.9). This 
highlights a data need for this anti-cancer drug especially in light of the fact that this 
compound targets the same receptor as EE2, the oestrogen receptor (see Section 4) and 
has log kow of 6.3 (Table 2.1). With reference to the OSPAR Convention, any 
pharmaceutical with a log Kow of > 4.5 should be screened for persistence, 
bioconcentration and toxicity (PBT; European Chemical Bureau, 2003). Despite the wide 
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variation in surface water concentration, eight out of the ten pharmaceuticals investigated 
from the published literature frequently had a mean measured concentration above the 10 
ngl
-1
 action limit set by the EMEA for further environmental risk assessment (Table 2.5). 
This finding is important when considering the effects these compounds may be having 
on non target organisms. If mean concentrations are regularly above 10 ngl
-1
, then 
maximal concentrations will be far greater. This finding indicates a need for retrospective 
risk assessment of these pharmaceuticals. Chronic ecotoxicity studies need to be 
performed for these compounds in order to determine the PNEC and the RQ so that the 
environmental concentrations can be put into context. Retrospective risk assessment for 
these compounds would help reduce the scientific uncertainty about what effects they 
may be having on aquatic ecosystems and determine whether action should be taken to 
mitigate these risks. 
There was a lack of surface water concentration data for ethinylestradiol (EE2) 
and fluoxetine (Table 2.3 & 2.4). Available data reveals that these two pharmaceuticals 
did not generally exceed the 10 ngl
-1
 action limit. This is not surprising for EE2 since the 
therapeutic dose is relatively small in comparison to other drugs. The recommended daily 
dose for EE2 is 0.03 mgs (RX list), and is only prescribed to women of reproductive age. 
The average excretion of EE2 per person per day is 0.89µg and sewage treatment 
removes 65-85% of this (Jobling et al., 2006). The recommended initial adult daily dose 
for adults for fluoxetine is much higher than EE2 at 20 mgs (RX list) and the excretion 
rate of fluoxetine is reportedly between 17 and 25% (Carballa et al., 2008). Removal in 
tertiary sewage treatment plants has been shown to be greater than 90% (Zorita et al., 
2008). Environmental concentrations of both pharmaceuticals are likely to be small as a 
consequence. This was supported by the MECs reported in the literature (Table 2.3 & 
2.4). The method detection limits reported for these compounds were generally quite low 
e.g. 0.5 ngl
-1
 for both compounds (Peng et al., 2008; Vanderford & Snyder, 2006). This 
suggests that these compounds are often not present in surface waters.  
Both these compounds are endocrine disrupters which have an effect on hormone 
regulation. EE2 has attracted a lot of attention over the past decade and has been studied 
extensively. It is a highly potent endocrine disrupter shown to cause intersex 
characteristics in fish downstream from sewage treatment plants (Jobling et al., 2002) and 
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has been shown to cause adverse affects on non target organisms at concentrations as at 
less than 1 ngl
-1
 (Caldwell et al., 2000). This indicates a disparity between the MEC data 
and the effects observed in the environment. One potential reason for this may be that 
naturally occurring oestrogens such as oestriol and oestrone are producing combined 
endocrine disrupting effects in wildlife (Liu et al., 2010). 
Fluoxetine is in the top 100 prescribed drugs in the UK and USA and is also 
attracting interest due to environmental concerns. Several chronic ecotoxicity studies 
have been published recently indicating that fluoxetine may cause effects on behaviour 
and reproduction of aquatic organisms (Painter et al., 2009; Foster et al., 2010; De-Lange 
et al., 2006; Mennigen et al., 2010).  In an ERA performed by Oakes et al., (2010) an RQ 
of greater than 1 was obtained, indicating a potential risk to the environment for 
fluoxetine. However the data collected in this study indicate that it is rarely detected in 
surface water (Table 2.3). 
Fluoxetine’s principal metabolite is norfluoxetine, which is also pharmaceutically 
active and considered to be more potent than the parent compound (Fong & Molnar, 
2008). The findings of this study show that this is one of the only metabolites of 
pharmaceuticals that have been measured in the environment (see appendix 1). The 
Environment Agency produced a briefing note in April 2005 for fluoxetine, which 
concluded that if monitoring revealed fluoxetine or its metabolite, norfluoxetine are 
present in rivers in England and Wales they will be at levels too low to cause acute 
impacts (EA, 2005). However, it was considered that monitoring data for rivers and 
sewage works in England and Wales was needed. At present this has not been carried out. 
The ERA of human pharmaceuticals currently only applies to applications for 
marketing authorisation of new medicines. Licensing applications for carbamazepine, 
diclofenac, gemfibrozil, ibuprofen, paracetamol, propranolol, trimethoprim and 
tamoxifen as new medicines would require phase 11 of the ERA including 
ecotoxicological examination as the findings of this study show that they are all present 
in the environment at concentrations above the 10 ngl
-1
 action limit. The EMEA ERA 
processes any pharmaceuticals which are known to affect reproduction of vertebrates and 
lower animals are exempt from the action limit of 10 ngl
-1
. Consequently fluoxetine and 
EE2 would require the second phase of ERA if being licensed today. Presently no official 
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retrospective risk assessments have been performed for any existing pharmaceuticals in 
the UK (Private communication with the EA). However the EA (England and Wales) has 
concluded that the weight of evidence for endocrine disruption in fish is sufficient to 
develop a risk management strategy for estrogenically active effluents that discharge to 
the aquatic environment (Gross-Sorokin et al., 2006). 
The Environment Agency conducted an extensive study in 2003 on 
pharmaceuticals in surface waters in the south of England. The conclusion of this was 
that concentrations of pharmaceuticals were too low to be of environmental concern. The 
study was hampered by two issues, a lack of analytical methods for measuring many 
pharmaceuticals that had been prioritised as potentially problematic and a lack of chronic 
ecotoxicity data for the majority of the pharmaceuticals investigated. The study only 
related impacts to acute toxicity data, which does not reflect the actual exposure situation.   
The situation for aquatic organisms to human pharmaceuticals is a chronic low level 
continual exposure to a considerable mixture of drugs.  
2.6.1.1 Degradation 
The rate of degradation of pharmaceuticals in the environment is a contributing 
factor in their surface water concentration. Breakdown of some pharmaceuticals e.g. 
diclofenac and propranolol are dependant on sunlight, (Buser et al., 1998; Yamamoto et 
al., 2009) while this is not the case for others e.g. fluoxetine (Kwon & Armbrust., 2006). 
The findings of this research show that diclofenac is detected regularly in surface waters 
at an overall total mean concentration of 40.7 ngl
-1
 and a maximum mean of 272 ngl
-1
 
(Fig 2.3) despite a rapid half life of less than one day (Zuccato et al., 2000). This suggests 
that although photolysis is an important degradation mechanism, continual discharge, 
environmental distribution affecting exposure to sunlight and the possibility of 
accumulation in some environmental compartments are contributing factors to the overall 
surface water concentration. This finding supports the theory that the continuous input of 
pharmaceuticals causes a pseudo persistence effect even when they are readily degraded 
(Daughton & Ternes, 1999).   
Ibuprofen was also frequently detected at high concentrations in the aquatic 
environment (Fig 2.4) even though it also has a reported environmental half life of <1day 
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(Castiglioni et al., 2004). High consumption of ibuprofen is probably the main reason for 
its high detection rate (Table 2.1). A half life of 660-9900 hours has been reported in 
photolysis experiments, considerably more than diclofenac. In fact biodegradation by 
microorganisms is thought to be a more important removal mechanism for this 
pharmaceutical (Yamamoto et al., 2009).  
Adsorption to sediments may occur for some pharmaceuticals effectively 
removing them from the water body. Octanol-water partition coefficients (log Kow) have 
been shown to be poor indicators of actual adsorption of pharmaceuticals because of their 
ionic nature (Williams et al., 2006; Oppel et al., 2004). Carbamazepine has a low 
sorption coefficient (Scheytt et al., 2005). However, nearly seventy times the 
concentration of carbamazepine was measured in river sediment compared to the water 
column in the USA (Thacker, 2005). Diclofenac, ibuprofen and trimethoprim have also 
been shown to have some sorption to particles (Khunjar & Love, 2011). Fluoxetine also 
has a low sorption coefficient (Monterio, 2008), which is below the action limit for 
terrestrial risk assessment. However, it has been found in high concentrations in sludge 
and sediments (Kwon & Armbrust, 2006). This may account for the lack of detections 
and low concentrations measured in surface waters found in this study. Fluoxetine is one 
of the most persistent pharmaceuticals in the environment raising concerns about 
accumulation (Redshaw et al., 2008). It is resistant to bacterial biodegradation, photolysis 
and hydrolysis in the environment and has a half-life greater than 100 days (Kwon & 
Armbrust, 2006).  
The degradability and persistence of pharmaceuticals in water and sediment is of 
great importance to chronic exposure of aquatic organisms however there is little data 
available on degradation (Calisto & Esteves, 2009). It is crucial that pharmaceutical 
sediment concentrations and their bioavailability to aquatic organisms are assessed.  
2.6.2 Sewage effluent 
The results of this comprehensive study found that all ten of the pharmaceuticals 
investigated were regularly detected in sewage effluents worldwide. The concentrations 
reported are quite varied although always within the ng –μgl-1 range. The most likely 
explanation for such variability in effluent concentration data is sewage treatment 
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efficiency and is probably one reason for the difficultly in accurately predicting surface 
water concentrations (see below).   
Sewage treatments appear not to remove pharmaceuticals effectively. Differences 
in removal efficiency were striking (Table 2.8). The removal of carbamazepine, 
diclofenac, ibuprofen and gemfibrozil by different STPs was calculated wherever 
possible within individual studies reported in the literature. The results show that removal 
efficiency varied between STP and treatment type, (biological, physico-chemical). The 
season and weather conditions within the same plant also affected efficiency (Santos et 
al., 2009; Gomez et al., 2007). The results show that removal efficiency varied 
substantially even for the same pharmaceutical, at the same plant under the same 
conditions (Tauxe-Wuersch et al., 2005). 
  One finding of this study was that STP technologies and methods vary 
considerably and that these variations can affect the removal efficiencies of 
pharmaceuticals (Table 2.8). This means it is difficult to make accurate predictions about 
removal rates of pharmaceuticals after sewage treatment. Not only do removal 
efficiencies vary between different drugs, removal rates for the same pharmaceutical 
differ due to a variety of factors. These include the treatment level employed, (primary, 
secondary, tertiary), the method (activated sludge, trickling filter, lagoon etc) hydraulic 
retention times (HRT), sludge retention times (SRT), biological oxygen demand (BOD), 
pH, and temperature (Zabczynski et al., 2010; Zorita et al., 2009). These continually 
altering variables at the same STP and between STPs make pharmaceutical removal 
predictions very difficult and complex. These variables are not taken into account 
sufficiently well when applying STP removal to PECs. For example the results from 19 
separate studies where sewage treatment removal could be calculated for diclofenac, 
percent removal ranged from as little as 4.7 %  in a modern 3 stage biological plant to 
99.8% after tertiary treatment and chlorination (Table 2.8 & appendix 10). One of the 
reasons for this variation could be that diclofenac removal is dependant on sludge 
retention time and is only significantly degraded when SRT was at least 8 days 
(Kreuzinger et al., 2004). Six studies revealed an increase in concentration of diclofenac 
after sewage treatment. The highest calculated was an increase of 143% in a study by 
Lishman et al., (2006) (appendix 10). Increases in concentration of the other three 
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pharmaceuticals for which sewage treatment efficiency was assessed were also found 
(Table 2.8). Carbamazepine increases have been regularly reported (Santos et al., 2009; 
Clara et al., 2003) (appendix 10). There were fewer increases in concentration found for 
gemfibrozil and ibuprofen; the possible reasons for these increases are discussed below.  
In general ibuprofen removal in secondary treatment STPs was quite high, usually 
around 80-90% and 100% in more than one study (Table 2.8). This finding indicates that 
high MECs in surface waters are probably due to the high consumption of this 
pharmaceutical (see Section 2.6.1) rather than recalcitrance to STP removal. However, 
the fact that some low removal efficiencies and some increases in concentration have 
been reported (Table 2.8) means that caution needs to be taken when incorporating STP 
removal into PEC calculations. Ibuprofen has shown low adsorption to sewage sludge 
(Horsing et al., 2011), meaning that high removal efficiencies are likely to be due to 
microbial degradation for this pharmaceutical. Tertiary settlement lagoons appear to be a 
poor removal system for some pharmaceuticals like ibuprofen in comparison to 
microbiologically active systems like activated sludge.  In a recent study by Horsing et al., 
(2011), to determine sewage sludge sorption, tamoxifen was so readily adsorbed to the 
glass bottles that it was not possible to calculate sewage sludge adsorption. These two 
extremes in adsorption potential of pharmaceuticals highlight some of the difficulties 
when estimating removal in STPs.  
Carbamazepine seems highly resistant to removal with STPs achieving removal 
efficiencies of between 0 and 30% (Table 2.8). In fact, none of the sewage treatment 
technologies employed removed carbamazepine effectively. It is therefore considered that 
STP upgrades would probably not decrease the environmental concentrations of this drug.  
There was a lack of data for STP removal of gemfibrozil but available figures 
suggest its removal can vary from 0 to 100% (appendix 10). This highlights a potential 
research need. However, if a removal efficiency of zero occurs at any STP, then a 
removal rate of zero must be assumed when calculating a PEC for ERA in order to 
provide a precautionary and worst case scenario.  
In the publications reviewed the authors generally analysed the liquid phase of the 
influent or effluent, and rarely measured the concentration in solids or sludge. This may 
be of greater relevance for some pharmaceuticals than others due to differences in 
95 
 
adsorption to solid particles.  Fluoxetine is known to have a high adsorption to sludge but 
paracetamol, ibuprofen and diclofenac and gemfibrozil are thought to have little tendency 
to bind and will occur mainly in the aqueous phase (Zabcynski et al., 2010). One of the 
difficulties with predicting sorption of pharmaceuticals is that they tend to be ionic, 
therefore, sorption may increase at lower pH (Ternes et al., 2004). High quantities of 
fluoxetine were found in bio solids produced at an STP (4.7 mgkg
-1
) (Kinney et al., 2006). 
Hydrophobic EE2 adsorbs readily to digested sludge with no significant degradation. 
Temes et al., (2002) reported a concentration of 17 ngg
-1
 of EE2 in sewage sludge, which 
is quite high considering the small quantities of EE2 entering sewage treatment plants 
(see above). A high adsorption to sludge could pose risks from run off in ground and 
surface water when sludge is applied to agricultural fields.  
Removal of pharmaceuticals during sewage treatment is assumed to be zero in the 
initial crude PEC calculation for an ERA but can be included as a refinement. In this 
study, increases in pharmaceutical concentration after sewage treatment were often found. 
This has been reported previously for diclofenac (Zorita et al., 2009; Heberer & Feldman, 
2005) and for carbamazepine (Vieno et al., 2006).  This finding means that any 
refinements made to the PEC for STP removal may over estimate actual removal. In 
order to be precautionary it may not be appropriate to refine PECs for STP removal for 
some pharmaceuticals.  
It is thought increases in concentration may be the result of microbial activity 
during secondary sewage treatment (Panter et al., 1999; Gros et al., 2010). During 
metabolism some pharmaceuticals such as EE2 and carbamazepine become conjugated 
with glucuronide groups. The faecal bacterium Escherichia coli produces very large 
amounts of the enzyme ß-glucuridase (Ternes, 1998). It is likely, therefore, that these 
glucuronides are readily cleaved reproducing the parent compound and hence increasing 
the concentration after sewage treatment (Calisto & Esteves 2009; Bound & Voulvoulis 
2006; D’Ascenzo et al., 2003). Apparent increases in concentrations, though, may be due 
to other reasons. The detection method may produce errors e.g. suppression of the 
MS/MS detector signal due to the high concentrations of pharmaceutical in the raw waste 
water effluent, can result in apparent increases in concentration after STP treatment 
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(Roberts & Thomas, 2006). So some care may be needed to interpret these data and 
reproducing the results is important.  
Wide-ranging concentrations of pharmaceuticals measured in sewage may be 
caused in part by the time of day the sample was taken. Tracking of influent sample to 
final effluent can be problematic when quantifying removal efficiencies. The method 
used to collect the sample may also affect concentration measurements, for example, a 24 
hour composite sample may provide different data than a grab sample.  
All this makes including STP degradation in refined PEC calculations very 
difficult. The EMEA state that STP modeling using the Simple Treat model described in 
the European Union System for the Evaluation of Substances (EUSES) can be used, 
incorporating adsorption of substances to sewage sludge in STPs, using the data from the 
estimation of the adsorption coefficient (OECD 106), and the test for ready 
biodegradability in the STP (OECD 301). It can be seen from the calculations in this 
study illustrating the differences with the variety of sewage processes and the variation in 
concentrations from the same STP (Table 2.8 & appendix 10), that the impact of the 
sewage treatment process is complex and dependant on a number of constantly changing 
variables. It could therefore, be difficult to get robust and accurate data to use in a 
modeling software package.  
The EMEA recommend using the SimpleTreat package to estimate removal of 
pharmaceuticals in STPs as part of the PEC refinements for an ERA. However this 
package may not be particularly accurate. A large variability in removal prediction has 
been found when incorporating parameters such as: sewage flow, degradation rates, pH 
and dissociation constants when using SimpleTreat. The problem may be because it is a 
steady state model describing a highly non-steady system (Kah & Brown, 2011). Another 
criticism of Simple Treat is that it uses log kow to predict partitioning which has been 
shown to be a poor indicator of sewage sludge adsorption because pharmaceuticals are 
generally polar ionic compounds (Williams et al., 2006). Further investigation into the 
reliability of the SimpleTreat model in light of the sewage treatment removal analysis 
done here, is an important research need. 
The sheer variety of STP practices and combinations of treatment types may also 
complicate matters in calculating refined PECs. Many STPs can run two different 
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treatment streams simultaneously e.g. activated sludge and trickling filter beds. Individual 
STP practices vary throughout the year with sludge and hydraulic retention times varying 
from week to week within a plant. Such variations have significant impacts on removal 
efficiency. For example, increased residence times have been shown to increase 
degradation of ibuprofen significantly (Tauxe-Wuersch et al., 2005). Individual treatment 
processes vary substantially in efficiency as well. Santos et al., (2009) found high 
variability in removal of the same pharmaceutical at different STPs despite them all using 
activated sludge.  
Clearly, accurately predicting pharmaceutical removal by STPs is difficult. An 
underestimation of the environmental concentration in a study by Morasch et al., (2010) 
was caused by over estimation of the removal of pharmaceuticals during sewage 
treatment gathered from the literature. Organisms present in the receiving waters, of 
course, are exposed to these fluxes in concentration suggesting any assumed average 
concentration may not represent the real exposure situation. PEC calculations involving 
sewage treatment removal are problematic and clearly should be used with extreme 
caution. The variation in removal and the measured increases in concentration of the 
selected pharmaceuticals during sewage treatment (Table 2.8) meant that no refinement 
to PECs 1 & 2 could be made.  
 
2.6.3 Population size and pharmaceutical concentrations 
The greatest contribution of pharmaceuticals in the environment is thought to be 
through human use and subsequent excretion. Theoretically, the number of people served 
by an STP should affect the amount of pharmaceutical discharged. Population is not used 
in the EMEA guidelines (Eq 1) instead a default Fpen (market penetration factor) of 0.01 
is used. It is, however, incorporated when consumption data is used (Eq 2) and when 
local surface water PECs are calculated (Eq 3). 
 There was no correlation between size of population served by an STP (capacity) 
and effluent concentration of selected pharmaceuticals, except in the case of gemfibrozil 
(see Section 2.5.5 & Fig 2.19-2.22). The reasons for no clear relationship between size of 
population served and outfall drug concentrations are unclear. Differences in sampling 
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procedures (see above) used by the researchers compared in the calculation of correlation 
may have had an effect, as might differences in biological oxygen demand (BOD) and pH 
of the effluent (Horsing et al., 2010). The hydraulic retention times (HRT) and sewage 
retention times (SRT) (Zabcynski et al., 2010) may all have an impact through altering 
STP efficiency. In light of the fact that concentrations in effluent are highly variable with 
time, season, weather etc (see above) it is unlikely that a correlation would be found. 
Gros et al., (2010) also found no obvious correlation between the size of population 
served and the total load of pharmaceuticals at seven activated sludge STPs. While a 
higher ibuprofen MEC was found in a river surrounded by a small population base 
compared to a highly populated area in West London (Bound & Vouvoulais, 2006). In 
contrast, others have found that STPs serving larger populations result in the highest 
environmental loads (Ashton et al., 2004).  
  Lack of a clear relationship may be influenced by factors not related to STPs. 
Some regions may have a higher usage of certain drugs depending on the average age of 
the community (Kostich et al., 2010). Consumption of certain drugs is also dependant on 
the time of year. For example, the use of paracetamol and decongestants increases in the 
winter months, and an increased consumption of antihistamines (for hay fever) in the 
summer. There are also large discrepancies in excretion rates of pharmaceuticals. For 
example variation in diclofenac excretion has been reported from 2-75% and 1-61% for 
carbamazepine (Carballa et al., 2008) between individuals. The initial crude PEC 
accounts for this by usually applying a conservative assumption of 100% excretion. 
However, if the risk quotient (RQ) exceeds 1, then refinements for human metabolism 
may be made. Any refinements of this type may lead to an underestimate of the actual 
environmental concentration.  
 The general lack of correlation between population served by an STP and effluent 
pharmaceutical concentrations poses a difficult problem when deriving an accurate PEC 
for any ERA. Usually the calculation for predicted surface water concentration involves 
an estimate of usage and population size. This figure is divided equally across the country 
and per person. If there is no correlation between the population size and the quantity of 
pharmaceutical discharged into the environment then this method breaks down. Letzel et 
al., (2009), however, used load per capita data from nine different STPs in Germany to 
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calculate a surface water PEC for diclofenac.  These exactly matched the highest MEC in 
receiving waters.  
ERAs are performed prior to the medicinal product being marketed, which means 
that an estimate of sales volume is used for PEC calculations. Trends in prescriptions and 
usage change year on year as new pharmaceuticals become available, their popularity 
changes or side effects become apparent. Pharmaceuticals are also consumed in different 
amounts country to country for example sales of fluoxetine in the UK are three times that 
of Germany (Oakes et al., 2010) therefore a PEC in one country may not be valid for 
another. Over time an active ingredient may be included in several brands, which could 
change any PEC. This can occur when a pharmaceutical comes off patent or new uses for 
a new drug are discovered (Sannella et al., 2008). In reality the crude PEC is only 
applicable prior to marketing of a drug. This study indicates that after market 
authorisation a new PEC should be calculated based on consumption data annually and 
that each PEC should be calculated on a regional basis. Changes in PEC are important as 
they will alter the associated risk quotient (RQ) which is calculated by dividing the PEC 
by the predicted no effect concentration (PNEC) from ecotoxicity tests. If the RQ is over 
1 then an ecotoxicological risk is perceived in the ERA. 
2.6.4 Predicted environmental concentrations (PECs)  
The crude calculation of the PEC was in general above or aligned to MECs (Table 
2.9). When the MEC exceeded the PEC it was commonly only by the maximum recorded 
concentration. This suggests that the crude PEC calculation does produce a realistic or 
precautionary estimate of environmental concentration perhaps surprising given the 
assumptions it makes. The concern however, is that the PEC may be an underestimate of 
concentrations when refinements are made for loss due to metabolism in the body, 
sewage treatment or environmental degradation. Letzel et al., (2008) reported a PEC, 
which had not been refined for metabolism, removal during sewage treatment or 
environmental degradation which was equal to the MEC. This is an important finding 
because according to the guidelines refinements to the PEC could justifiably be made 
thereby reducing the prediction to a value below that which has been detected in the 
surface water. Ibuprofen, paracetamol and tamoxifen were all measured above the PEC 
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when these refinements were made (Table 2.9). The reason for this may be errors in the 
calculation of refined PECs arising from inaccurate or unreliable data being used in the 
refinements (Castiglioni et al., 2004; Bound & Voulvoulis, 2006).   
Other authors have made similar findings from data in the literature. Ferrari et al., 
(2004) found that unrefined PEC and MEC for carbamazepine were generally similar, 
while Letzel et al., (2008) found the maximum MEC for diclofenac equivalent to an 
unrefined PEC. In a comprehensive study, Zhang & Geissen., (2010) calculated refined 
sewage effluent PECs for 68 countries using sales volumes, metabolism, disposal, 
municipal water withdrawal (in place of wastewater production) and removal in STPs for 
carbamazepine and compared these to effluent concentrations recorded for the same 
countries in the literature.  They found that although effluent MECs were in a comparable 
range they often exceeded PECs. Predicted concentrations were generally not below 
MECs in this analysis of literature (Table 2.11), but it is important nevertheless that the 
measured concentrations always fall below the prediction in order to ensure that non-
target organisms and ecosystem system and function as a whole are protected. This was 
certainly not always the case. The variation in MECs highlights the importance of 
calculating a precautionary and conservative PEC and the potential need for monitoring 
of some pharmaceuticals. 
 Despite the assumptions and crude nature of Eq 1 which includes no actual sales 
or consumption data, the resultant PECs were predominantly above or in line with MECs 
found in the literature. However there were some exceptions, several MECs did exceed 
the PECs. This suggests the PEC calculation may not be sufficiently conservative and 
that some of the default parameters need reconsideration.  
PECs calculated using prescription and sales data were lower than the crude PECs 
using the default market penetration factor (Fpen) of 1% except in the case of 
paracetamol (Table 2.10).   This is a reflection of paracetamol having a higher market 
penetration factor than the default 1%. It appears, therefore, that the default Fpen was a 
precautionary figure for the majority of pharmaceuticals analysed. In the absence of 
marketing data, however, it remains important that a realistic market penetration factor be 
obtained using similar licensed drug sales data or drug manufacture market penetration 
predictions to obtain a consumption figure in place of a default Fpen. This will strengthen 
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the resilience of PEC calculations prior to marketing. The fact that some licensed 
pharmaceuticals have been detected in surface waters above the 10 ngl
-1
 action limit for 
further risk assessment leads to the conclusion that accurate prediction is an important 
requirement for the protection of the environment and that PEC calculations should be 
revisited after marketing.  
The most recent prescription data available for England was from 2008. 
Unfortunately surface water MECs for England were not available in 2008 for direct 
comparison with PECs calculated using this data (Table 2.11). The lowest PECs 
generated in all the equations, therefore, were compared to maximum concentrations 
reported in the literature in England from a total of 8 studies between 2000 and 2011. 
Maximum surface water concentrations have been reported above these PECs for only 
three of the pharmaceuticals investigated; tamoxifen, trimethoprim and propranolol 
(Table 2.11). It should be noted that trimethoprim is also sold in combination with 
another antibiotic sulfamethoxazole as co-trimoxazole. The calculation for trimethoprim 
proportion of the active ingredients for this product was not specified in the prescription 
analysis and therefore not incorporated in the PEC thereby underestimating actual 
consumption. However co-trimoxazole accounted for approximately 2% of total 
prescriptions containing trimethoprim. No MEC data was available for either gemfibrozil 
or fluoxetine representing a substantial knowledge gap. Both had PECs greater than 10 
ngl
-1
 (using all four calculations) the action limit for further risk assessment and both 
have chronic ecotoxicity effects (Nentwig, 2007; Painter et al., 2009; 2008, Mimeault et 
al., 2005).  
In order to gain a more accurate picture of the reliability of PECs a much more 
tailored study should be performed. Sales of drugs differ year to year and the prescription 
data collected for 2008 may differ from precise prescription amounts in each of the years 
in which data was reported. This lack of data and a lack of any investigation for some 
pharmaceuticals mean that the analysis is inconclusive. It would appear that although 
maximal concentrations occasionally exceed PECs, overall PECs are higher than 
measured environmental concentrations. However, MECs do occasionally exceed PECs 
and therefore they are not the worst case scenario they purport to be.   
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2.6.5 Pharmaceutical PECs, effluent concentrations and surface water dilution 
effects 
The derived surface water PECs were compared to reported effluent 
concentrations. Concentrations of diclofenac, trimethoprim, ibuprofen (Hilton et al., 2003) 
and tamoxifen (Roberts & Thomas 2006) in effluent have all been reported at levels 
exceeding PECs 1 & 2 (Table 2.11). Propranolol has been reported above PEC 2 where 
consumption data was used (Roberts & Thomas 2006) but has not exceeded the PEC 
generated in Eq 1.  
The EMEA guideline for a PEC calculation includes a default value of 10 for the 
dilution from sewage effluent to surface water. When this was applied to the 
trimethoprim and tamoxifen effluent concentrations they still exceeded the surface water 
PEC 2 (consumption data). This was not the case for the Eq 1 PECs using the default 
Fpen. Trimethoprim has been measured in sewage effluent in Wales at a maximum 
concentration of 3.05 μgl-1 (Kasprzyk-Hordern et al., 2009), as the consumption of 
trimethoprim is similar in Wales and England (Welsh Government, 2011) the PEC (Eq 2) 
is exceeded by over 10 times with the dilution factor applied. The sales of co-trimoxazole 
alone cannot account for this. It should be noted that the PECs 1 & 2, have not been 
refined either for excretion or removal in STP.  Moreover, PECs of course should be 
greater than MECs in order to be conservative, precautionary and offer adequate 
protection for water bodies.  
The validity of a dilution factor of 10 was investigated for carbamazepine, 
diclofenac, ibuprofen and gemfibrozil. It was found that concentrations of these 
pharmaceuticals could increase as well as decrease downstream from a sewage outfall. 
This may be due to other sources of pharmaceuticals such as release from other sewage 
treatment plants, untreated sewage, storm overflow events, misconnections, 
pharmaceutical manufacture and even desorption from sediment. The underlying 
concentration of a drug in a water body through previous contamination, lack of natural 
degradation and potential accumulation in different environmental compartments are 
important factors to be considered when estimating surface water concentrations. The 
PEC calculation is based on new inputs of pharmaceuticals and is not inclusive of 
existing concentrations. On one occasion gemfibrozil was not detected in the sewage 
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effluent but was found at concentrations of 1.3µgl
-1
 in the receiving water (Metcalfe et al., 
2003). Despite this finding, on the whole results indicated that the majority of surface 
water concentrations were less than the sewage outfall. However, the results also show 
that the concentration was not reduced by 90% of the original concentration and therefore 
surface water dilution was less than the default factor of ten.  
Clearly a default dilution does not reflect reality well. There was also a notable 
lack of studies that investigated MECs at more than one point downstream from a sewage 
outfall. There are a number of factors that might make the use of a default dilution factor 
problematic. Firstly, because the dilution factor for each river is different. For example, 
the dilution factor in the Ebro river was found to be 30-40 times but the river Agra in 
Pamplona was closer to 5 (Gros et al., 2010) and the river Gardon in the south of France 
was found to be nearer 3(Coetsier et al., 2009). The dilution factor can change daily 
because of the volume of water in the river fluctuates with flow and weather conditions. 
Another factor is the effect of existing pharmaceutical surface water concentrations. Even 
when daily fluctuations in receiving water body volume were applied to calculate an 
accurate dilution factor, large variations in day to day MECs were still recorded (Ter 
Laak et al., 2010). The variation in reliability of the dilution factor seems to be large. 
Although the findings in this study suggest the dilution factor is an underestimate in some 
cases as well as often overestimating concentrations.  
Clearly the use of a default dilution factor of 10 is appropriate for some water 
bodies e.g. those with dilution factors >10 and becomes a problem only when the water 
bodies dilution effect drops below this. Inevitably there will be variability in dilution both 
seasonal e.g. dry periods, and potentially daily with peak flow times at the STP e.g. early 
mornings. Low flow occurrences maybe become an increasing problem with climate 
change. It may be appropriate to identify worst-case scenarios for the dilution effect of a 
water body when calculating a refined PEC given this variability and the need for a 
precautionary stance. Alternatively a lower default dilution factor might be set, but this 
will not be appropriate where water bodies have large dilution capacities. 
 Drug consumption and sales figures are important parameters for the calculation 
of refined PECs. This investigation highlights two issues here. First, the default market 
penetration factor, which may be greater than 1%, is problematic.  For over the counter 
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medicines actual sales volumes are unknown in the UK. The market penetration factor for 
paracetamol must be higher than 1% because the PEC generated in Eq 2 using 
consumption data is much higher than Eq 1 using the default 1%. Grung et al., (2008) 
also found the default Fpen of 1% to be an underestimate for paracetamol and ibuprofen 
in Norway where excellent sales records are maintained. The actual sales volume for an 
unlicensed medicine is unknown, of course. 
Second, the official prescription or sales data may not actually reflect the amount 
consumed (Halling-Sorensen, 2000). The assumption made in PEC calculations is 100% 
consumption. This may overestimate the PEC but is precautionary.  Propranolol for 
instance has a 30% non compliance rate (Mulleners et al., 1998) and in the UK 
approximately half of prescriptions may be unfinished (Bound and Voulvoulis, 2005). 
There is some variation with country, however, the Swedish Medicinal Products Agency 
(2004) claim that 90% of pharmaceuticals sold in Sweden are consumed. Unused drugs 
kept in the home or disposed in the bin will, of course, reduce the concentration going to 
water bodies, but disposal via the sink or toilet with no degradation in the body will tend 
to increase environmental loads. Accounting for societal effects in PEC calculations is 
clearly problematic. 
There are no precise sales statistics in most countries for pharmaceuticals used in 
hospitals or for over the counter drugs (Grung et al., 2008; Castiglioni et al., 2004; 
Calamari et al., 2003). PECs calculated with prescription data for paracetamol and 
ibuprofen were found to be significantly lower than river MECs although the use of 
production figures for paracetamol significantly increased the PECs making them more 
representative (Bound & Voulvoulis, 2006). It appears that production figures may be a 
more reliable data set for over the counter drugs. In the same study, however, the 
maximum MEC for salbutamol was 1200 times greater than the PEC even though this 
drug is not available without prescription. Clearly other factors are at play.  
The consumption and disposal of pharmaceuticals, of course, is directly related to 
the concentration in sewage effluent and surface waters (Ashton et al., 2004; Ter Laak et 
al., 2010). It is, therefore, critical to find accurate production, sales and consumption data 
to generate a reliable PECs. The EMEA PEC calculation provides a 200L per day per 
person default value for wastewater production. This may not be a valid assumption for 
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some countries and can vary with location. For example, 150L for France and 140L for 
Germany are probably more realistic figures (Ferrari et al., 2004), whereas in Norway 
216L of wastewater is produced per person per day (Grung et. al., 2008). Such values 
would increase the PEC by up to 30%. It appears that wastewater production should be 
determined on a location by location basis if realistic PEC values are to be calculated. 
Finally it cannot be discounted that one of the problems with comparing PEC and 
MECs is the quality of the analytical data. Despite advances in analytical chemistry over 
the last 20 years there still remain difficulties with collecting accurate data on 
pharmaceuticals in the environment at these miniscule concentrations. On occasion 
concentrations can be reported which could not realistically be present in the environment 
because the quantity required is simply not manufactured. Metcalfe et al., (2010) 
calculated a raw sewage PEC for fluoxetine which is not available without prescription 
based on sales data of 32 ngl
-1
 which was exceeded by a measured concentration nearly 3 
times (91 ngl
-1
). There is evidence of studies which have compared different laboratories 
abilities to analyse water samples with worrying results (Van Leeuwen et al., 2006).  
Bound & Voulvoulis, 2006 report an average error of 13% for measured concentrations. 
As mentioned above it was thought that increases in sewage concentration may be due to 
suppression of the MS/MS signal. 
One of the problems is the complexity of the variables required to accurately 
predict environmental concentrations. GREAT-ER and Phate are computer packages 
which use geo-referenced river models to predict environmental concentrations of 
pollutants. They are easy to use, cost effective and can incorporate processes such as STP 
removal and dilution in rivers. Diclofenac and several beta blockers have had successful 
exposure rate predictions using these models (Johnson et al., 2007; Alder et al., 2010). 
Although the lack of accurate STP removal efficiency and consumption data still remains 
a limitation.    
The fact remains that when considering the expense of determining environmental 
concentrations, inaccuracies with measurement and the sheer number of compounds and 
water bodies, PECs are necessary and crucial for environmental risk assessment. They are 
a valuable first indicator of environmental risk for a pharmaceutical or chemical. They 
can help prioritise pollutants to avoid unnecessary toxicology experiments. It is 
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paramount therefore that the data which is entered into these calculations is accurate and 
reliable. When the data used in calculations is reliable and accurate, and assumptions are 
minimised and precautionary, the resultant estimate could be more accurate than 
available analytical chemical techniques. 
2.6.6 Pharmaceuticals in other matrices 
The most important findings in regard to other matrixes were that there is still a 
lack of research into pharmaceuticals in drinking water, ground water and marine waters. 
However, there are reports of several pharmaceuticals being detected in all three of these 
matrixes (Table 2.13).  
Currently under ERA procedures for pharmaceuticals, even if an environmental 
risk is identified, a pharmaceutical cannot be restricted for human use. It is human health 
that is paramount above any environmental concern. The presence of pharmaceuticals in 
groundwater and drinking water also has potential health implications as well as 
environmental ones. Pharmaceuticals can enter drinking water through abstraction from 
surface water as well as ground water. The few measurements of drugs available in the 
literature, however, have been far below the therapeutic dose in finished drinking water 
(Table 2.13). The concern here is that certain drugs such as anti cancer medicines may be 
damaging to vulnerable groups such as pregnant women and children (Rowney et al., 
2009). Despite the long established existence of pharmaceuticals in river water used for 
abstraction, there is insufficient data on concentrations and almost no data available on 
occurrence in drinking water. There are no reports of tamoxifen, fluoxetine, trimethoprim 
and EE2 being detected in drinking water so far. However, this may be due to the lack of 
testing rather than their non existence. The incidence of pharmaceuticals in surface water 
suggests their presence in abstracted water. Although no detections of propranolol have 
been reported in drinking water, a concentration of 50 ngl
-1
 was recorded in a reservoir in 
Sweden (Ferrari et al., 2003). Also 18 ng/l of atenolol another beta blocker has been 
detected in drinking water (Thomas et al., 2007). Reported concentrations of 
pharmaceuticals in drinking water suggest that concentrations above 10 ngl
-1
 can occur. 
However, there is no quality standard or limit set for pharmaceutical concentration in 
drinking water. The Drinking Water Inspectorate, (2007) used probability modelling to 
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estimate concentrations in drinking water and concluded they were generally equal to 100 
ngl
-1
. In fact data suggests that concentrations can exceed 100 ngl
-1
. Although 100 ngl
-1
 is 
reported to be below the therapeutic dose for most pharmaceuticals (Choi et al., 2008), 
chronic exposure data is rarely available. Some pharmaceuticals may work in conjunction 
causing additive or combined effects that may lower the active concentration of 
individual pharmaceuticals. Combinations may be complicated and impacts unforeseen. 
There are no analytical methods for measurement for all 3000 pharmaceuticals on sale 
and their associated metabolites. It is important that these methods are developed in order 
to monitor levels in river and drinking water. It may be appropriate for pharmaceutical 
companies to be required to develop analytical detection methods for their products and 
establish their metabolites as part of the ERA required for licensing. 
2.6.7 Critical analysis of reporting methods and standards for pharmaceuticals in 
the environment. 
A considerable number of papers have been published on environmental 
concentrations of pharmaceuticals. This number must now be in excess of 1000, not 
including ecotoxicological assessment studies of pharmaceuticals. This is a valuable and 
substantial contribution to knowledge on the fate and effects of drugs in the environment. 
Monitoring studies are time consuming and costly exercises, making it paramount that the 
data generated in these studies should be accurate, reliable and complete.   
Measurement of pharmaceuticals in water provides a useful case study to 
determine the reporting standards on pollutants in peer reviewed articles. It is clear from 
the analysis here of 128 articles reporting pharmaceutical concentrations in freshwater 
and effluents that in the vast majority of cases significant environmental data and 
statistical analysis was missing from the papers (Table 2.14). The lack of specific 
sampling, statistical and environmental data renders concentration data almost 
meaningless. The ranges of concentrations of pharmaceuticals reported worldwide are 
quite wide and the environmental and sampling variables need to be specified in order to 
allow useful analysis. Published data provided must be of a scientifically acceptable 
standard enabling an assessment of the environmental risks (Kuster et al., 2009). Method 
validation was a common reason for measuring pharmaceutical concentrations in water in 
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many of the surveyed articles, however, even in this context the lack of repeat 
measurements and statistical analysis means that the error associated with the use of the 
technique on field samples cannot be established. Overall a clear opportunity to add 
invaluable information to build a comprehensive picture of the fate of pharmaceuticals in 
the environment is being missed. It is important that literature data provides valuable 
supplementary information for risk assessment processes (Kuster et al., 2009). It is 
essential that policy makers have access to a high quality and wide ranging evidence base. 
Decision makers must be confident that evidence is robust and stands up to challenges of 
credibility, reliability and objectivity (H M Government, Guidelines on Scientific 
Analysis in Policy Making, 2005). Over the last ten years the UK government has 
strongly promoted the more effective use of science to inform policy-making and 
regulation (Holmes & Clark, 2008). Yet from this analysis much of the information 
available in the academic literature is not of an appropriate standard to provide ‘sound’ 
scientific evidence. Setting standards for academic reporting of environmental and health 
information that go beyond peer review to provide policy makers a sound evidence base 
for decisions seems essential. A set of standards for reporting environmental pollutant 
data in peer reviewed literature may help provide a basis for informed policy and 
regulatory decision making. This would also ensure that the body of knowledge could 
expand. It is a shame when work becomes meaningless because simple information is 
missing. A set of uniform standards for reporting of concentrations of all pollutants not 
just pharmaceuticals would enable valuable science to inform policy and regulation 
decision making.  
‘WikiPharma’ is a new database set up to provide free publically available 
ecotoxicity data for pharmaceuticals (Molander et al., 2009). The database uses 
information from peer reviewed journals as a quality control. It is an excellent example of 
how peer reviewed journal research articles can be used to provide ecotoxicological 
information or other scientific knowledge on existing and novel pollutants. It is essential 
that this type of database provides reliable and robust data. Only ‘sound science’ can 
support policy and regulatory controls. 
In the current climate of fiscal constraint continued pressure on research funding 
and on the work of regulators is inevitable (McEldowney et al., 2010). Setting reporting 
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standards for academic research would not only provide a sound evidence base for policy 
decisions but would help provide value for money in research outcomes for funders.  
 The results of the critical reporting standards analysis has led to the development 
of a list of criteria for data that should be available in publications of environmental 
concentration data in aquatic environments: 
 
1. Uniform statistical analysis including mean, standard deviation and sample 
size. 
This would enable comparisons to be made between studies and meta analysis of 
concentration data possible. 
2. Access to raw data in a supplementary section. This should be available on 
line permanently.  
Access to raw data would make expensive monitoring data generally available and 
further statistical analysis possible. Meta analysis could be performed between studies. 
3. Description of sewage treatment processes discharging effluent into water 
bodies. 
The effectiveness of different sewage treatment processes for pharmaceutical removal 
could be assessed and more rigorous sewage removal refinement applied in PEC 
calculations.  
4. Sewage effluent to surface water dilution factor at the time of sampling. It 
would be helpful to supply a low flow and an average dilution factor for the 
water body analysed. 
This would enable risk assessment of the average dilution for a water body and also worst 
case scenarios. The time of sampling may not reflect the range of dilutions in that water 
body. 
5. Population size serviced by STP, specifically population equivalent to take 
into account industrial contribution on population. 
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The local water PEC calculation in the EMEA documents requires a figure for the 
capacity of the STP. Population size is an important parameter when assessing predicted 
concentrations. 
6. Specific data on location. Including distance from sewage outfall, direction of 
water flow and other discharges into the water body and their location. 
This type of information would enable assessments to be made on the persistence of 
pharmaceuticals in water bodies. 
7. Specific time and date of sampling. 
This information would enable daily and seasonal changes in pharmaceuticals effluents 
and surface waters to be assessed. This information could help explain reasons for 
fluctuations in pharmaceutical concentrations. 
8. LOD or LOQ for the method used. 
9. Season and weather conditions at time of sampling. 
Changes in pharmaceutical concentration in water bodies and removal by STPs may be 
highly dependent on weather conditions. In order to determine the effects that decreased 
temperature or increased rainfall may have it is necessary to know the weather conditions 
at the time of sampling. This information may allow comparisons across different studies. 
 
Some of this data could be included in the publication itself, other material in an on-
line resource as appropriate. Other reporting standards should be developed by 
knowledge exchange between, scientific journals, academics and environmental 
regulators to establish any other information that would make environmental data 
produced fit for use by regulators and policy makers.  
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2.7 Conclusion 
 A great deal of data is available on pharmaceutical concentrations in surface water 
and sewage effluent. Analysis of this data shows that concentrations between different 
pharmaceuticals, water bodies and sewage treatment plants are wide ranging. The most 
surprising and interesting feature being that concentrations often vary for the same 
pharmaceutical in the same water body or STP by an order of magnitude. Sewage 
treatment does not remove pharmaceuticals efficiently and concentrations may increase 
after treatment. The situation for non target organisms in water courses appears to be a 
continuous exposure to a large number of human pharmaceuticals at fluctuating 
concentrations. 
PEC calculations are a vital stage of ERA of pharmaceuticals (Coetsier et al., 
2009; Ginebreda et al., 2010). There are questions, however, over current guidelines for 
PEC calculations. Although MECs are commonly in range of PECs, they are not 
precautionary enough as they are sometimes exceeded. This disconnect between PEC and 
MEC may find its basis in some of the assumptions made in calculating PECs. Some of 
these may need revising, including the surface water dilution factor of 10 and the 200 L 
per day wastewater production volume. Standardizing drug consumption over the 
population over the year is questionable and there are clear inaccuracies in consumption, 
sales and excretion data. There appear also to be overestimates of sewage treatment 
removal.  
There are analytical problems associated with measuring small pharmaceutical 
concentrations in water bodies, however, which may raise questions over the accuracy of 
some reported MECs. An indicator that analytical problems may be occurring is that 
environmental concentrations can be measured far above that which could have entered 
the environment. Comparison of different laboratories also suggests differences in the 
accuracy of measuring pharmaceuticals in water samples (Farre et al., 2008). Such 
difficulties in measuring MECs, however, do not undermine the argument that the 
assumptions made for PEC calculation should be valid and representative of the factors 
effecting pharmaceutical concentrations in individual countries, localities and water 
bodies. PECs are a valuable first indicator of environmental risk for a pharmaceutical, can 
help prioritise pollutants to avoid unnecessary toxicology experiments and provide a 
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margin of safety for aquatic ecosystems. They should provide a realistic estimate of the 
maximum possible exposure of a water body to a pharmaceutical. At present there can be 
no great confidence that this is so. 
Peer reviewed literature provides a valuable wealth of information on 
environmental and ecotoxicological issues. In the current financial climate this source of 
knowledge should be used to its full potential. With a robust, reliable set of reporting 
standards in academic publications for data on environmental pollutants, the opportunity 
is presented to provide sound science to underpin and inform regulation and policy.
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Section 3 
Interview Analysis 
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3.1  Aim for Section 3 
The aims of the work performed in this section were to engage key individuals involved 
in environmental protection related to human pharmaceuticals, including representatives of water 
companies, pharmaceutical companies, regulatory organisations and academics. Different 
perspectives were sought on, the potential inadequacies and successes of the ERA and the 
proposed solutions and mitigation mechanisms that could minimise the risks to the aquatic 
environment. These were then examined to determine where there was consensus and differences 
about the best route for environmental protection from pharmaceuticals.  
3.2 Introduction 
 Pharmaceuticals are frequent pollutants of the aquatic environment (Section 2) with a 
continual input of low concentrations of a large (3000+) mixture of compounds that are designed 
to cause a specific biological effect (Section 4). Two pharmaceuticals, one for human use and 
one used for both human and veterinary medicine ethinylestradiol (Jobling et al., 2002) and 
diclofenac (Oakes et al., 2004) respectively have been shown to cause serious adverse effects on 
wildlife. New research on the chronic effects of human pharmaceuticals on aquatic wildlife is 
being published all the time. Recent publications include: Alterations of gene regulation in fish 
brain after propranolol exposure (Lorenzi et al., 2010) and enzymatic stress in gills, liver and 
muscles of fish after carbamazepine exposure (Malarvizhi et al., 2012). This situation has led to 
the development of an ERA for human pharmaceuticals (EMEA, 2006).  
In accordance with Article 8(3) of Directive 2001/83/EC, as amended, an ERA should 
include the evaluation of the potential environmental risks posed by a medicinal product and an 
environmental impact assessment. This should also include an evaluation of the positive 
therapeutic effects of the medicinal product in relation to the risks associated with undesirable 
effects on the environment. Precautionary management action should be considered to reduce the 
release of pharmaceuticals into the environment and should include shareholders, stakeholders, 
consumers, pharmacists and medical practitioners in order to find solutions (Kummerer, 2009). 
Expert knowledge can often provide valuable information for the assessment of environmental 
problems and help fill in knowledge gaps that may be present in the peer reviewed literature 
(Doerr-MacEwen & Haight, 2006; Human & Davies, 2010). Recently, there have been calls 
among decision makers, interest groups, citizens, and scientists for more science-based 
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environmental policy (Johnson et al., 1999; Sarewitz et al., 2000). Including scientists in early 
stages of policy formation will improve the quality of complex policy decisions and facilitate the 
resolution of environmental decisions by providing objective scientific information to 
policymakers (Mazur, 1981; Steel et al., 2004). Over the last 10 years the UK Government has 
strongly promoted the more effective use of science to inform policy-making and regulation 
(Holmes & Clark, 2008). The Cabinet Office (1999) summarises the core competencies of good 
policy-making including using evidence which is described as the “best available evidence from 
a wide range of sources and involves key stakeholders at an early stage’’. This should include 
evidence from stakeholder consultation, expert knowledge and the critical evidence held in the 
minds of front line staff in departments, agencies and local authorities and those to whom the 
policy is directed. Effective access to information and expertise is a necessary precursor to the 
use of science to inform policy-making and regulation (Holmes & Clark, 2008). External experts 
(including researchers, consultants and experts in other Government departments and agencies) 
are an important source of scientific advice (Holmes & Clark, 2008). These experts synthesise 
and interpret information for policymakers and their involvement may lend credibility to the 
ensuing policy decision. The addition of diverse experts can also lead to a more comprehensive 
understanding of ecological hazards and can improve problem formulation by generating an 
ecologically robust set of information on which to base the subsequent, more technical 
environmental risk assessment (Dana et al., 2012). The participatory ERA process can also 
increase the transparency of the ERA by exposing the logic and rationale for decisions made at 
each step (Dana et al., 2012). 
Hajer (2003) identifies an ‘institutional void’ between policy and practice in the field. In 
recent decades, there has been increased interest on participation in environmental decision 
making (Reed, 2008; Hansen & Mäenpää, 2007; Abelson et al., 2007). Techniques such as 
interviews, analyses of reports and minutes from meetings can increase the probability of an in-
depth understanding of the science process and is important for decision making (Blackstock et 
al., 2007). By focusing upon different expert knowledge, deeper insights can be gained into the 
day to day management and governance of environmental problems (Bracken & Oughton, 2012). 
Policy makers should use the best available evidence from research and legitimate sources of 
knowledge, such as expert knowledge, when making decisions on environmental policy and 
management (Bracken & Oughton, 2012).   
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This leads to the conclusion that engagement with expert knowledge holders including 
pharmaceutical company employees, water company managers, government bodies and 
academics that are involved in and are knowledgeable about the current ERA for human 
pharmaceuticals may be beneficial for gaining insight into its effectiveness and for its 
development into the future. In depth knowledge of the ERA protocol and guidelines was 
required in order to answer the in depth interview questions, so other stakeholders, e.g. 
pharmacists, doctors and shareholders were not sort for interview. 
There are a number of potential inadequacies with the current ERA of pharmaceuticals. 
These include, issues around the 10 ngl
-1 
action limit for ecotoxicological assessments, the 
accuracy of PEC calculations (Section 2), the spectrum of ecotoxicology tests applied (Section 4), 
a lack of monitoring, a lack of retrospective ERAs for existing drugs, a lack of mitigation 
measures and ultimately the fact that at present a pharmaceutical cannot be refused for human 
use on environmental grounds. Therefore, engagement with environmental regulators from water 
companies, pharmaceutical companies, government and academia could provide valuable insight 
and potential remedies for the shortfalls in the current ERA. This section assesses opinions 
provided by experts working in the field of pharmaceuticals on a number of issues outlined 
below. 
3.2.1 The 10 ngl
-1 
action limit 
The 10 ngl
-1 
action limit for ecotoxicological assessment may be set at an inappropriate 
level. Having the same trigger limit for all pharmaceuticals may not be appropriate. A 
concentration of 10 ngl
-1 
may be insufficiently precautionary for some pharmaceuticals and set at 
an unnecessarily high level for others. For example pharmaceuticals such as EE2 are highly 
potent and are known to adversely affect fish at concentrations <1 ngl
-1 
(Lange et al., 2001; 
Caldwell et al., 2008). However, many toxicity studies report effect concentrations for other 
pharmaceuticals at levels of an order of magnitude or more above 10 ngl
-1
 (Santos et al., 2009). 
3.2.2 Retrospective ERAs 
Most of the pharmaceuticals in this study have been reported in surface waters at 
concentrations far higher than 10 ngl
-1
 (Section 2). 
 
If these were new medicines they would 
require an ERA prior to market authorisation, however, current legislation does not
 
require 
retrospective risk assessment of pharmaceuticals. Many authors recommend that ERAs should be 
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performed for some existing medicines (Agerstrand et al., 2009). As there are a considerable 
number of existing pharmaceuticals which were authorised prior to the requirement for an ERA, 
it has been suggested that a prioritisation or ranking strategy is the most pragmatic way to decide 
which medicines may pose a risk to the environment (Roos et al., 2012).  
3.2.3 PECs 
 The generation of PECs is an essential stage of the ERA however their calculation 
involves many assumptions and uncertainties (Section 1). The current PEC calculation lacks the 
real world complexities of the parameters involved in the exposure of pharmaceuticals. Without 
sufficient data for removal by sewage treatment, dilution factors of specific water bodies, 
environmental degradation and projected consumption data it will always be an inaccurate 
estimate of what exposure concentrations might be (Section 2) (Coetsier et al., 2009; Bound & 
Voulvoulis, 2006). This leads to a degree of uncertainty when using PECs to assess the risks to 
the environment including species populations and communities they support. The development 
of computer packages for estimating environmental exposure is one potential way of reducing 
scientific uncertainty as they provide a range of probable concentrations and incorporate much 
more information on site specific factors such as hydrological information, season and pH 
(Johnson et al., 2007). 
3.2.4 Mitigation 
The precautionary principle emphasizes that where evidence of a threat to the health of 
the environment exists, scientific uncertainty must not be allowed to delay reasonable forms of 
management action (CEPA 1999, Quijano 2003, United Nations General Assembly 1992). 
However, management action and mitigation strategies tend to be one of the key areas lacking in 
the environmental management of pharmaceuticals that have been found to present a potential 
risk in an ERA. Pharmaceuticals cannot be restricted for human medical use on environmental 
grounds. Currently the only suggestion in the EMEA, (2006) guidelines in light of an 
environmental concern is to include a statement on the package leaflet which should read: 
 
“Medicines should not be disposed of via wastewater or household waste. Ask your 
pharmacist how to dispose of medicines no longer required. These measures will help to 
protect the environment.” 
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As human consumption and subsequent excretion is thought to be the main source of 
pharmaceuticals in the aquatic environment (Cunningham et al., 2006; Sanderson et al., 2003). 
This measure will not reduce the environmental input of pharmaceuticals from human 
consumption; therefore, other control measures need to be considered. Upgrading of sewage 
treatment facilities with tertiary treatments such as activated charcoal and ozonation could reduce 
exposure (Wang et al., 2009; Schaar et al., 2010; Schroder et al., 2012). However, the wide 
ranging capabilities of different sewage treatments for removing pharmaceuticals means this may 
not be the most suitable option (Zabcynski et al., 2010). The question then arises as to who 
should pay for any improvements if needed. The polluter pays principle also known as extended 
producer responsibility (EPR) is defined by OECD Environment Directorate, Paris, France (2006) 
as: 
a concept where manufacturers and importers of products should bear a significant 
degree of responsibility for the environmental impacts of their products throughout the 
product life-cycle, including upstream impacts inherent in the selection of materials for 
the products, impacts from manufacturers’ production process itself, and downstream 
impacts from the use and disposal of the products. Producers accept their responsibility 
when designing their products to minimise life-cycle environmental impacts, and when 
accepting legal, physical or socio-economic responsibility for environmental impacts that 
cannot be eliminated by design.  
It is necessary therefore, to establish who is the polluter, the pharmaceuticals industry, the water 
industry or the consumer?  
3.2.5 Green Pharmacy 
A further proposal for the reduction of pharmaceuticals in the environment is green 
pharmacy. The term green pharmacy stems from the concept of green chemistry. Green 
chemistry, describes the development of more environmentally acceptable and sustainable 
chemical processes and products (Greenwood et al., 2010).  Green pharmacy is the design of 
pharmaceutical products and processes that eliminate or significantly reduce the use and 
generation of hazardous substances and the prevention or reduction of environmental safety and 
heath impacts at the source (Clark, 2009). It has been recommended by several authors that green 
pharmacy should incorporate the whole life cycle of the drug including, design, manufacture, 
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transport, prescription, sales, storage, usage, disposal, sewage treatment and environmental 
degradation or persistence. The European Parliament and the European Commission agreed in 
2001 that within a generation chemicals should be produced and applied that do not have any 
impact on the environment (EU Parliament and EU-Commission, 2002). This should also hold 
true for pharmaceuticals (Kummerer, 2010). The concept of green pharmacy falls into three 
broad categories or stages where the environmental protection should be considered. These are 
green manufacture, environmental stewardship and environmentally friendly design of 
pharmaceuticals (Daughton & Ruhoy, 2008; Kummerer, 2007; Clark et al., 2010; Greenwood et 
al., 2010). 
3.2.5.1 Green Manufacture 
Firstly the green manufacture and synthesis of pharmaceutical compounds, including the 
reduction of hazardous waste products and energy costs is an important element of green 
pharmacy. This can include novel green catalytic methods, reduced solvent use, waste 
minimisation and elimination of hazardous reagents, production of enantimerically pure 
compounds and reduction of production steps. This is one of the aspects of green pharmacy that 
is being incorporated into pharmaceutical production. Cleaner synthesis methods and green 
production methods are being adopted by the pharmaceutical industry. Merck and 
GlaxoSmithKline have established best practice awards to reward their staff for embracing these 
initiatives (Greenwood et al., 2010). Green improvements in the manufacture and production of 
pharmaceuticals have been applied to new products and to existing drugs. The new green 
synthesis of ibuprofen in 1992 reduced the process steps from six to three and virtually 
eliminated all waste products by recovery and recycling (www.greenchemex.org). The synthesis 
of sildenafil citrate (Viagra) has had new green chemistry techniques applied to reduce the 
amount of waste created during its production from over 1000kg to 6kg per 1kg of product 
(Kuzemko et al., 2007).  
3.2.5.2  Take back schemes 
The second aspect of green pharmacy is to consider environmental stewardship of 
pharmaceuticals, ‘cradle to grave’ or including sustainability as well ‘cradle to cradle’. Two 
authors Christian Daughton and Ilene Ruhoy have written extensively on this topic. Post 
marketing surveillance of pharmaceuticals by medical, pharmaceutical, pharmacy and regulatory 
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industries to track adverse effects is termed pharmacovigilance (Blake et al., 2012). They believe 
that pharmacovigilance should be extended to include environmental issues such as adverse 
effects on wildlife (Daughton & Ruhoy, 2008; 2011). This would involve consumers, 
pharmacists, manufacturers, prescribing physicians and veterinarians taking action to reduce the 
introduction and release of pharmaceuticals into the environment, its pioneers believe they do not 
need to invoke the precautionary principle to justify such a programme.  Take back schemes 
involving classification and labelling are heavily reliant on communication and education of 
those involved including doctors, pharmacists and the general public (Daughton & Ruhoy, 2008). 
Directive 2004/27/EC requires that take back schemes are available for unused and expired 
medicine. Reference to these collection schemes are to be acknowledged on the package label or 
leaflet. This is to target not only environmentally friendly disposal of medications but also 
prevents build up of products in the home which can lead to accidental poisonings. The 
effectiveness of these schemes is unknown; however, surveys have indicated that potentially fifty 
percent of prescribed medication is not taken and that many consumers do not return unused 
medication to the pharmacy (Grass & Lalande, 2005). Take back schemes are one of the more 
deliverable solutions when considering prevention of pharmaceutical exposure. Although it is 
unknown what contribution they make to the overall problem, source control is widely 
recognised as having a large potential for reduction (Vidaurre et al., 2010). The key problem 
with the success of these schemes seems to stem from a lack of public awareness and clarity 
(Kampa et al., 2010). It has been identified that a fundamental part of this aspect of green 
pharmacy is a need to engage with doctors, manufacturers, water companies and environmental 
regulators to address the different issues at each stage of drugs life cycle (Greenwood et al., 
2010). 
3.2.5.3  ‘Benign by Design’  
One aspect of green pharmacy is based on the concept that drugs should be sustainable 
from the very beginning ‘benign by design’ (Kummerer, 2007). It may be possible to ‘design’ 
pharmaceuticals to limit their adverse environmental effects while retaining their therapeutic 
benefits. The idea is that a drug should be stable enough to survive degradation by the body in 
order to have the desired therapeutic effect but should also biodegrade to harmless elements once 
in the environment (Kummerer, 2007). Khetan & Collins, (2007) have suggested methods for 
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green chemistry such as including a ‘chemical switch’ to be built into the drug that would lead to 
rapid decomposition outside the body or attachment of affinity groups that could lead to 
quantitative sorption onto a particular support to be used in STPs. This is the aspect of green 
pharmacy that has seen the least research and progress. There are few examples of benign drug 
design. One is the anti-cancer drug ifosamide, which is highly recalcitrant, however by attaching 
sugar molecules, another compound glufosfamide is obtained which retains the therapeutic 
activity of ifosamide but is much more biodegradable (Kummerer et al., 2000; Keil, 2008).    
3.2.6  Ecotoxicology tests 
 It was found (see Sections 2 & 4) that there was a distinct lack of data for some aspects of 
the ecotoxicological assessment part of the ERA. This included gaps for chronic effects data 
using MoA related end points and mixture effects for pharmaceuticals (Agerstrand et al., 2009). 
Ecotoxicology also uses a narrow spectrum of species that may not reflect the most sensitive 
organisms in exposed habitats. There is also lack of data on routes of exposure including 
bioconcentration and transport through food webs (Carbonell et al., 2000; Boxall & Greenwood, 
2010; Nfon et al., 2011).  
Standardized ecotoxicology tests may underestimate the effects of pharmaceuticals. This 
is because traditional tests do not incorporate the MoA of the drug or a mixture of compounds 
which may produce antagonistic, synergistic or additive effects. For example Cleuvers, (2008) 
found toxicity of a mixture of analgesics decreased reproduction by 100% but had no effect on 
survival. Tests, however, could be based usefully on MoA, for example, the induction of 
vitellogenin in fish by oestrogens (Sumpter et al., 2006). 
Metabolites of pharmaceuticals that can be produced by breakdown products through the 
human body, sewage treatment, microorganisms in the environment or by sunlight (Liu et al., 
2009; Wei et al., 2011) may also be toxic to aquatic organisms. There is virtually no data in the 
literature on the toxicity of pharmaceutical metabolites. Biotransformation products of 
pharmaceuticals in the environment, i.e. intermediate products that resist total mineralisation, can 
be more stable than the parent compound thus increasing their potential for accumulation 
(Kummerer, 2009). 
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3.3  Method 
Structured in depth interviews were conducted with eleven people who either had expert 
knowledge of the environmental issues related to pollution of the aquatic environment by human 
pharmaceuticals or worked in relevant industries and governmental bodies. These included, a 
pharmaceutical company, a water company, The Department for the Environment, Farming and 
Rural Affairs (DEFRA), the Environment Agency (EA), an environmental consulting company, 
and 5 academics from a NERC funded research council and 2 universities.  
The interviewees were recruited by formal letter. Ten of the interviews were conducted in 
person and recorded. One interviewee responded by email. The interviewees gave written 
permission for anonymous responses to be recorded and used in this thesis.  
Participants were selected due to their contribution to the peer reviewed literature on the 
subject of pharmaceuticals in the environment, recommendations by colleagues, or by their 
organisations. Interviewees were chosen in order to explore the length and depth of views of a 
variety of expert knowledge holders rather than randomly selected to generate statistical 
information.  
All the interviewees were asked ten main open ended questions and then if time allowed 
six further short supplementary questions. Most interviews lasted between thirty minutes and one 
hour. Interviewees were offered a transcription of the interview and a copy of the results analysis 
of all the interviews when completed as an incentive for taking part. 
The interviews were fully transcribed (Appendix 13) and comments were collated into 
broad topic areas including: PECs, the 10 ngl
-1 
action limit, retrospective risk assessment, the 
precautionary principle, ecotoxicity tests, the polluter pays principle and mitigation strategies.  
 
3.3.1 Interview questions  
 
Current EU Environmental risk assessment 
 
1. Do you think that the current EU guidelines for environmental risk assessment of human 
pharmaceuticals (laid out by Article 8(3) of directive 2001/83/EC as amended including 
guidelines EMEA//CHMP/SWP/4447/00) sufficient to protect aquatic organisms and 
ecosystems? Can you explain why? 
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2. Is the 10 ngl-1 trigger limit in Europe an appropriate mechanism and set at an adequate 
level to evoke the second phase of environmental risk assessment and ecotoxicity testing? 
 
3. What are your views on the accuracy of predicted environmental concentrations? (3a. 
what are your thoughts about computer packages using GIS for example for estimating 
environmental concentrations?) 
 
Remedies/mitigation 
 
4. What are your opinions on monitoring of environmental concentrations of human 
pharmaceuticals?  
 
5. If a substantial ecotoxicological risk for a human pharmaceutical is identified what 
strategies can be employed to mitigate the risks to the environment?  
 
6. Sewage treatment methods have different capacities for removing different 
pharmaceuticals. Do you think that upgrading sewage treatment plants is the most 
effective way to reduce pollution by pharmaceuticals? Is it necessary? Who should pay 
for this? 
 
7. One of the routes of entry for human pharmaceuticals is disposal down sinks and WC’s. 
Although not the most important route it is one of the more easily remedied. For example 
30% of Propranolol (beta blocker) is never taken, potentially due to the side effects. In a 
survey by Bound & Voulvoulis, (2005) it was found half of respondents (400) did not 
finish prescriptions.  
a. Should healthcare professionals take more responsibility over non compliance of 
medicines and take steps to monitor this? 
b. Should health care professionals make people aware of correct disposal of unused 
medicines when prescribing? 
c. Should dispensing pharmacies make people aware of correct disposal of unused 
medicines? 
 
Ecotoxicity testing 
 
8. Do you think the current guidelines for the ecotoxicity testing of human pharmaceuticals 
are sufficient to protect ecosystems? 
 
9. What would be the obstacles for pharmaceutical companies in sharing information about 
human and animal toxicity results obtained during drug discovery and development to aid 
and direct ecotoxicity tests for environmental risk assessment? For example read across 
data? 
 
10. What do you think about the potential of computer generated packages to predict 
ecotoxicity? For example QSAR packages. 
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Supplementary questions 
 
11. Does the trigger limit need more scientific evidence including chronic ecotoxicity data to 
support its level?  
 
12. Do you think PECS are an appropriate tool for environmental risk assessment 
 
13. ERA is only required for new medicines. Do you think we need to conduct retrospective 
environmental risk assessments? If so who should be responsible for this? Which 
pharmaceuticals and why? 
 
14. Do you believe there sufficient scientific uncertainty of environmental risk of human 
pharmaceuticals to invoke the precautionary principle? 
 
15. Pharmaceutical metabolites can also be toxic. Should pharmaceutical companies be 
required to identify the metabolites of new pharmaceuticals? 
 
16. Should there be incentives for pharmaceutical companies to design green pharmaceuticals? 
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3.4  Results and Discussion 
 The results of the interview analysis provided an interesting insight into the different 
views of people involved in the regulation and control of the release of pharmaceuticals into the 
environment. The areas covered are the current ERA, its successes, limitations and ideas for 
improvement, the 10 ngl
-1 
action limit, mitigation of risks including STP upgrades, take back 
schemes and green pharmacy. 
3.4.1  Current EU environmental risk assessment 
The interviewees identified several shortfalls with the current environmental risk 
assessment of human pharmaceuticals and made suggestions for improvements that could be 
made to better protect ecosystems. Criticisms of the current ERA and suggestions for 
improvements that could be made fell into two main categories, effects and exposure.  
3.4.1.1  Ecotoxicological effects 
Positive aspects of the effects assessment were related to the development of a risk 
assessment for pharmaceuticals and the fact that in 2006 the guidelines shifted from a focus on 
acute effects to chronic effects of pharmaceuticals including a full lifecycle assessment on 
Daphnia and algae and a sub chronic, partial lifecycle effects assessment on one fish (EMEA, 
2006). This change better reflects the exposure route of pharmaceuticals (Section 2). One 
academic interviewee said:  
 
“The effects data side is good; we have over a decade of effects data and so can do fairly 
good species distribution effects.”  
 
One EA interviewee commented: 
 
“The progression of the risk assessment has been quite good especially since historically 
environmental data on pharmaceutical compounds was limited.”  
 
In regard to the current set of ecotoxicological tests required for an ERA, opinions were 
very mixed. The water company interviewee thought that the current ecotoxicity tests were 
sufficient and stated: 
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“That’s a reasonable spread of tests, how many companies do you want to put out of 
business by doing long term chronic mutigenerational tests at varying concentrations.” 
 
Financial burden is of course a very important consideration when performing ecotoxicity 
tests. It is obviously not possible to test all pharmaceuticals on all species including all possible 
end points because chronic tests are time consuming and too expensive to conduct on a 
compound by compound basis. Another academic interviewee concurred by saying: 
 
“To be honest it’s quite nice to have new drugs developed for our health.” 
 
Although a different academic interviewee thought that:  
 
“The cost is a tad small compared to the overall cost of developing a new pharmaceutical.”    
 
The respondent from the environmental consultancy agency stated: 
 
“Yes – as long as assessors can request further studies beyond fish, algae and daphnids 
if there is evidence for a mode of action that might not be covered by these taxonomic 
groups. This should not be seen as carte blanche for the more bonkers regulators from 
certain Member States to feel that they can ask for lots of unnecessary testing on weird 
critters!” 
3.4.1.1.1 Intelligent ecotoxicity testing 
Regulators have to take a pragmatic approach; a standard suite of tests that are relatively 
cheap and can be done by standard ecotoxicology companies is required for an ERA. However, 
seven interviewees voiced negative opinions about with the current effects testing regime. Six of 
these interviewees raised one of the key criticisms with the current ecotoxicology tests. Despite 
the move toward chronic ecotoxicology tests, the tests were still very traditional and standardised 
for all chemicals. Pharmaceuticals are designed to have a specific MoA and that this needed to 
be reflected in the ecotoxicology tests. It was thought by three academics, the pharmaceutical 
company interviewee, and the EA interviewees that the idea of intelligent testing or targeted 
ecotoxicology testing should be developed. This should incorporate the use of chronic test end 
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points that reflect the MoA of the drug and any known side effects. Four respondents thought 
there was an opportunity to make better use of mammalian toxicology data. One academic 
interviewee said: 
 
“The specific mode of action might mean they pose a greater risk than standard tests 
reveal. There is a risk of underestimates of hazard.”  
 
Another academic interviewee commented: 
 
“Intelligent ecotoxicity incorporating mode of action in the human might be relevant to 
the wider environment and then testing more appropriately with that information. Rather 
than testing a drug that targets depression on algae.” 
 
A third academic interviewee thought that: 
 
“Chronic and sub lethal effects assays should be focussed on the known side effects of 
those drugs, and known mode of action…for example the chronic growth test isn’t 
particularly helpful because growth isn’t a particular end point for pharmaceuticals.” 
 
One EA interviewee said: 
 
“The concern is the unwitting mode of action effects that might arise, that you don’t pick 
up from the rather narrow array of ecotox tests. It’s a blunt instrument.” 
 
The choice of ecotoxicological test end points can change the no effect concentration 
(NOEC) substantially. It is likely that short term growth and reproduction responses are not 
related to target-mediated responses, which may be observed at concentrations that are orders of 
magnitude lower than the standardized chronic toxicological benchmark concentrations (Boxall 
& Greenwood 2010). Stanley et al., (2007) and Valenti et al., (2009) reported  lower effect 
concentrations for feeding behaviour of fish, a response related to the mammalian therapeutic 
MoA of the antidepressants fluoxetine and sertraline respectively, than the effect concentration 
for growth (Berniger & Brooks, 2010).  
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The responses of the interviewees in respect to a more intelligent chronic test strategy 
related to the MoA of the drug supports the validity of the work carried out in Section 4. The 
MoA of pharmaceuticals as a potential guide for choice of chronic test end points is clearly 
desirable and would better reflect the effects that may be occurring on non target organisms after 
pharmaceutical exposure. Bioinformatics and molecular docking could provide a useful tool to 
aid the choice of chronic test end points in ecotoxicity tests (Section 4). A recent study on the 
effects of the selective serotonin reuptake inhibitor (SSRI) anti-depressant sertraline on fish 
found a combination of a serotonin receptor binding assay and observations of behaviour to be a 
useful ecotoxicity strategy. It was found that a decrease in the binding of serotonin to the 
serotonin receptor was linked with shelter seeking behaviour of fish after sertraline exposure 
(Valenti et al., 2012). This study highlights the validity of using bioinformatics information such 
as that carried out in Section 4 to make predictions about pharmaceutical effects based on 
conservation of drug target sequence homology.  
3.4.1.1.2 Laboratory versus field  
Another point that was made about the limitations of current ecotoxicological tests was 
that tests are carried out in the laboratory and may not reflect the real life situation. One 
academic interviewee thought: 
 
“A general criticism of ecotox is that it’s carried out in laboratories and they don’t look at what the 
real effect might be in the field. Might be lesser or greater effect depending on how the other 
environmental variables effect how the animal is affected. Combinations of stressors, mixtures and 
physical stressors” 
 
Many environmental stressors occur in the real environment which are not replicated in the 
laboratory such as: combinations of mixtures of pharmaceuticals and/or other compounds, 
fluctuating concentrations (Section 2), changes in bioavailability, environmental degradation or 
sorption to sediments, natural changes in environmental conditions, effects on other organisms 
which can alter ecosystem dynamics (e.g. predators, competitors and organisms that are food 
sources) and anthropogenic stressors such as the presence of other pollutants. Current 
ecotoxicology tests do not reflect all the routes of exposure and in reality there is a general lack 
of data on routes of exposure including trophic magnification and bioconcentration. The near 
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extinction of vultures caused by the veterinary drug diclofenac highlighted evidence of this 
concern. The guidelines for ERA (EMEA/CHMP/SWP/4447/00) state that an assessment factor 
(AF) of 10 should be applied to the PNEC to account for laboratory to field impact extrapolation. 
Currently there is a lack of evidence in the literature that this AF is set at an appropriate level to 
account for differences in laboratory to field effect concentrations for pharmaceuticals and 
highlights a potential research need.  
3.4.1.1.3 Species selection 
Three respondents mentioned a need for an increase in the numbers of species that are 
used in ecotoxicity tests. Molluscs were highlighted as a species that should be included on more 
than one occasion. The DEFRA interviewee said:  
 
“We do need to increase the numbers of species across the board. We haven’t got any 
tests for molluscs and we know that they are susceptible to compounds. We are trying to 
develop them but it takes time. There’s huge groups of which we have no idea.”  
 
The pharmaceutical company interviewee mentioned that:  
 
“Some mollusc species seem to be more sensitive than some of the other species. I know 
that’s true for propranolol and fluoxetine.”  
 
Molluscs and mussels have been highlighted as a species that should be covered by 
ecotoxicity testing of chemicals and pharmaceuticals but which are not currently (Rittschof & 
McClellan-Green, 2005). Several studies have found that molluscs may be sensitive to 
propranolol and fluoxetine (Lazzara et al., 2012; Bringolf et al., 2010; Ericson et al., 2010). 
Conservation of drug targets in molluscs may also lead to similar a MoA occurring in these 
organisms (Section 4). Clearly molluscs should be considered as an important addition to 
ecotoxicity tests. 
 Selection of sensitive test species is important for ecotoxicity studies. At present the test 
species selection is quite narrow and may not reflect the species that are likely to be exposed. 
Bioinformatics and molecular docking techniques may be a useful tool to identify species that 
have conserved drug targets that could be used in MoA directed chronic tests (Section 4). 
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3.4.1.1.4 QSARs 
A number of new approaches are being developed using quality structure activity 
relationships (QSARs) for chemicals. These bioinformatics computer packages can help make 
predictions about toxicity, persistence, biodegradation and lipophilicity of organic compounds 
(Jager & Kooijman, 2009; Mekenyen et al., 2005). They provide structural alerts using non test 
data, existing databases and assignments of modes of actions for compounds (Jager & Kooijman, 
2009; Clark et al., 2010). The general consensus from all interviewees was that present computer 
generated packages for predictions of toxicity were poor. Three academic interviewees 
commented that: 
 
“To date they have failed abysmally, impossible to think of an example where a QSAR 
has predicted something we didn’t know previously.”  
 
“It’s an obvious one to look at but the messages I’ve had about their effectiveness have 
been very mixed.” 
 
“I think they are getting better. QSARs are predicting chemical properties base on 
structures and whether something would degrade quickly or whether it would adsorb, 
sediment phase. Toxicity is trickier, I wouldn’t trust it.” 
 
One of the main drawbacks for using current QSARs to predict toxicity is that they predict acute 
toxic effects and this is not appropriate for human pharmaceuticals (Carlsson et al, 2006; Fent et 
al., 2006). One EA interviewee said: 
 
“We tried that and it was probably a bit dodgy. We did that in the prioritisation work five 
or six years ago. They tend to focus on acute effects and that’s not the issue here. Also 
they only really tell you with confidence something about baseline toxicity and we are 
dealing with specific effects.” 
 
Although they have been shown as satisfactory to predict acute toxicity (Torapova et al., 2012), 
QSARs have been shown to be inaccurate tools for predicting chronic toxicity or acute chronic 
toxicity ratios (Dom et al., 2012). Seven of the interviewee’s were sceptical about QSARs at 
present but were optimistic about their potential in the future. Six interviewees hoped that they 
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could become a useful tool for predicting persistence, bioaccumulation and toxicity (PBT) or 
providing guidance for ecotoxicity testing. The government interviewee thought that: 
 
“A lot of potential but they need to be used carefully though. They can give you an 
indication of likely toxicological impacts. Still have to go out and do the science after. A 
good basis for starting. I see them as plugged into an intelligent ecotox strategy.” 
 
The water company interviewee asked: 
 
“Have we got enough experience to have faith in what they are telling us? Another 
screen….another tool in the box.” 
 
One academic interviewee expressed the view that: 
 
“I think that all of the computer generated packages have something to contribute. No 
single test or computer model will give all the information. Part to play especially in the 
context of new substances, can’t test all of them, on all organisms. Computer modelling 
has a role to play in establishing a prioritisation, sometimes you miss things.” 
 
The pharmaceutical company interviewee believed that: 
 
“In the short to medium term they’ve got a long way to go. In the longer term I think 
they’ve got a lot to offer. For ecotox tools like genomic tools, looking at pathways for 
gene expression, protein expression…they might point you to the type of definitive studies 
that you need to do and the types of endpoints…As you are sequencing more data from a 
larger range of species, the likelihood that if you know the mode of action in man, what 
the end point, what the gene target is, you can see whether that target exists in the wider 
wildlife and the most appropriate species. Although I don’t see us changing a lot of what 
we do, we may supplement it with more intelligent end points to direct the types of studies 
we are doing and maybe encompass a range of different species.” 
 
Another academic interviewee thought that: 
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“They are potentially very good as we got them from the medical community. If there 
was a group of compounds you could use QSARS its pharmaceuticals.” 
 
The overall impression was that although the environmental community like the idea of 
QSARs, the reality is that at present QSARs are not capable of predicting PBT. Biodegradation 
systems using QSAR systems may be flawed because they do not mimic real conditions 
(Greenwood et al., 2010).  A recent study on using QSARs for predicting PBT within REACH 
(Registration, Evaluation and Authorisation of Chemical Substances) legislation found that 
widely used QSAR databases might have some errors (Zachary & Greenway, 2009). The 
KNAPPE Workshop, (2008) also concluded that current QSAR approaches are probably 
inappropriate for use on pharmaceuticals (Boxhall & Greenwood, 2010). Lienert et al., (2007) 
found there were limitations with QSAR modelling for hydrophilic and ionisable drugs.  
 It can be seen from the views expressed by the interviewees that they hoped QSARs 
could become a useful tool for risk assessment but could not replace traditional ecotoxicity tests. 
The comments from the pharmaceutical interviewee were supportive of the bioinformatics work 
carried out in Section 4. Bioinformatics and molecular docking packages such as AutoDock 
could provide a tool to guide the selection of sensitive organisms and MoA related end points for 
toxicity tests. Although QSARs still need substantial development and validation to be used as 
an accurate predictor for toxicity, it is clear from the comments from interviewees that these 
tools are desirable. The potential exists to use bioinformatics to supplement ecotoxicity tests. 
3.4.1.2 Exposure 
Five interviewees thought the exposure data side of the ERA needed to be improved. One 
reason for this was the lack of data for degradation in the environment, degradation during 
sewage treatment and human metabolism. The pharmaceutical company interviewee commented: 
 
“The current exposure model does not account for ionisable compounds or compounds 
that have a charge that may shift depending on pH or ionic strength. Chemicals with a 
polar charge or low log Kow (octanol water coefficient) may not fit the exposure model.”  
 
The same interviewee also believed that: 
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“Bio concentration estimates based on log Kow may be inappropriate for some drugs, so 
we could be overestimating or underestimating the bio concentration potential. Some of 
the pharmaceutical industry is starting to look at this.” 
 
The octanol water coefficient log Kow is used as an indicator for adsorption and 
bioconcentration. In fact it appears that log Kow is a poor descriptor of environmental behaviour 
for either sorption to sediments, sewage sludge or bioaccumulation. This is because the majority 
of pharmaceuticals are polar ionisable compounds (Besse & Garric, 2010). For example 
ciprofloxacin has a reported log Kow of -1.74 (Brooks et al., 2003) and hence would be assumed 
to adsorb to sludge very poorly and be disregarded for PBT assessment in the ERA guidelines as 
it is well below the 4.5 threshold limit. However, ciprofloxacin adsorbs strongly to sewage 
sludge (Golet et al., 2002). A further issue with the use of log Kow for these assessments is the 
high variation in reported figures in the literature. For example a log Kow as low as 1.57 (Brooks 
et al., 2003) and as high as 4.6 (Oaks et al., 2010) has been reported for fluoxetine. It is thought 
that pH corrected log Dow may be a better indicator for sewage sludge adsorption (Kah & Brown, 
2008). It has also been found that the liposome/water distribution ratio (Dlip-water) may be a more 
useful descriptor for predicting bioaccumulation and toxicity as there is very little ionic strength 
dependence for the partitioning of compounds across liposome membranes (Nakamura et al., 
2008). The problem with using Kow for estimating removal of pharmaceuticals during sewage 
treatment are apparent in models such as SimpleTreat, which is the model recommended in the 
EMEA guidance for the ERA of pharmaceuticals to estimate removal during sewage treatment. 
These models are not able to handle ionised compounds or characterize biodegradation rates 
accurately (Seth et al., 2008). 
Another problem with predicting exposure that was highlighted by interviewees was that 
the current ERA assumes there is no metabolism in the patient in the initial PEC calculation. 
However, a number of medicines are highly metabolised. The pharmaceutical company 
interviewee said: 
 
“One or two drugs we know will degrade to something else within the STP, and some 
drugs are hydrolytically unstable and fall apart quite quickly in STPs, therefore the 
active ingredient is not always the compound we should be testing.” 
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This comment covers two important points, one is that the lack of inclusion of metabolism data 
means that the exposure models will overestimate concentrations of pharmaceuticals in the 
environment and therefore produce a worst case scenario which is perhaps highly precautionary. 
However, the other point is more of a worry in regard to protecting the environment in that the 
ERA does not adequately consider situations where not only the parent compound will enter 
rivers and streams but their breakdown products will also enter water bodies. The impact and fate 
of these metabolites is not known and should be examined.  
3.4.1.3 Retrospective risk assessment 
Currently the EMEA guidelines for environmental risk assessment of pharmaceuticals 
only apply to the registration of new medicines. Retrospective risk assessment for 
pharmaceuticals is not currently required. However, the scientific literature contains several 
ERAs for pharmaceuticals that were licensed prior to 2006 which may pose a potential risk to the 
environment. Some examples are: mefenamic acid (anti inflammatory) (Tauxe-Wuersch et al., 
2005), ibuprofen, paracetamol and acetylsalicyclic acid (Stuer-Lauridsen et al., 2000), 
propranolol (Miege et al., 2006) ciprofloxacin, diclofenac (Grung et al., 2008) and fluoxetine 
(Oaks et al., 2010). The findings of these studies are not, however, fed into any regulatory 
procedure. This issue was touched upon during the interviews. One academic commented:  
 
“We are not good in the UK with dealing with the findings. We need to ensure follow 
through to action.” 
 
In 2003 the EA produced a report on pharmaceuticals in the environment (EA, 2003). 
This report was essentially a retrospective ERA for pharmaceuticals starting with a priority 
system, however, a lack of effects data and scarcity of methods for measuring the chemicals 
identified as priority led to a considerable amount of uncertainty about the risks in the report. 
One EA interviewee said: 
 
“We had our fingers burnt here, we are happy to do it but the problem came when we got 
into discussions with the pharmaceuticals industry, they weren’t keen on picking up the 
challenge. It wasn’t helped by the fact that we had to make so many assumptions about 
the risks.”  
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Eight interviewees were in favour of retrospective ERA of pharmaceuticals. It was 
thought that a system for prioritisation was the key to this issue because of the high numbers of 
pharmaceuticals involved. Besse & Garric, (2010) stated that prioritization of pharmaceuticals is 
necessary due to the high numbers of pharmaceuticals hindering the possibility of assessing the 
ecotoxicity of every compound. There is a need to accurately assess exposure and the 
environmental effects. The consultant interviewee commented:  
 
“Yes, there should be an ERA during reauthorisation of older medicines, paid for by the 
authorisation holder. There could be an appropriate sales volume cut off for this so that 
minor but useful medicines are not removed from the market.”  
 
One academic interviewee expressed the view that: 
 
“It’s sensible to know what the environmental risk is with all the drugs we use today…I 
would like to see that” 
 
Another academic interviewee highlighted the fact that: 
 
“The difficulty is how to rank the pharmaceuticals” 
 
The pharmaceutical company interviewee believed that: 
 
“For existing products I think some prioritisation is needed, there are some data gaps 
that need to be filled.”  
 
It is apparent from these findings that retrospective ERA for pharmaceuticals is a failing of the 
current regulations. The introduction of a prioritization scheme is an important starting point for 
implementation of any retrospective analysis. One example put forward for prioritisation is that 
of Sweden which is based on biodegradability, potential for bioaccumulation and toxicity. It is 
based on both hazard and associated risk (Agerstrand & Ruden, 2009). Many other suggestions 
by other authors are being proposed for prioritisation systems (Besse & Garric, 2008; Kumar & 
Xagoraraki, 2010; Roos et al., 2012; Cooper et al., 2008).  
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The Water Framework Directive 2000/60/EC (WFD) may be a mechanism by which 
retrospective risk assessment and environmental monitoring of priority pharmaceuticals may be 
achieved (von der Ohe et al., 2011). WFD requires “good chemical status” of water bodies in the 
EU by 2015. WFD contains a defined list of priority substances that can adversely affect the 
ecosystem. This list does not contain any human pharmaceuticals at present, however, the list is 
to be reviewed every four years. WFD put emphasis on the precautionary principle stating that 
especially in identifying priority hazardous substances, any potential adverse effects of the 
product should be taken into account and should lead to scientific assessment of the risk (recital 
11 & 44, WFD). Inclusion on the priority list is governed by toxic, persistent and bio 
accumulative characteristics. On this basis three pharmaceuticals have been suggested for 
inclusion by the German Environment Agency; carbamazepine, diclofenac and ibuprofen 
(Kampa et al., 2010). However, in a recent press release it was stated that EE2 and diclofenac are 
to be added to the next updated list (European Commission, 2012). 
3.4.1.4 Trigger limits 
Six interviewees did not agree with the 10 ngl
-1
 trigger limit. The pharmaceutical 
interviewee commented: 
 
“For the most part I can live with it. I have some issues around the market penetration 
factor…for most drugs; one percent is extremely over protective for other compounds it’s 
extremely under protective.” 
 
There were several reasons given for disagreeing with either the trigger limits level or 
having a set limit at all. The main reason given was that EE2 has a detrimental effect on aquatic 
organisms at concentrations below 10 ngl
-1
. In fact five interviewees, (3 academics, the 
government and the water company interviewees) mentioned this point. Although the ERA has a 
caveat for endocrine disrupting substances that mean they must conduct the second phase of the 
ecotoxicological tests, it was thought that the limit was insufficiently precautionary because EE2 
has an effect at 0.3 ngl
-1
 and could kill a fish at 10 ngl
-1 
(Caldwell et al., 2008). If the 
requirement for an ERA had been in existence when EE2 was first marketed it would not have 
been picked up as a potential problem because concentrations of EE2 would never reach 10 ngl
-1
 
in surface waters simply because of its high potency and the low tonnage marketed. The fact that 
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ERA does exist now presents an opportunity to learn important lessons from past mistakes by not 
discounting compounds which may act at low concentrations but are not endocrine disrupting 
substances.  
 Analytical chemistry techniques may not be reliable or sensitive enough to measure 
compounds as low as either 10 ngl
-1
or more importantly at concentrations that can cause 
ecotoxicological effects i.e. analytical chemistry detection limits are too high for some 
compounds (Johnson et al., 2008). One academic interviewee believed that: 
 
“It should be a trigger limit that’s based on the ability to detect the material.”  
 
Another academic interviewee agreed: 
 
“There are some pharmaceuticals that are actually quite difficult to measure at ten 
nanograms per litre.” 
 
The water company interviewee concurred: 
 
“I suspect that for a lot of these compounds for analytical chemistry to get down to ten 
nanograms is rather optimistic” 
 
In fact there are several problems with analytical chemistry techniques that have been 
highlighted in the literature. The fact that techniques cannot measure as low as 10 ngl
-1 
is one.
 
Analytical chemistry measurements for pharmaceutical compounds can be unreliable and may be 
inaccurate at very low levels or in difficult matrixes such as sewage. For example, results of 
pharmaceutical measurements in the literature have been discredited in the case of EE2 (Johnson 
et al., 2008). An inter-laboratory exercise showed that measurements of organic contaminants 
can differ by two orders of magnitude despite state of the art equipment (Van Leeuwen et al., 
2006). In regard to these issues with the capabilities of analytical chemistry, one academic 
interviewee thought:  
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“One big caveat to threshold values if we are using them if we are using them for 
enforcement or some way as part of the regulatory process it has to be something we can 
measure.”  
 
Two academics disagreed with having a trigger value at all. One believed that: 
 
“No regulation based on an arbitrary number for any chemical whatsoever is 
scientifically sustainable.” 
 
The other academic agreed:  
 
“I don’t think you should have a single number for any trigger because…ethinylestradiol 
affects fish at 1 ngl
-1
 or even less. It’s always dangerous to have a single trigger value.” 
 
 Incorporating the MoA of each pharmaceutical in the ERA was a common thread among 
many of the interviewees (see above). Another recommendation by an academic interviewee was: 
 
“The trigger limit should bet set at a level that incorporates data on the bioavailability 
and blood or plasma circulating concentrations of the pharmaceuticals in organisms.” 
 
This could well be considered if pharmaceuticals were examined on a case by case basis and 
should incorporate data from non mammalian trials for blood circulation levels. This type of 
approach could help prevent unnecessary animal tests for ecotoxicological purposes. Despite 
these criticisms the water company interviewee commented: 
 
“You can always criticise but you have to start somewhere” 
 
The government interviewee expressed the view that: 
 
 “Trigger limits are useful”  
 
and the pharmaceutical company interviewee thought that: 
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“It’s fair to have a trigger limit but people need to be aware of the short comings.” 
 
It appears that trigger limits are intrinsically flawed. It would seem a more intelligent approach is 
to establish what the effect concentration is first by conducting some ecotoxicological tests. 
These tests should be conducted on a compound by compound basis, incorporate the MoA of the 
drug and potentially mammalian toxicology data. The other crucial aspect of setting exposure 
limits for pharmaceutical relates to analytical chemistry techniques. If methods are not sensitive 
enough to measure concentrations below the effect concentration then potentially other 
techniques for estimating environmental concentrations need to be employed as well.  
3.4.1.5 Predicted environmental concentrations (PECs), measuring, modelling and 
monitoring  
There are several issues with the current PEC calculation used in ERAs (Section 2). The 
problems are the default values it contains i.e. the default market penetration factor (Fpen) of 1%, 
the default dilution factor of 10, the default figure for waste water produced per person per day 
(200L), the assumptions that it makes i.e. an even distribution across the geographical area, even 
consumption over a whole year, the maximum daily dose is taken by every user and the 
refinements that can be made for metabolism or sewage treatment removal. Many of these 
problems were mentioned by the interviewee’s. The water company interviewee believed that 
PECs: 
 
 “Require some pretty heroic assumptions.”  
 
The government interviewee concurred:  
 
“They have to be taken with a good dose of scientific salt”  
 
The pharmaceutical company interviewee expressed a similar view: 
 
“It’s a bit of an art as much as a science”  
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The pharmaceutical interviewee also highlighted that the 1% default market penetration factor 
was often either an underestimate or overestimate of what actual sales would be (for quote see 
section 3.4.2). The pharmaceutical company interviewee then said: 
 
“My problem comes in a little bit more when a drug will go off patent, at that point there 
is an assumption made by the regulators that those generics will move in to that sector 
and that they will just take up that market share that the branded company had and that’s 
not always the case because the price comes down and the market can grow” 
 
This means that a PEC or MEC could increase some years after the ERA was conducted and a 
new drug was licensed.  Therefore, it would seem reasonable to require companies which market 
generics to also conduct an ERA once a patent has expired. The pharmaceutical company 
interviewee also had an issue with the maximum daily dose used in the PEC calculation. 
 
“The maximum daily dose is an assumed daily dose whereas some therapies you might 
take intermittently or for a short period until you are better.” 
 
This may seem somewhat over protective for some pharmaceuticals, however, the ERA has to 
reflect a worst case scenario and once you incorporate factors relating to differences in regimes 
of therapy you could incorporate more uncertainty into the PEC. 
Other criticisms of the PEC calculation that echo the findings from Section 2, were that 
the dilution factor of ten is often not precautionary enough for some water bodies especially 
during dry seasons. Some drugs are likely to have an uneven distribution across the UK 
landscape due to factors such as increased use of some drugs in more elderly populated areas and 
also near hospitals or nursing homes. Towns with a high population elderly people can discharge 
considerably more compounds such as anti-inflammatory drugs (Ahonen et al., 1992). These 
factors could lead to regional hot spots. The pharmaceutical interviewee commented: 
 
“In the UK we can get a grip on what the total tonnages or total kg per medicine that are 
prescribed but we don’t know the geographical distribution between different healthcare 
trusts and different areas. This can result in uneven distribution across the UK landscape. 
So you can get regional hot spots.” 
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An EA interviewee thought: 
 
“It involves a lot of assumptions in terms of how much is used. How much of the market 
things are going to take up……things that have been picked up previously are in terms of 
hot spots.” 
 
The water company interviewee said: 
 
“If you are working from usage, you are making a lot of assumptions about how much is 
broken down even before it gets to sewage treatment works, what the breakdown is 
through the works, what different breakdown you get through different treatment 
processes, and then what dilution you’ve got.” 
 
An academic expressed the view that:  
 
“Many areas or seasons may have a dilution factor a lot less than 10” 
 
With regards to initial PEC refinements, the interviewee from the pharmaceutical company 
commented that: 
 
“We rarely refine our PECs and tend to leave them as the crude initial worst case figure 
for water.” This was partly because drugs rarely pass the ready biodegradation study 
and therefore a default rate constant for sewage treatment removal cannot be calculated 
to refine a PEC and the water sediment study fails to predict fate in a river.” 
 
It was interesting to note that this interviewee also mentioned that:  
 
“For all our products at the moment we don’t have a risk quotient greater than 1 and we 
only have one that is greater than 0.1.”  
 
This means that no refinements are required as all the compounds pass the ERA. Despite the 
criticisms on PECs there were several positive comments. Four interviewees felt that PECs were 
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a necessary part of risk analysis that allows us to make a decision. Academic interviewees 
believed: 
 
“They are just an estimate; they give you a ‘ball park figure’.” 
 
 “Risk assessment requires an estimate of exposure and that at present there is a lack of 
an alternative.”  
 
“PEC estimates are usually rather poor, but that’s fine so long as they err in a 
conservative direction during early tiers of a risk assessment.” 
 
The consultancy interviewee said: 
 
“Yes – I don’t know what else you can use. Surely the question should be about the way 
in which the PECs are derived. They need to be quick, cheap and highly conservative at 
lower tiers and more realistic (therefore much more expensive) at higher tiers in a risk 
assessment framework.” 
 
3.4.1.5.1 Exposure modelling  
 Exposure modelling packages have the potential to reduce some of the uncertainties that 
the assumptions in the PEC calculations (dilution factors and even geographical usage) and 
deficiencies with analytical chemistry techniques create. Several exposure modelling packages 
have been developed to predict environmental concentrations of organic compounds. These 
include European Union for Evaluation of Substances (EUSES), Geography-referenced Regional 
Exposure Assessment Tool for European Rivers (GREAT-ER) and Pharmaceutical Assessment 
and Transport Evaluation (PhATE). Overall interviewee’s views on exposure modelling 
packages were quite positive. Four academic interviewees commented:  
 
“Well, I think if it’s done properly, it’s excellent and possibly almost better than 
measurements.”  
 
“PECs are more reliable than measured concentrations.”  
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“I am confident that concentrations they predict are a reasonable starting point.” 
 
“If the models are used appropriately they provide very useful information.” 
 
One of the advantages with exposure modelling packages was that you can change the 
parameters of the model. For example you can change the flow of the water body, temperature 
and pH. Another advantage is that the models provide a range of concentrations, so that you can 
find out the difference in low or high flow situations. A single measurement at one time, on one 
particular day, at one location doesn’t provide as much information. It is important to be able to 
put measurements into context. It was also thought that exposure models could overcome some 
of the difficulties with the reliability and accuracy of analytical chemistry especially when 
measuring at such low concentrations and in difficult matrices such as sewage. Finally they are 
quick to run and cheap to do. Problems with the use of these packages included: possibility of 
overestimates, some uncertainties with knowledge about fate and behaviour, choosing the right 
model and an understanding of the models limitations. The consultancy interviewee commented: 
 
“Packages such as GREAT-ER are fine, as long as they are not used as “black boxes” 
with little chance of understanding how input data are converted into pretty-looking 
outputs.”  
 
Geo-referenced point source water quality models such as PhATE and GREAT-ER 
incorporate factors such as geography, hydrology and dilution and complex information such as 
sewage discharge and abstraction points and annual low and high river flow information 
(Cunningham et al., 2011; Price et al., 2009). The European Union System for the Evaluation of 
Substances (EUSES) is a multimedia model that can predict the fate of organic chemicals in 
water, air, soil and sediment and is used in chemical risk assessment in the EU (Schwartz et al., 
1998). The greatest value of such models is the ability to compare the fate and partitioning of 
chemicals to one another, but they are much less suitable for predicting real world surface water 
concentrations (Johnson et al., 2008). A small scale targeted monitoring study should always be 
used to corroborate a models prediction (Johnson et al., 2008). 
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Without detailed knowledge of fate and behaviour, PECs will always be an estimate. 
Models such as GREAT-ER and PhATE hold much promise for offering a more detailed and 
informative predicted range of environmental concentrations of pharmaceuticals and could assist 
with some of the limitations associated with analytical chemistry techniques. However, they need 
to be used with some caution. The answers that they provide are only as reliable as the data that 
is fed into the model. Therefore some environmental measurements will still need to be taken 
and some monitoring may need to be performed. The most sensible solution appears to be a 
combined approach incorporating some modelling and some measurements. Although it seems 
that a definitive answer on exposure cannot always be reached, the most important feature of 
PECs must be that they are precautionary and represent a worst case scenario. The findings from 
Section 2 indicate that this is not currently always the case which is unsurprising considering the 
assumptions that the PEC calculation makes.  
3.4.1.5.2  Monitoring 
There were several valid points made that highlighted the problems with monitoring of 
pharmaceuticals. There was a general feeling that monitoring for its own sake was a waste of 
time and that some indication of an adverse impact needed to be evident in order to warrant a 
monitoring campaign. The consultancy interviewee stated: 
 
“I see little point in monitoring for its own sake. There would need to be a good reason to 
require monitoring of effluents or receiving waters, such as unexplained adverse effects below a 
discharge.”  
 
The water company interviewee asked: 
 
“How much effort are you going to throw into monitoring before you think you have an 
effect? If there no effect then what’s the problem?” 
 
There are a lot of pharmaceuticals on the market and it would be clearly unfeasible and 
probably unnecessary to monitor all of them. Monitoring any pollutant is very expensive so it is 
important to establish that a compound does in fact pose a risk before starting a monitoring 
campaign. The most sensible way is probably to prioritise or rank pharmaceuticals to establish 
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which may warrant monitoring. It is essential to identify at as an early stage as possible those 
compounds that are of the highest priority so that monitoring can be focused and not wasted on 
products that do not pose a risk (Greenwood et al., 2010).One academic expressed the view that: 
 
“You really have to target which compounds you are most concerned with. The 
compounds I would have the greatest curiosity knowing what’s out there and in what 
concentrations is the groups of cancer chemotherapy, cytotoxic drugs and anything to do 
with hormonally acting drugs.” 
 
Once it is established that monitoring of a certain compound is required, the second 
problem is deciding where the measurements should be taken. A concentration of a 
pharmaceutical in a water body in one location doesn’t tell you what concentrations will be in 
other water bodies or for that matter what concentrations are likely to be further up or 
downstream. Differences in hydrology, degradation, and particulate binding also need to be 
considered. The findings in the data analysis performed in this work (see Section 2) highlighted 
these problems. Many researchers do not examine different locations when testing for 
pharmaceuticals and may only take a single grab sample at sewage outfall. This gives you 
limited information about the actual exposure situation in the bulk of the water body. Potentially 
the use of modelling software packages could be used in conjunction with a monitoring 
campaign. Although modelling needs validating with some actual measurements, modelling can 
be a useful tool to tell you where to measure, and help develop a monitoring strategy. A 
combination of measuring and modelling would provide the most robust approach to the risk 
assessment of micro contaminants in the freshwater environment and scientists in both 
disciplines should cooperate more closely to achieve this (Johnson et al., 2008). If diclofenac and 
EE2 are added to the list of priority pollutants as part of WFD, monitoring of these compounds 
will become a reality. One academic said: 
 
“There needs to be a balance between monitoring strategy and some link with a 
modelling prediction of where to look.” 
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The next problem is choosing an analytical chemistry technique that is reliable and robust 
enough to measure concentrations especially when they are likely to be very low, as in the case 
of EE2. One academic interviewee thought that:  
 
“Analytical chemistry has some limitations that have to be recognised.”  
 
Important factors mentioned by interviewees when considering monitoring of 
pharmaceuticals were that it is difficult, very expensive and time consuming. The methods can 
be quite difficult to develop and perform and the subsequent data analysis requires some 
expertise. Another academic commented: 
 
“Its expensive, analysis is difficult and the results are probably unreliable.” 
 
A lot of measurements are required for robust results that could be used in an ERA. A third 
academic interviewee said: 
 
“The techniques don’t lend themselves to cheap rapid robust methods that you can use in 
a regulatory environment with high throughput.” 
 
And then suggested: 
 
“What we can do is a total measurement of a particular type of compound, for example 
we had a total pesticide concentration in the water.” 
 
A total concentration measurement of similarly acting pharmaceuticals may be useful. 
This could also be applied when thinking about ranking pharmaceuticals for monitoring by 
environmental concern i.e. by treating similar compounds as a group (Greenwood et al., 2010). 
However, Kummerer, (2009) advises against this strategy because even small changes in 
chemical structure may have significant impacts on solubility, polarity, toxicity and MoA. 
Bioinformatics and molecular docking packages could be extremely valuable for this type of 
approach. The work carried out in Section 4 highlights the potential of molecular docking to 
establish whether different pharmaceuticals bind to the same target protein and thus act in a 
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similar way. If they do as in the case of ibuprofen and diclofenac then potentially a total 
concentration of these drugs could be more useful than individual amounts. It is important to also 
consider whether these compounds act in an additive or synergistic manner or in an antagonist 
manner. If drugs can cancel out or lower the effects of other drugs then perhaps a total 
concentration is not particularly helpful when considering what effects may be occurring on non 
target organisms. 
Bioassays were mentioned as an alternative to doing chemical monitoring. One academic 
said: 
 
“If we were to use a type of bioassay for example a vitellogenin response that would 
integrate some of the signals from multiple substances, both estrogenic substances, SSRIs 
and other substances to be more additive.” 
 
Many substances have estrogenic properties like EE2. The effect concentrations and 
environmental concentrations are very low making it difficult for analytical chemistry 
measurements to be accurate (see above).  The use of biomarkers may hold some promise for 
offering a more informative assessment of what effects a considerable mixture of 
pharmaceuticals may be having on aquatic ecosystems. One example of a potential biomarker is 
the vitellogenin response. Vitellogenin 1 and 3 are particularly expressed when male zebra fish 
are exposed to a concentrations of EE2 greater than 10 ngl
-1
 (Martyniuk et al., 2007). Induction 
of vitellogenin has also been demonstrated as an indicator of oestrogenic activity of mianserin 
(serotonergic antidepressant) in the aquatic environment (Van de Ven et al., 2006). Another 
potential biomarker is the cytochrome P450 which has an essential function in the metabolism of 
many pharmaceuticals. Expression levels of this can be used to indicate exposure to 
pharmaceuticals (Hong et al., 2007). The bioinformatics results in Section 4 indicate that 
cyclooxygenase enzymes would be inhibited in three species of fish (and potentially more) 
leading to reduced prostaglandin production. Experimental work has supported this finding 
(Mehinto et al., 2010). Bioinformatics may be valuable for the indication of suitable biomarkers. 
Bio assays such as ELISA (enzyme linked immunosorbent assays) offer specificity and accuracy 
at low concentrations and could be used to measure selected biomarkers. One proposal to help 
with development of techniques for bio monitoring was improving communication between 
pharmaceutical companies and ecotoxicologists and regulators. An academic interviewee said: 
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“The science community need to talk to the drug companies with regards to techniques 
that have been used in the drug development process that we could use for bio 
monitoring for example bioassays, antibody assays, ELISA and cell based assays. There’s 
no need to reinvent the wheel. There needs to be a mechanism to release the protocol 
without releasing any confidential, commercial information that’s in the dossier for that 
drug. These problems have been met before with workshops.”  
 
The pharmaceutical company interviewee said that they did not actively do any 
monitoring of pharmaceutical concentrations apart from at manufacturing facilities. However, 
they did compare their PECs to measured concentration data from the literature and would revise 
a PEC in the light of a higher MEC in order to be more precautionary. As an example of this the 
interviewee mentioned that recently they set a PEC for a generic drug using published MEC data 
because a substantial quantity of monitoring data was available for that product. This was 
interesting because although the other interviewees felt that monitoring was not warranted and 
potentially a waste of time and money, the pharmaceutical company were making use of data 
that was produced from monitoring campaigns.  
One of the problems that the pharmaceutical company regularly encountered when using 
the peer reviewed literature to set PECs and PNECs was a lack of reliable data in many 
publications. This was problematic on the exposure and the effects side. The pharmaceutical 
company interviewee said: 
 
“80-90% of data that is published we can’t use for regulatory purposes.”  
 
This echoes the findings during this study in which the majority of publications in the peer 
reviewed literature lacked important information that would make exposure concentration data 
fit for analysis (see Section 2). The non governmental organisation, ECETOC (The European 
Centre for Ecotoxicology and Toxicology of Chemicals) is addressing these issues by providing 
a mechanism for scientists to come together and publish things around what a good, robust 
monitoring program might look like and encourages people to follow these guidelines (Kuster et 
al., 2009). The development of standards and guidelines for publication of environmental data is 
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of paramount importance if work carried out by the academic community is to be used for 
regulatory purposes.  
The EA interviewees and the government interviewee thought that some monitoring was 
warranted and thought that a 2 year post market monitoring campaign was a good idea. The 
government respondent said: 
 
“For new pharmaceuticals that are coming on stream and for those we know little about, 
I think there is a good case for monitoring those.”  
 
One suggestion from the EA was that a condition to licence for post market monitoring 
could be imposed on pharmaceutical companies especially if the PEC and PNEC were quite 
close. This is often applied to other chemicals such as pesticides. This would seem like a sensible 
idea as currently once a pharmaceutical is licensed and released into the environment, risk 
assessment ends. In fact ERA needs to be a more ongoing process that incorporates the entire life 
cycle of the drug. 
 It appears that the most practical approach for monitoring of pharmaceuticals is to begin 
with a system of prioritisation to establish compounds of concern. This should include existing 
pharmaceuticals and new pharmaceuticals. When compounds that pose a potential risk are 
identified and it is established that they pose a risk to the environment, a monitoring campaign 
should be devised. It is at this point before any measurements are taken that a set of standards 
which make the monitoring campaign meaningful and sound needs to be developed. Modelling 
software could then be used in order to establish where to take measurements.   
3.4.2 Mitigation 
 Although the EU and the US have devised ERAs for pharmaceuticals over the past 
decade, risk mitigation measures are still somewhat lacking. An academic expressed the view 
that: 
 
“The requirement for environmental data or risk doesn’t preclude their registration. New 
drugs even if they have an environmental issue wouldn’t be turned down on that 
basis.”ERA does not work because the requirement for environmental data does not 
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preclude their registration meaning that new drugs wouldn’t be turned down on an 
environmental basis.”  
 
This is one of the crucial deficiencies of the current ERA. Even if an environmental problem is 
identified this would not prevent the drug being licensed because it is for human medical use. 
Human health is of course the priority.  The choice was often seen as a cost to the environment 
versus benefit to human health analysis. Another academic interviewee said: 
 
“The main thing is, understanding what the concentrations will be, where, and making a 
societal judgement on it……benefit versus harm.” 
 
The consultancy respondent said:  
 
“I would first exhaust all possible tiers in an ecological risk assessment to ensure that 
simpler assessments are not over-precautionary. If risks still remain, then a 
socioeconomic assessment should show what the costs to the environment might be 
versus benefits to human health. Depending on the balance between these one might wish 
to put restrictions on use.”  
 
The issue with any environmental harm versus human health benefit is what level of 
environmental damage should actually outweigh the benefit of human health? The government 
interviewee said: 
 
 “In the case of ethinylestradiol the societal benefits are very huge in terms of population 
control.” 
 
The pharmaceutical company interviewee commented that: 
 
“The cost benefit and environmental benefit analysis is starting to come into the 
medicines application from either later this year or next year. The environmental 
consideration is coming in, it still won’t block it, but it just means it’s moving higher up.” 
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 This issue led to some discussions about what strategies could be put in place to reduce 
an ecotoxicological risk if identified without preventing human use of a drug. Mitigation 
suggestions included use of the drug in a targeted way, for example restricting use to hospitals, 
and then incorporating extra treatment stages for hospital sewage. This was mentioned by several 
interviewees. An academic asked: 
 
“Can we use the drug in a targeted way, only in hospitals and we are going to put 
hospital waste through extra layers of treatment?” 
 
A suggestion by another academic was the potential of substitution of a pharmaceutical 
compound with a more environmentally friendly one: 
 
“If say a particular beta blocker caused rotifers to swim upside down or commit suicide, 
could say well, there are ten other beta blockers on the market and there’s no evidence to 
say that this one is better, so substitute.” 
 
 If there are several drugs that treat the same medical problem with similar results, the less 
environmentally problematic one could be chosen. This is the method that has been adopted in 
Sweden. The Swedish Association of Pharmacy Industries (LIF), Apoteket, the Swedish 
Association of Local Authorities and Regions and Stockholm County Council have developed a 
voluntary scheme to promote consideration of persistence, bioaccumulation, toxicity, 
environmental hazard and associated risks of pharmaceuticals. Committees establish 
recommendations for choice of drug for each clinical condition based on firstly medical aspects 
and secondly environmental classification. Although the system is voluntary it has been having a 
positive effect on both the procurement of bulk drugs in hospitals and on individual prescribers 
(Wennmalm & Gunnarsson, 2010; Clark et al., 2010). The Swedish system has gained 
considerable attention from other countries and there is a likelihood that the scheme will be 
rolled out across Europe in future (Clark et al., 2010). 
 One academic interviewee mentioned trying to reduce exposure at the drug delivery stage. 
This could be done by reducing the prescribed dose by increasing the half life of the drug in the 
body. If a serious environmental risk profile emerged the dose could be reduced to once a day. 
The pharmaceutical company interviewee expressed the view that: 
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“Intravenous treatment with drugs is much more effective and could reduce the amount 
required but is very unpopular with the public.” 
 
 The pharmaceutical company interviewee also said: 
 
“Labelling is the other alternative you’ve got…But we’ve always got that concern that if 
you were to put on the message that this drug could seriously affect the health of fishes 
you’ve got the risk that the patient wont take the medicine so that could impact on that 
person.”  
 
It appears that this may not however be the case. In Sweden pharmaceutical producers were 
initially concerned that some patients would not take medicines which might cause negative 
environmental impacts; however, no such effects have been observed (Wennmalm & 
Gunnarsson, 2010).  
 Generally ideas for mitigation are somewhat limited with adoption of the Swedish system 
for classification and substitution being the most practical approach. This is also a system that 
has been actually implemented and seems to be having some success. The questions then 
focussed on other mitigation strategies including upgrading of STPs and pharmaceutical take 
back schemes.  
3.4.2.1 Improving sewage treatment 
Upgrading STPs is likely to be one of the most straightforward and workable ways to 
reduce the input of medicines to receiving waters because sewage effluent is considered to be the 
main source. However, all respondents thought that it was not a good option because of the 
associated costs. It was highlighted that at present the evidence was not strong enough that 
pharmaceuticals in British rivers are adversely affecting wildlife. It was considered that the risk 
had to be tangible and not theoretical in order to take this action. It was thought that it was 
important to exhaust alternatives first, such as detailed ecological risk assessment. The reasons 
for STP upgrades being unpopular were the cost and environmental burden of increased carbon 
emissions. The water company interviewee believed that: 
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“The environmental costs of something like activated carbon are huge…..energy costs 
and carbon emissions are real issues for us.”  
 
At present sewage treatment is relatively cheap and quite efficient. More environmental impact 
may be produced than removed by advanced sewage treatment technologies (Wenzel et al., 
2008). Respondents often highlighted the fact that removing the last trace amount of a compound 
is the most expensive option. The water company interviewee asked: 
 
“For every order of magnitude you drop in detection limit the cost escalates 100 fold. 
On a good day with bolt on’s you can get below 1 ngl-1 for ethinyl estradiol, but is it 
worth it?” 
 
This is a valid point. The cost of extra treatment steps could be expensive financially and 
environmentally in terms of carbon emissions. If EE2 can adversely effects fish at concentrations 
as low as 0.3 ngl
-1
(Caldwell et al., 2008), it may not be possible to reduce emissions to a level 
below this even with a substantial amount of extra sewage treatment. 
 
Another point that was 
raised by the pharmaceutical company interviewee was: 
 
“I think sewage treatment; obviously connectivity has gone up over the years. In terms of 
standards discharges have always improved with time.” 
 
An academic interviewee considered: 
 
“The advantage is that, (and loads of money is being spent already) is that it should deal 
with a wide range of organic chemicals and inorganic ones, phosphorous and nitrogen 
levels and anything you can imagine basically.” 
 
These are also valid points. There is already a substantial amount of money being spent on 
sewage treatment improvements in the UK. Thames Water embarked on a £675m project to 
improve its 5 STPs (www.thameswater.co.uk/cps/rde/xchg/corp/hs.xsl/10094.htm). Removal of 
organic compounds and inorganic substances such as nutrients, nitrogen and phosphorous is 
required to meet good ecological status in water bodies for WFD. 
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Suggestions for reducing the cost of STP upgrades if found to be necessary included: 
only applying further processes if the population age in the area was quite high and therefore had 
an increased usage of pharmaceuticals or if the population size was very large; rather than adding 
expensive tertiary treatments such as UV or charcoal you could extend the biological process 
itself, increasing residence times for instance and additional treatments could be switched off at 
certain times of year, i.e. when there was a greater dilution in the receiving water. 
It was also mentioned that STP treatments can be substance specific, some compounds 
might pass through and not be suitable for treatment. Upgrading STPs, then, might not tackle 
substances of concern especially if that concern is related to their lack of degradability and 
persistence.  
3.4.2.2  Take back schemes and pharmaecovigilance 
One of the routes of entry of human pharmaceuticals into the aquatic environment is 
disposal down sinks and WC’s. Although it is thought not to be the most important route it is one 
of the more easily remedied. In a survey by Bound & Voulvoulis, (2005) it was found half of 
respondents (400) did not finish prescriptions. The first point that was made in respect of take 
back schemes was that it would be useful to know what contribution disposal of unused 
medicines down the drain actually makes to the overall exposure situation. Two academics said: 
 
“I don’t think that we do definitively know that it’s not the major route of exposure. 
There’s no data in the literature. People assume inappropriate exposure is not a major 
contributor, and it may not be.” 
 
“I would like to know more about what happens to unused pharmaceuticals, what is the 
size of the problem, I’d like to have data on that.” 
 
When taking into consideration the fact that medicines disposed of in this way will not be 
degraded by metabolism, they could alter a PEC refined for excretion rates substantially. All 
interviewees felt that more should be done to address the issue because source control was a 
better and more easily remedied solution than end of pipe control. Respondents thought that both 
physicians and pharmacies should take more of an active role in communicating the importance 
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of correct disposal of unused medicines and remind people that they must be returned to the 
pharmacy. One academic interviewee said: 
 
“Doctors and pharmacists should take considerably more responsibility, it’s managed 
effectively in other countries and I don’t know why we can’t manage it in this country.” 
 
 The pharmaceutical company interviewee mentioned the importance of the media in this 
issue by saying that a highly popular TV soap opera had recently portrayed a character flushing 
their anti-depressants down the toilet. This sends the wrong message to the general public. The 
water company interviewee commented: 
 
  “We are generally running campaigns, bin it don’t flush it.” 
 
Take back schemes are an important way to decrease pollution of the aquatic 
environment of pharmaceuticals. The views of the interviewees indicate that this is not being 
currently achieved adequately. The media clearly has a part to play in reminding the public about 
returning medications to the pharmacy. Some countries run occasional newspaper adverts to 
remind people as well as ensuring that doctors and pharmacies return medications. Sporadic 
campaigns on top of permanent take back schemes, calling for consumers to return medicines 
can help raise awareness (Vidaurre et al., 2010). There is a clear research need here for more 
accurate data on the contribution that used medicines make to overall exposure.  
Environmental stewardship is an important aspect of green pharmacy. A potential way to 
achieve this is through ‘pharmaecovigilance’ (Daughton & Ruhoy, 2011). This would see the 
current system of pharmacovigilance of drugs which monitors adverse medical effects after 
market authorisation being extended to include environmental issues. This includes factors such 
as prescription, disposal and take back schemes. Some of the factors that should be considered 
for pharmecovigillance were mentioned by interviewees. This included factors such as smaller 
initial prescriptions. One academic interviewee said: 
 
“Packaging should be smaller. If you know twenty percent is not generally taken, reduce 
the size of the prescription, less wastage. It’s in everyone’s interests to save money.” 
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Three interviewees thought that doctors should take more responsibility with reminding 
the patients about returning unused medication but also to think carefully about what and how 
much of a drug they are prescribing. The pharmaceutical company interviewee gave an example: 
 
“The first line of defence for high cholesterol within the UK is simvastatin, but it is 
known that a great number of people do not respond to this drug so are then prescribed 
atorvastatin (Lipitor). When this happens the remaining simvastatin is not requested back 
by the GP, too much is often prescribed originally as most things are prescribed on a 28 
day cycle. A smaller initial prescription of simvastatin should be given initially to see if 
the patient responds.” 
 
In a stakeholder engagement exercise in 2006, interviewees were uncertain about the 
feasibility of convincing doctors to reduce prescription rates when patients expect to be given a 
prescription when they visit the doctor and that the doctors are subject to considerable 
advertising pressure from the pharmaceutical industry to do so (Doerr-MacEwen & Haight, 
2006). Correct disposal, i.e. incineration is an important issue with regards to unused 
medications. However, it was thought by some interviewees that pharmacies on the whole did 
not appreciate people returning unused medication because they had to pay for disposal. An EA 
interviewee believed that: 
 
“The pharmacy will simply flush it down the drain anyway.” 
 
One of the key points made was that by nature people are pretty lazy, forget and cannot 
be bothered to return unused drugs. One academic interviewee suggested: 
 
“There are some very practical things we could do but don’t. GP surgeries should have a 
return bin, every surgery.” 
  
This would have two advantages in that it could be anonymous, therefore people could drop the 
unused medicines into the bin without having to admit to the GP that they hadn’t taken or 
finished the prescription. The other advantage would be that people could do this whenever they 
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went to the doctors. When asking the water company interviewee what they thought of this idea 
they asked: 
 
“What about supermarkets?” 
 
This obviously has drawbacks in that someone would have to take responsibility for safe 
collection and disposal. However, most large supermarkets do have pharmacies, so if the return 
bin was at the pharmacy they could take responsibility. The real advantage to supermarkets is 
that people visit them regularly.  
Take back schemes for unused or expired medicines are required by EU legislation, 
Directive 2004/27/EC. Reference to collection schemes should be made on the label or package 
leaflet. However the direction may simply be to ask the pharmacist about disposal and not give 
actual direction about how to dispose of the medication. In a survey of 28 European countries, 
only 30% could provide data on the performance of their take back schemes (Taylor & Poulmair, 
2007). France and Sweden are considered to have the most comprehensive take back schemes. In 
France a take back scheme CYCLAMED has been in force since 1993, which collected, and 
redistributed unused medications to non government organisations (NGOs) for third world 
countries (Vidaurre et al., 2010). However, France encountered problems with fraudulent resale 
of medications. Since 2008 pharmacists must collect unused medicines, free of charge for 
incineration. Sweden also incinerates all the returned pharmaceuticals (Vidaurre et al., 2010). 
The “Swedish model” 2005 is a collaboration of the Swedish Association of Pharmacy 
Industries (LIF), Swedish Medicinal Products Agency, Apoteket, the Swedish Association of 
Local Authorities and Regions and Stockholm County Council. It is the most comprehensive 
classification and labelling scheme within the EU, information on environmental impacts is 
made public on websites and in booklets (Vidaurre et al., 2010). The system is voluntary but has 
a high compliance with the expert group’s recommendations informing doctors and patients. 
Sweden is unique from other countries in Europe in that until January 2010 all pharmacies 
belonged to one company, Apoteket. This meant that they could exert a big influence over 
informing doctors and the public about environmental hazards and associated risks of 
pharmaceuticals, and promote return schemes in their pharmacies. The system is based on 
ranking of pharmaceuticals for environmental harm including PBT assessment, (persistence 
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bioaccumulation and toxicity) to aquatic organisms. Factors such as therapeutic efficiency, side 
effects and price are also used to select drugs that are recommended for use by the healthcare 
system.  
There seems to be some discrepancies in the data for the success of take back schemes. 
CYCLAMED reports collection of 5.7% of medicines sold annually. However, the European 
Federation of Pharmaceutical Industries and Associations estimate a recovery rate of 80% for the 
take back schemes in France (Taylor & Poulmair, 2007). Grass & Lalande, (2005) have 
estimated that 50% of medicines sold are not consumed in France. There is an obvious 
discrepancy in estimates of effectiveness of the scheme. Sweden report that 73% of the 
population return unused medicines to the pharmacy (Apoteket, 2006). All this leads to the 
conclusion that more information is required on the success of these return schemes. This should 
be combined with data on the contribution to pharmaceutical concentrations made by unused 
medicines. 
3.4.3  Pharmaceutical companies and sharing information 
A higher degree of communication between and transparency of pharmaceutical 
companies and environmental regulators, risk assessors and ecotoxicologists could improve the 
risk assessment of pharmaceuticals. Nine interviewees agreed that a sharing of information 
especially in respect to ecotoxicological techniques would be beneficial. An academic 
interviewee agreed: 
 
“In principle it’s a good idea, why do the tests more than once?” 
 
Interviewees were asked what the limitations would be with sharing information obtained 
during drug development and mammalian toxicology tests. The main problems highlighted were 
linked intellectual property rights, confidentiality and patent infringements. It was thought, 
however, that there should be no problem with sharing this information, it was covered by patent 
and should be in the public domain, the more openness and access the better. The consultancy 
interviewee expressed the view: 
 
“In most cases there shouldn’t be any real obstacles, however, regulators need to find a 
way to encourage this information release.” 
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An academic interviewee believed that: 
 
“There should be no stumbling blocks at all; it’s just the neuroses of companies that feel 
the information should be confidential. Covered by patent so should be in the public 
domain. Many companies are moving toward this. It’s a man power, cost of doing issue.” 
 
Three respondents said that it was entirely up to the pharmaceutical company whether 
they wanted to release this information because it was theirs, they had paid for it and patent time 
was small already. There was also a concern that if some of the mammalian data were published 
it could worry end users unduly. An academic interviewee believed that: 
 
“It shouldn’t be in the public domain, an LD50 for lab rats would worry patients.” 
 
 Three interviewees felt that it was important to encourage pharmaceutical companies to 
share this information with regulators and the ecotoxicology community in a way that protected 
their need for confidentiality. It was mentioned that making this data available can take time, 
money and man power. The pharmaceutical industry interviewee said: 
 
“Things are changing from regulatory perspective. I’ve been led to believe that from 
next year the ERAs are going public through the Commission and the same may be 
happening with the tox data. I think the regulatory pressures mean that transparency is 
going to be lot greater. I believe our risk assessments and our data will start appearing 
on our web pages. PECs will be published based on a worst case for Europe, I can’t tell 
you the country. We will include the data that contributed to the PEC and PNEC, test 
species and the guideline. A lot of that data sits on a Swedish site at the moment. More 
scientific scrutiny of the studies is the only thing.” 
 
An increase in communication between pharmaceutical companies, regulators and 
ecotoxicologists would be a positive step in terms of increasing the efficiency of ERAs. This 
could be especially valuable in the development of ecotoxicological techniques and bioassays for 
monitoring purposes. The release of mammalian toxicology data could provide further scope for 
assessing the potential use of this data for ‘read across’ to ecotoxicological assessment. The 
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interviewee responses indicate that pharmaceutical companies are beginning to do this. In order 
for an increase in communication and data flow to be successful regulators need to explore 
mechanisms to release this data to ecotoxicological and regulatory communities without 
worrying the general public.  
3.4.4  Metabolites 
Seven interviewees were in favour of pharmaceutical companies identifying the 
metabolites of new pharmaceuticals including the consultancy interviewee, the government 
interviewee , the  water company interviewee all agreed and 4 academics. An EA interviewee 
said: 
 
“This is something that is picked up quite late in the risk assessment; there is a mention 
right at the end. I think metabolites should be looked at a little earlier in the process, the 
industry should indicate key metabolites and these should go through the process.” 
 
The other EA interviewee asked: 
 
“Are we overstating it? It’s unlikely that a drug would be more potent after it’s been 
metabolised.” 
 
One academic interviewee considered:  
 
“Huge task…interesting scientific issue but not the most important thing to be doing.” 
 
Another academic thought that: 
 
“Desirable but often questionable how much benefit we’d get from this. I can’t think of a 
pharmaceutical breakdown product that we are concerned about.” 
 
The pharmaceutical company interviewee commented: 
 
“We have to identify them in terms of the human breakdown products. For environmental 
ones we do something called the water sediment study CD308. Anything that’s formed at 
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greater than 10% in that study we have to make an attempt to identify it. Sometimes we 
can’t. We might test the metabolite, we fill in data gaps sometimes”  
 
The current ERA states that pharmaceutical metabolites should be identified if they are 
produced at levels greater than 10% of the parent compound; however, this was a final stage of 
the process. It would seem logical that identification of any major metabolites should be 
performed much earlier on in the risk assessment process and that these should undergo a risk 
analysis.  
One relevant point that was made several times was that, there were no metabolites at 
present that have been highlighted as ecotoxic. This could be through a lack of data or research 
into pharmaceutical metabolites and breakdown products. The KNAPPE workshop also found 
that limited data is available on the ecotoxicity of pharmaceutical metabolites (KNAPPE, 2010). 
However, some pharmaceutical metabolites could be toxic. The key metabolite of fluoxetine, nor 
fluoxetine has been shown to be more toxic than fluoxetine in bioassays with the protozoan 
Spirostomum ambiguum and the crustacean Thamnocephalus platyurus (Nalecz-Jawecki, 2007).  
Another rare example is a key metabolite of the Tamiflu vaccine, which has been shown to 
increase the overall toxicity when in a mixture with the parent compound (Escher et al., 2010). 
One of the problems with incorporating the metabolites into the ERA is the sheer number 
of new compounds that may be formed through metabolism and transformation during sewage 
treatment or in the environment by biotic or abiotic processes. There is potential to use QSARs 
to make predictions about the relative toxicity of a metabolite in comparison to the parent 
compound. Information on factors that make pesticide transformation products more ecotoxic 
than the parent compound have been identified (Boxall & Greenwood, 2010; Belfroid et al., 
1998; Neuwoehner et al., 2010). These factors include alterations in a compounds properties 
which might increase lipophilicity or dissociation behaviour. This could be incorporated into 
QSARs. This type of tool could then be applied to pharmaceutical metabolites as a first screen to 
predict an increase in toxicity (Boxall & Greenwood, 2010).  
3.4.5  Precautionary Principle 
The precautionary principle emphasizes that where evidence of a threat to the health of 
the environment exists, scientific uncertainty must not be allowed to delay reasonable forms of 
management action (CEPA 1999, Quijano 2003, United Nations General Assembly 1992).  All 
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respondents thought that it was unnecessary to invoke the precautionary principle and that in 
general we were already being precautionary in having a risk assessment. The water company 
interviewee thought:  
 
“I  get nervous about being over precautionary, safety factors etc.” 
 
The consultancy interviewee believed that: 
 
“No – I don’t think that there is any more uncertainty about human pharmaceuticals than 
for other substances – indeed there is probably a lot less. The precautionary principle 
(and I mean the one adopted by the EC, not some half-arsed version espoused by certain 
NGOs) should only be invoked if there are likely to be widespread, serious and 
irreversible effects on the environment. I can’t honestly see this being the case for any 
human medicine.” 
 
In some respects the precautionary principle has been already been applied to 
pharmaceuticals in the aquatic environment in the fact that an ERA must be performed prior to 
licensing. However, the findings of this research indicate that there are several limitations with 
the current ERA guidelines. One of the key problems is that even in the event of an 
environmental risk being identified; market authorisation cannot be refused because the drug is 
for human use. The only option is to attempt to reduce the exposure, however, mitigation 
measures for reducing pharmaceutical exposure are still quite limited (see above). There is also 
lack of any retrospective risk assessment for old medicines. In light of the problems encountered 
from environmental exposure of diclofenac and EE2 this is something that needs to be addressed. 
The results of these expert knowledge holder interviews support this finding. Although 
respondents did not feel that scientific uncertainty was sufficient to invoke the precautionary 
principle, responses to earlier questions clearly indicate that there are gaps to be filled in order to 
increase the protection of the environment from human pharmaceuticals.  
3.4.6  Polluter pays principle 
The critical problem with applying the polluter pays principle to pharmaceuticals as 
pollutants is identifying who is the polluter. This was reflected in the responses of the 
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interviewees. In respect to who should pay for monitoring of pharmaceuticals one academic 
interviewee said: 
 
“At the moment when the drug company are preparing their dossier on their new drug 
they will pay for all the toxicology tests and clinical trials and it would be a relatively 
small cost in the overall cost for them to also build in an environmental package, they 
will pay for the ERA but not necessarily the monitoring that follows on from that. I think 
that the principal that the polluter pays should still apply to pharmaceuticals as it does to 
other companies….. It makes sense that they should make a contribution to 
monitoring ….we shouldn’t be reliant on the Environment Agency to take a sample. The 
downside is that the regulator doesn’t have any control over when the samples are taken 
or quality of the work.” 
 
In response to possible retrospective ERAs, the pharmaceutical company interviewee expressed 
the view that: 
 
“Who should pay? It is the inventor and those with a financial issue. Lily is picking up 
ninety five percent of the burden for the pharmacovigilance of things like Prozac and they 
don’t actually make that much money from it anymore. The generic industry needs to 
raise their game as part of the pie issue.” 
 
However, in regards to who should pay for improvements in sewage treatment it was widely 
accepted that water companies should pay and pass the costs on to the consumer. The water 
company interviewee stated that: 
 
“If we have to put in a new stage of treatment, it is termed a new obligation; this goes 
into our five year programming and is reflected in our pricing that is charged to 
customers.” 
 
The pharmaceutical company interviewee responded: 
 
“For 1 or 2 drugs that may be a problem the water utilities companies may have to start 
investing in tertiary treatments. The tax payer will have to pay for that and at that point I think 
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society and politicians need to start thinking is the investment going to be addressing a real and 
significant risk or is it a theoretical risk? That’s something that the pharmaceutical company 
can’t do alone we are just one of many stakeholders in that debate.” 
 
An academic interviewee said: 
 
“The principal is already accepted that it’s the water user that should pay as opposed to 
the pharmaceutical company” 
 
 Does this therefore mean that the drug consumer is the polluter? Of course it is the 
consumer that will pay regardless of whether the cost comes from an increase in the price of 
medicine or an increase in the cost of clean water. Most interviewees felt that society did not 
want increased water bills. Another academic interviewee said: 
 
“Would I like higher quality effluents in rivers? Absolutely yes. Would I be willing to pay 
for it? Absolutely yes, but society probably wouldn’t.” 
 
The question of who is polluter would seem to be unresolved with expert opinion divided. 
However, it would seem that different aspects of the problem could be broken down and 
assigned to different companies. Monitoring and retrospective ERAs could be potentially be the 
pharmaceutical companies, including producers of generics, responsibility. Whereas, 
improvements in water quality arising from upgrades in sewage and water treatment, should be 
paid for by the water companies. DEFRA and the EA could be responsible for any monitoring 
that is required under WFD. This approach will require cooperation and collaboration from all of 
these organisations if pollution by pharmaceuticals is to be reduced. The final bill will of course 
sit with the consumer and the tax payer. 
3.4.7  Green pharmacy 
The final question was about the potential of green pharmacy to reduce the risks of 
human pharmaceuticals to the environment. It received quite a mixed response. Two 
interviewees (the water company and an academic) thought that the idea of green pharmacy was 
ridiculous.  
165 
 
However, two interviewees thought that pharmaceutical companies already considered 
the environmental impacts of their products especially in regards to public perception and affect 
on share prices. The development of green pharmaceuticals is already being pursued by the 
industry (Doerr-MacEwen & Haight, 2006). One of the key problems with developing 
environmentally friendly drugs is that they need to be stable enough to persist in the body long 
enough to take effect. Easy degradation should be taken into account even before a 
pharmaceuticals synthesis (benign by design) (Kummerer, 2009). Although there is little 
progress so far in the benign by design approach there is an increasing consensus that the earlier 
the environmental impact of a pharmaceutical product is considered in the development process 
the greater the chance of adopting prevention and minimisation techniques (Greenwood et al., 
2010). Several drugs have had their manufacturing processes improved to be more 
environmentally friendly. For example ibuprofen, had its manufacturing process redeveloped 
which reduced the catalytic steps from 6 to 3 (EPA, 2012) to reduce impacts. Atorvastatin has 
had greener reaction conditions developed which increased yield and reduced waste and 
sertraline had its manufacturing process streamlined to reduce consumption of energy and raw 
materials while doubling yield (Greenchemex, 20120. The pharmaceutical industry is spending 
much time and money trying to reduce exposure at source. For example production of more 
enantiomerically pure drugs (Daughton et al., 2003). An example of a more benign by design 
drug, is the anti tumour drug ifosamide, which is highly recalcitrant, however by attaching sugar 
molecules, another compound glufosfamide is obtained which retains the therapeutic activity of 
ifosamide but is much more biodegradable (Kummerer et al., 2000; Keil, 2008).  
 Six interviewees thought that no financial incentives should be given to pharmaceutical 
companies for greener drug design. An increase in patent length has been suggested as an 
incentive that pharmaceutical companies would like, however, the pharmaceutical company 
interviewee thought that most of the incentives put forward for greener drugs were unlikely to 
come to fruition. One academic interviewee summed up green pharmacy in a positive way by 
saying: 
 
“Yes we should work together we need pharmaceuticals and we need environmental 
protection. No financial incentives.” 
 
166 
 
There has been a distinct change in the way new pharmaceuticals are ‘discovered’. 
Instead of observations of biological activity of natural products, there has been a shift towards 
the use of genomics involving drug target definition from gene interrogation methods. The 
understanding of the molecular basis of disease and the introduction of high throughput 
technologies for chemical and biological screening presents an opportunity to consider 
environmental aspects of a compound at the lead candidate stage. It is widely held that the 
environmental stability of a compound should be considered early on in the development stage, 
i.e. ten years before market authorisation (Sumpter, 2010). The sooner environmental impact is 
considered during the development of pharmaceuticals the greater the chance of adopting 
prevention and minimisation techniques (Butters et al., 2006). Bioinformatics databases and 
QSARs could be utilised at this stage to make predictions about lipophilicity and PBT. Once lead 
compounds have been identified structural alerts based on human toxicity could be used to 
disregard compounds which have PBT potential (Clark et al., 2010). For example fluorine is 
incorporated into many pharmaceuticals such as fluoxetine. Some drugs such as lipitor and 
fluoxetine contain very strong fluorine-carbon bonds which make them much more resistant to 
degradation in the body in order for them to reach their drug targets (Muller et al., 2007). The 
carbon-fluorine bond also decreases the biodegradability of compounds in the environment 
(Muller et al., 2007). Greener pharmaceuticals should not contain fluorine or other halogens 
(Sumpter, 2010). Although environmental aspects are not the priority for pharmaceutical 
companies, green pharmacy is becoming an increasingly important consideration (Lubick, 2008). 
‘Benign by design’ can be tackled in two ways. Can you design persistence out or build 
degradation in to a compound? The pharmacokinetic and pharmacodynamic profile or a drug can 
be optimized, so why cant the environmental degradation? In contrast to one of the more 
recalcitrant pharmaceuticals carbamazepine, another anti epileptic drug valporic acid has been 
used worldwide for over 40 years and is fully mineralized by environmental bacteria (Yu et al., 
2006; Kummerer, 2010; Kummerer, 2007). 
Expert computer systems have been developed that screen molecules for medical 
properties and environmental properties such as biodegradation (Kummerer, 2010), e.g. QSPRs 
(quantitative structure-property relationship) for the prediction of persistence of small organic 
molecules (Papa & Gramatica, 2008). 
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The advent of genomics in the drug development process with specific target definition 
means that bioinformatics and molecular docking packages are an important tool in the drug 
development process (Schoichet et al., 2002). For example the recent development of the anti 
viral drug for bird flu used this technology (Nguyen et al., 2009). The development of anticancer 
drugs is also an example of where molecular docking packages are being utilized (Mukherjee & 
Majumder, 2009). The bioinformatics work (Section 4) shows that these packages could also be 
used to predict toxicity of pharmaceuticals on aquatic organisms and aid and direct laboratory 
ecotoxicity tests. 
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3.5   Conclusion 
The results of the expert knowledge holder interviews provide a novel insight into the 
views of regulatory bodies, the pharmaceutical industry, water companies and academics that 
have substantial knowledge on the limitations of the ERA of pharmaceuticals. The main 
recommendations for improvements to risk assessment included a need for some retrospective 
ERAs for existing pharmaceuticals based on some prioritisation. Interviewees identified a need 
to reduce the scientific uncertainties created by the current PEC calculation for exposure 
potentially by modelling of environmental concentrations with the use of computer software. 
This was thought especially important in the context of monitoring. The 10 ngl
-1
 action limit was 
seen as an inappropriate mechanism for risk assessment of pharmaceuticals by many 
interviewees. It would seem that a more effective method would be to consider each 
pharmaceutical on a case by case basis considering aspects such as mode of action and PBT. It 
would be desirable to increase the effectiveness of QSARs for this task. Computer packages may 
also offer a valuable tool to aid and direct ecotoxicity tests by providing a more intelligent 
approach for selecting mode of action related test end points and choice of sensitive test species.  
 Green pharmacy still has some way to go with regards to ‘benign by design’ solutions; 
however, environmental stewardship was seen by many as a practical and achievable measure to 
reduce exposure. Research into the contribution that unused medicines make in the environment 
and the effectiveness of take back schemes is needed. 
In conclusion the key messages that can be drawn from the interview analysis are: 
 
 Pharmaceuticals are designed to have a specific biological effect and this should be 
reflected by the ecotoxicology tests incorporating the mode of action. 
 An increase in the spread of species included in ecotoxicity tests would be beneficial 
especially in the case of molluscs. 
 Development of QSARs and computer generated packages for prediction of toxic effects 
is highly desirable but at present provides poor indication of chronic ecotoxicological 
effects. 
 Retrospective environmental risk assessment of pharmaceuticals licensed before 2006 
needs to be performed using a system of prioritisation. 
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 Having a trigger limit for ecotoxicological risk assessment is flawed because some drugs 
such as ethinylestradiol have effects at concentrations lower than 10 ngl
-1
 .  
 PEC calculations need to be revised to take into account ‘hot spots’ caused by high usage 
of drugs in some areas or at certain times of year and low effluent to surface water 
dilution for some rivers. 
 Exposure modelling would aid environmental risk assessment. 
 Monitoring of pharmaceutical concentrations is expensive and time consuming and 
considered mostly unnecessary unless an adverse ecological effect is identified or the 
PEC and PNECs were very close in value. 
 STP upgrades are seen as an unfavourable option to decrease the input of 
pharmaceuticals into the environment because of associated financial and environmental 
(carbon emissions) costs.  
 Increasing public awareness about disposal of unused medicines is needed. 
 Increased communication between pharmaceutical companies, ecotoxicologists and 
regulators would help protect the environment. 
The in depth interviews with expert knowledge holders provided valuable insights into 
the limitations of the current ERA. The results provide information on where research should be 
focussed and improvements that need to be made to better protect the environment. The 
outcomes from the interviews reflect the real value of expert knowledge for policy development 
in developing techniques to protect the environment and for improving the ERA of 
pharmaceuticals. 
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4.1 Aim of Section 4 
The aims of this section of work are to: 1) investigate the usefulness of bioinformatics 
genome databases and analysis tools for identifying drug target homologues in aquatic species; 2) 
investigate the ability of molecular docking software to predict binding of drugs to identified 
target protein homologues in aquatic species; 3) evaluate the potential of current bioinformatics 
technology as a tool to aid and direct ERA of human pharmaceuticals by improving selection of 
sensitive species, informing choice on appropriate methodologies and appropriate end points for 
toxicology tests; 4) discuss the potential application of bioinformatics and molecular docking as 
a tool in green pharmaceutical design.  
4.2 Introduction  
Pharmaceuticals are designed to have a particular therapeutic effect. They target specific 
metabolic and molecular pathways and proteins as part of their MoA (Christen et al., 2010; 
Dorne et al., 2006; Kar & Roy, 2010). Due to their presence in the aquatic environment (Section 
2) they may adversely affect non-target vertebrates and invertebrates. These organisms may have 
a number of identical or similar proteins to humans and these may act as unintended drug targets 
(Christen et al., 2010).  
4.2.1 Ecotoxicology and environmental risk assessment 
Concentrations of pharmaceuticals in sewage effluent and surface waters are generally 
low i.e. in the ngl
-1
 to µgl
-1
 range (Section 2) and are usually at least an order of magnitude 
below the amount required to produce an acute toxic effect (Kummerer, 2009).  However the 
detrimental effects of the synthetic contraceptive 17α ethinylestradiol (EE2) have been well 
documented. EE2 causes intersex characteristics in fish downstream from sewage treatment 
outfalls (Jobling et al., 2006).  This pharmaceutical is highly potent at small concentrations. In 
fact as little as 1 ngl
-1
 has been shown to cause vitellogenin production in male fish, a precursor 
to egg production (Länge et al., 2001; Lattier et al., 2002; Parrott & Blunt, 2005) and the zebra 
fish (Danio rerio) showed complete reproductive failure at 10 ngl
-1
 (Segner et al., 2003). 
  Despite the pseudo persistent nature of aquatic organism exposure to human 
pharmaceuticals, this has been the only major in-situ toxicological effect that has come to light 
so far. One of the concerns related to this environmental problem is that it was unanticipated. 
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Retrospective analysis of course, suggests this effect was likely to occur because hormone 
receptor targets are highly conserved in fish. EE2 binds to oestrogen receptor proteins with high 
affinity in fish as well as in humans (Campbell et al., 1994). Another important factor in this case 
is that the problem was not caused by a non specific toxic effect but rather an effect directly 
related to the action of the drug in humans. This ecotoxicological effect highlights the possibility 
that other well conserved drug targets in non target species may also be affected by human 
pharmaceuticals (Gunnarsson et al., 2008).  
The constant input of low concentrations of pharmaceuticals into surface waters mean 
that the exposure of and toxicity to aquatic organisms is chronic rather than acute. To complicate 
matters further organisms are not exposed to a single drug in isolation but to a considerable 
mixture of chemicals. Thus may produce additive or synergistic or antagonistic effects, 
especially if compounds affect the same metabolic pathway or target protein (Schnell et al., 
2009). There is a distinct lack of data on the long term, full lifecycle and multigenerational 
chronic ecotoxicity of pharmaceuticals and mixtures (Dietrich et al., 2010). This is due to a 
variety of factors. Chronic ecotoxicity tests are time consuming and expensive. There can be 
difficulties in selecting appropriate and informative end points based on known pharmacological 
properties of the pharmaceutical (Ankley et al., 2007). Choice of organisms is difficult because it 
is unknown which species would be most sensitive to a particular drug. It is unfeasible and 
unethical to extensively test great numbers of organisms. As a result protecting the aquatic 
environment requires knowledge about conserved drug targets in exposed organisms. This is 
critical for assessing possible ecotoxicological effects, selection of potentially sensitive species 
and development of more efficient test strategies (Kostich & Lazorchak, 2008; Seiler, 2002).  
The current guidelines for risk assessment in the EU (EMEA, 2006) incorporate 
ecotoxicological data using the OECD guidelines. Since 2006 the EMEA has recommended 
using chronic effects data, this is rarely available prior to 2006 and as a consequence acute 
affects data is used. Standard long term toxicity tests are performed on three trophic levels. This 
should include full life cycle tests on daphnia and algae; and a semi chronic early life stage on 
one fish. The most sensitive of these organisms is used to predict the no-effect concentration 
(PNEC) in surface water. If the ratio between the PEC (see Section 2) and the PNEC is less than 
1 there is no need for further ecotoxicological testing. If this ratio is above 1 then a tailored risk 
assessment taking into account the MoA is required. This is also true for pharmaceuticals that are 
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highly potent with a PNEC of 10 ngl
-1
 or below such as EE2 and levonorgesterel (synthetic 
progesterone). Despite EU guidelines requiring relevant toxicity data, there is still little focus on 
targeted test strategies (Gunnarsson et al., 2008). Prospective testing could be made more 
powerful by including targeted test strategies based on known pharmacological properties of the 
tested pharmaceutical (Ankly et al., 2007). There is a need for a long-term focus on specific 
modes of action for pharmaceuticals to decrease uncertainties (Fent et al., 2006). 
4.2.2 Ecotoxicology and Green Pharmacy 
 Bioinformatics and molecular docking packages could be beneficial to achieving green 
pharmacy in several ways. Of course an ideal situation for the environment would be no adverse 
impacts on any of the life cycle stages of organisms by human pharmaceuticals, including all 
aspects of their manufacture, use and disposal. This would begin with a compound that was 
designed to be harmless environmentally i.e. the ‘benign by design’ approach (Kummerer, 2007). 
Bioinformatics computer packages such as quantity structure activity relationship’s (QSARs) 
may be a practical way to help with approaches such as this. For example, to help inform the 
decision making process of drug development at the lead candidate stage by considering 
environmental aspects using predictions about environmental persistence, bioconcentration and 
toxicity of compounds (Jager & Kooijman, 2009; Mekenyen et al., 2005). However, this type of 
approach is in its infancy and as yet there are limited examples of ‘benign by design’ compounds 
(see conclusion for further discussion).  
 A more pragmatic approach may be to reduce environmental impact of pharmaceuticals 
at the risk assessment stage. Some authors have suggested that ecotoxicity testing of 
pharmaceuticals could be made more intelligent by incorporating the MoA (Boxall, 2004). This 
could provide more relevant information about effects that are actually likely to occur when non-
target organisms are exposed to pharmaceuticals. The current standardised suite of 
ecotoxicological tests outlined above does not reflect the actual environmental situation in regard 
to pharmaceuticals well. Because aquatic organisms are exposed to continual low doses of a vast 
number of pharmaceuticals the general toxic effects investigated in the laboratory, especially 
acute effects, are unlikely to be observed in the real environment. In n order to move nearer to 
the goal of green pharmacy, i.e. a situation where no detrimental effects are caused to non target 
organisms, it is essential to know what the actual effects of low concentrations of mixtures of 
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pharmaceuticals may be. The choice of an appropriate toxicological end point is paramount. If a 
low concentration of a mixture of analgesics reduces prostaglandin production in humans, then 
they may cause a reduction in prostaglandin production in a fish.  
4.2.3 Bioinformatics and molecular docking 
Bioinformatics databases such as the NCBI database contain thousands of protein 
sequences from an increasing selection of organisms. It is possible to take the known drug target 
protein amino acid sequence and use BLAST to search for homologues i.e. similar protein 
sequences in other organisms. Nine pharmaceuticals were chosen for investigation: 
carbamazepine, diclofenac, ibuprofen, paracetamol, tamoxifen, propranolol, gemfibrozil, EE2 
and fluoxetine. The rationale for this selection was a high detection rate in the aquatic 
environment (Section 2), coverage of the main therapeutic classes and high prescription rate (see 
Table 2.1). The MoA and drug target information for the analgesics (diclofenac, ibuprofen and 
paracetamol) and the other selected pharmaceuticals is displayed (Table 4.1 & Table 4.2 
respectively).  
Once protein homologues have been identified it is then possible to model the 3 
dimensional structures of these proteins based on existing crystallised structures using modelling 
software such as Swiss Model. These free accessible databases and software make it possible to 
find aquatic organisms that may react to with drugs in a similar way to humans. This information 
could be highly relevant to environmental toxicologists. 
Molecular docking computational software can be used to predict the orientation of one 
molecule to another when bound together to form a stable complex (Lengauer & Rarey, 1996). 
Knowledge of the preferred orientation in turn may be used to predict the strength of association 
or binding affinity between the two molecules. The associations between biologically relevant 
molecules such as proteins, nucleic acids, carbohydrates, and lipids play a central role in signal 
transduction. Furthermore, the relative orientation of the two interacting partners may affect the 
type of signal produced (e.g., agonism vs antagonism). Docking is useful for predicting both the 
strength and type of signal produced. Molecular docking is frequently used to predict the binding 
orientation of small molecule drug candidates to their protein targets in order to predict the 
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affinity and activity of the small molecule. Hence docking plays an important role in the rational 
design of drugs
 
(Kitchen et al., 2004).  
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Table 4.1 Drug targets and mode of action for analgesic pharmaceuticals investigated 
(Information collected from DrugBank, 2012) 
 
 
Pharmaceutical Drug Targets Mode of Action 
diclofenac [1] Prostaglandin G/H synthase 1 precursor (COX1) 
[2] Prostaglandin G/H synthase 2 precursor (COX2) 
[3] Transthyretin precursor 
The antiinflammatory effects of diclofenac are believed to be due to inhibition of leukocyte 
migration and the enzyme cyclooxygenase (COX-1 and COX-2), leading to the peripheral 
inhibition of prostaglandin synthesis. As prostaglandins sensitize pain receptors, inhibition of 
their synthesis is responsible for the analgesic effects of diclofenac. Antipyretic effects may be 
due to action on the hypothalamus, resulting in peripheral dilation, increased cutaneous blood 
flow, and subsequent heat dissipation. 
ibuprofen [1] Prostaglandin G/H synthase 1 precursor 
(COX1) 
[2] Prostaglandin G/H synthase 2 precursor 
(COX2) 
[3] Serum albumin precursor 
The exact mechanism of action of ibuprofen is unknown. Ibuprofen is a non-selective inhibitor 
of cyclooxygenase, an enzyme involved in prostaglandin synthesis via the arachidonic acid 
pathway. Its pharmacological effects are believed to be due to inhibition cylooxygenase-2 
(COX-2) which decreases the synthesis of prostaglandins involved in mediating inflammation, 
pain, fever and swelling. Antipyretic effects may be due to action on the hypothalamus, resulting 
in an increased peripheral blood flow, vasodilation, and subsequent heat dissipation. Inhibition 
of COX-1 is thought to cause some of the side effects of ibuprofen including GI ulceration. 
Ibuprofen is administered as a racemic mixture. The R-enantiomer undergoes extensive 
interconversion to the S-enantiomer in vivo. The S-enantiomer is believed to be the more 
pharmacologically active enantiomer. 
paracetamol [1] Prostaglandin G/H synthase 1 precursor 
(COX1) 
[2] Prostaglandin G/H synthase 2 precursor 
(COX2) 
 
Paracetamol is thought to act primarily in the CNS, increasing the pain threshold by inhibiting 
both isoforms of cyclooxygenase, COX-1, COX-2, and COX-3 enzymes involved in 
prostaglandin (PG) synthesis. Unlike NSAIDs, paracetamol does not inhibit cyclooxygenase in 
peripheral tissues and, thus, has no peripheral anti-inflammatory affects. While aspirin acts as an 
irreversible inhibitor of COX and directly blocks the enzyme's active site, studies have found 
that paracetamol indirectly blocks COX, and that this blockade is ineffective in the presence of 
peroxides. This might explain why paracetamol is effective in the central nervous system and in 
endothelial cells but not in platelets and immune cells which have high levels of peroxides. 
Studies also report data suggesting that paracetamol selectively blocks a variant of the COX 
enzyme that is different from the known variants COX-1 and COX-2. This enzyme is now 
referred to as COX-3. Its exact mechanism of action is still poorly understood, but future 
research may provide further insight into how it works. The antipyretic properties of paracetamol 
are likely due to direct effects on the heat-regulating centers of the hypothalamus resulting in 
peripheral vasodilation, sweating and hence heat dissipation. 
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Table 4.2 Drug targets and mode of action for selected pharmaceuticals 
(Information collected from DrugBank, 2012) 
 
Pharmaceutical Drug targets Mode of Action 
carbamazepine Sodium chanel protein type 5 subunit 
alpha 
Carbamazepine inhibits sustained repetitive firing by blocking use-dependent sodium channels. Pain relief is 
believed to be associated with blockade of synaptic transmission in the trigeminal nucleus and seizure control with 
reduction of post-tetanic potentiation of synaptic transmission in the spinal cord. Carbamazepine also possesses 
anticholinergic, central antidiuretic, antiarrhythmic, muscle relaxant, antidepressant (possibly through blockade of 
norepinephrine release), sedative, and neuromuscular-blocking properties. 
 
ethinyl 
estradiol 
[1] Estrogen receptor 
[2] Orphan nuclear receptor 
Estrogens diffuse into their target cells and interact with a protein receptor. Target cells include the female 
reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Estrogens increase the hepatic 
synthesis of sex hormone binding globulin (SHBG), thyroid-binding globulin (TBG), and other serum proteins and 
suppress follicle-stimulating hormone (FSH) from the anterior pituitary. This cascade is initiated by initially 
binding to the estrogen receptors. The combination of an estrogen with a progestin suppresses the hypothalamic-
pituitary system, decreasing the secretion of gonadotropin-releasing hormone (GnRH). 
 
fluoxetine Sodium dependant serotonin 
transporter 
Metabolized to norfluoxetine, fluoxetine is a selective serotonin-reuptake inhibitor (SSRI), it blocks the reuptake 
of serotonin at the serotonin reuptake pump of the neuronal membrane, enhancing the actions of serotonin on 
5HT1A autoreceptors. SSRIs bind with significantly less affinity to histamine, acetylcholine, and norepinephrine 
receptors than tricyclic antidepressant drugs. 
 
gemfibrozil [1] Peroxisome proliferator- 
activated receptor alpha 
[2] Lipoprotein lipase precursor 
[3] Solute carrier organic anion 
transporter family member 1B1 
Gemfibrozil increases the activity of extrahepatic lipoprotein lipase (LL), thereby increasing lipoprotein 
triglyceride lipolysis. It does so by activating Peroxisome proliferator-activated receptor-alpha (PPARα) 
'transcription factor ligand', a receptor that is involved in metabolism of carbohydrates and fats, as well as adipose 
tissue differentiation. This increase in the synthesis of lipoprotein lipase thereby increases the clearance of 
triglycerides. Chylomicrons are degraded, VLDLs are converted to LDLs, and LDLs are converted to HDL. This 
is accompanied by a slight increase in secretion of lipids into the bile and ultimately the intestine. Gemfibrozil also 
inhibits the synthesis and increases the clearance of apolipoprotein B, a carrier molecule for VLDL 
 
propranolol [1]Beta- 1- adrenergenic receptor 
[2]5-hydroxytryptamine 1A receptor 
[3] Beta- 2- adrenergenic receptor 
[4] 5-hydroxytryptamine 1B receptor 
[5] beta- 3- adrenergenic receptor 
Propranolol competes with sympathomimetic neurotransmitters such as catecholamines for binding at beta(1)-
adrenergic receptors in the heart, inhibiting sympathetic stimulation. This results in a reduction in resting heart 
rate, cardiac output, systolic and diastolic blood pressure, and reflex orthostatic hypotension. 
tamoxifen [1] estrogen receptor 
[2] estrogen receptor beta 
[3] epoxide hydrolase 
[4] multidrug resistance protein 1 
[5] thymidine phosphorylase 
Tamoxifen binds to estrogen receptors (ER), inducing a conformational change in the receptor. This results in a 
blockage or change in the expression of estrogen dependent genes. The prolonged binding of tamoxifen to the 
nuclear chromatin of these results in reduced DNA polymerase activity, impaired thymidine utilization, blockade 
of estradiol uptake, and decreased estrogen response. It is likely that tamoxifen interacts with other coactivators or 
corepressors in the tissue and binds with different estrogen receptors, ER-alpha or ER-beta, producing both 
estrogenic and antiestrogenic effects 
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4.2.4  Choice of pharmaceuticals for molecular docking 
Two pharmaceuticals were chosen for molecular docking, diclofenac and 
ibuprofen. These two compounds were selected for several reasons. Firstly, they were 
found to be ubiquitous pollutants of the aquatic environment (see Section 2). A second 
reason was that diclofenac has been shown to seriously adversely affect non target 
organisms i.e. the mass decline of the vulture population in Asia (Oaks et al., 2004) (see 
below). There is also increasing evidence in the literature that diclofenac may cause 
subtle chronic effects on aquatic organisms (Mehinto et al., 2010; Schwaiger et al., 2004; 
Hoeger et al., 2005). Chronic ecotoxicity studies have reported that exposure to 
environmentally relevant concentrations of diclofenac at 0.5 and 1 µgl
-1
/L can result in 
adverse affects in various organs and possibly compromise the health of fish (Schwaiger 
et al., 2004; Trieskorn et al., 2004; Hoeger et al.,. 2005; Mehinto et al., 2010). The PEC 
results from Section 2 provide a crude PEC of 1 µgl
-1
 and a prescription data PEC as low 
as 0.7 µgl
-1
. MECs of 2.35 µgl
-1
 in sewage effluent and 0.57 µgl
-1
 in surface waters have 
been detected in the UK (Hilton et al., 2003) and concentrations as high as 2.3 µgl
-1
 in 
surface waters in Germany (Jux et al., 2002). It seems that chronic effects may be 
occurring. According to the EMEA guidelines an assessment factor of 10 should be 
applied to the NOEC to account for inter/intra species variations and lab data to field 
impact extrapolation. If the NOEC for diclofenac is 0.05 µgl
-1
 (with assessment factor), 
and the PEC (from section 2) is 1 µgl
-1
 the risk quotient for PEC/PNEC ratio would be 20. 
This far exceeds the limit of 1 for further risk assessment and indicates a strong 
possibility of an environmental risk. This value is considerably higher than reported 
previously by Carlsson et al., (2006) who derived a PEC/PNEC quotient of 4.8 using the 
current ERA. It has been highlighted that recent release from prescription only will 
increase use and the environmental concentration of diclofenac (Mehinto et al., 2010).  
It was also desirable to investigate two drugs that target the same drug receptor 
for potential synergistic or additive effects. Diclofenac and ibuprofen both target the same 
cyclooxygenase (COX) enzymes (Table 4.1). Finally, in order to test the feasibility of 
using molecular docking as part of an intelligent ecotoxicological approach for risk 
assessment, it was necessary to have the presence of similar drug target homologues in 
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aquatic organisms that have been well characterised in humans. Thus providing a suitable 
template on which to model aquatic species protein homologues.   
Diclofenac is a non steroidal anti-inflammatory drug (NSAID) which is widely 
used in veterinary and human medicine. In humans it acts by inhibiting the 
cyclooxygenase (COX) enzymes (Vane & Botting, 1998) (Fig 4.1). These enzymes 
catalyse the synthesis of prostaglandins which are involved in inflammation, blood flow 
regulation, platelet aggregation and secretion of gastric mucus (Mutschler, 1996; Sali, 
2005). Diclofenac was found to occur ubiquitously in sewage effluents and removal 
during sewage treatment was highly varied and not at a level sufficient to prevent its 
continued detection in surface waters worldwide (Section 2). Diclofenac has also been the 
cause of a major decline of vultures in India and Pakistan due to its use in veterinary 
medicine. Vultures feed on the dead carcasses of cattle treated with diclofenac causing 
renal failure and visceral gout (Oaks et al., 2004). The reasons for this are also related to 
its designed mode of action, and adverse renal side effects are common in human patients 
(Taggart et al., 2007; Banks et al., 1995).  
Ibuprofen is another NSAID extensively used in human medicine and available 
cheaply without prescription. It was found to be ubiquitous in sewage effluents despite 
treatment removing over ninety percent in most activated sludge STPs (Section 2). This 
apparent persistence is probably due to its high usage across the world.  Mean 
concentrations in surface waters can be as high as 2.1µgl
-1
. Ibuprofen acts upon the same 
metabolic pathway as diclofenac (Fig 4.1) and also targets and inhibits COX enzymes 
(and therefore there is a strong possibility of additive, synergistic or antagonistic effects 
between ibuprofen and diclofenac).  
 The other pharmaceuticals investigated during this work were unfortunately 
unsuitable for molecular docking studies. A lack of ecotoxicity data in the scientific 
literature on the mode of action for tamoxifen, gemfibrozil, carbamazepine and 
propranolol prevented their use in molecular docking experiments. Fluoxetine as yet 
lacks a crystallized human serotonin receptor structure on which to model homologues 
and was therefore also unsuitable for molecular docking experiments at this time. 
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Fig 4.1 Metabolic pathway for the NSAIDs diclofenac and ibuprofen (adapted from 
Pharmacotherapy, 2003) 
 
Investigation into the presence of drug target homologues in other species could 
provide evidence of a likelihood of ecotoxicological impacts; however, the presence of 
the gene target does not mean that the expressed protein will be functional. Small changes 
in the amino acid sequence may change the proteins 3D structure substantially. Molecular 
docking experiments in-silico may provide more scientific evidence that a protein 
homologue will bind to and respond in a similar way to the human type or conversely that 
a protein is sufficiently different that interaction between it and the drug is unlikely.  
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4.3  Method 
4.3.1 Software and data sources 
 The bioinformatics software and databases in this study are all freely available for 
academic use and include: 
 Drug Bank (http://drugbank.ca/) a unique bioinformatics and cheminformatics 
resource that combines detailed drug (i.e. chemical, pharmacological and 
pharmaceutical) data with comprehensive drug target (i.e. sequence, structure, and 
pathway) information. The database contains 6707 drug entries including 1436 
FDA-approved small molecule drugs, 134 FDA-approved biotech (protein/peptide) 
drugs, 83 nutraceuticals and 5086 experimental drugs. Additionally, 4228 non-
redundant protein (e.g. drug target/enzyme/transporter/carrier) sequences are 
linked to these drug entries. Each drug card entry contains more than 150 data 
fields with half of the information devoted to drug/chemical data and the other 
half to drug target or protein data.   
 NCBI BLAST (http://blast.ncbi.nlm.nih.gov/Blast.cgi). The Basic Local 
Alignment Search Tool (BLAST) identifies regions of local similarity between 
sequences. The program compares nucleotide or protein sequences to sequence 
databases and calculates the statistical significance of matches. BLAST can be 
used to infer functional and evolutionary relationships between sequences as well 
as help identify members of gene families. 
 RCSB Protein Data Bank (http://www.pdb.org/pdb/home/home.do). An 
information portal to biological macromolecular structures. It holds over 77101 
structures mainly determined by x-ray diffraction and solution NMR. 
 Swiss Model (http://swissmodel.expasy.org/). A fully automated protein structure 
homology-modeling server, accessible via the ExPASy web server, or from the 
program DeepView (Swiss Pdb-Viewer). The purpose of this server is to make 
protein modeling accessible to all biochemists and molecular biologists across the 
world.  
 CLUSTAL W Multiple sequence alignment (www.genome.jp/tools/clustalw/). 
182 
 
ClustalW2 is a general purpose multiple sequence alignment program for DNA or 
proteins. This tool can be used to align amino acid sequences in order to locate 
conserved binding domains and enzymatic active sites. 
 AutoDock 4.0. A molecular docking software package (The Scripps Research 
Institute, (www.scripps.edu). The package is used in combination with AutoDock 
Tools (ADT) - an accessory programme that allows the user to interact with 
AutoDock from a Graphic User Interface (GUI). AutoDock is a suite of 
automated docking tools designed to predict how small molecules/ligands such as 
substrates or drug candidates, bind to a receptor/protein of known 3D structure. 
AutoDock consists of three separate programmes: AutoDock which performs the 
docking of the ligand to a set of grids describing the target protein; AutoGrid pre-
calculates these grids describing the target protein and AutoTors determines 
which bonds will be treated as rotatable in the ligand. 
4.3.2 Drug target protein identification and gene sequence homology search 
 Drug target proteins for ten selected pharmaceuticals: carbamazepine, diclofenac, 
ethinyl estradiol, fluoxetine, gemfibrozil, ibuprofen, paracetamol, propranolol, tamoxifen 
and trimethoprim were identified using Drug Bank (for pharmaceutical selection rationale 
see Section 2.2 methods).  The amino acid protein sequences for the drug targets were 
then collected in the FASTA format. This is a standard text-based format originating 
from the FASTA software package that represents nucleotides or amino acids as single-
letter codes in either nucleotide or peptide sequences respectively. The format also allows 
for sequence names and comments to precede the sequences. Some drugs have more than 
one protein target, where this was the case all the protein targets were collected.  
All available genomes were searched for similar, potentially conserved protein 
sequences to each of the drug target protein sequences using BLAST at the NCBI.  Using 
a heuristic method, BLAST finds homologous sequences, not by comparing either 
sequence in its entirety, but rather by locating short matches between the two sequences. 
A standard BLAST search only returns the top 20 taxa that are matches. These taxa were 
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then excluded from subsequent searches. The results were then filtered for aquatic 
organisms including fish, frogs and invertebrates.  
4.3.3 Creation of 3D protein models  
The order of drug targets listed in DrugBank generally reflects their importance 
regarding therapeutic indication or physiological effect (Wishart et al., 2008). The 
primary drug target protein for the NSAID (non-steroidal anti-inflammatory drug) 
diclofenac was identified as prostaglandin endoperoxide H synthase 2 (PGHS2) (also 
called cyclooxygenase 2 (COX2). COX2 is also a drug target protein for another 
pharmaceutical investigated, ibuprofen (NSAID). The human COX2 (hCOX2) sequence 
was used in a BLAST sequence homology search to find similar proteins in aquatic 
organisms. Atlantic salmon (Salmo salar), zebra fish (Danio rerio), rainbow trout 
(Oncorhynchus mykiss) and the water flea (Daphnia pulex) were selected due to their use 
in ecotoxicity testing and the presence of a high homology protein identified by BLAST 
search. The four FASTA sequences: sCOX2 (S.salar), zCOX2 (D.rerio), tCOX2 
(O.mykiss) and dCOX2 (D.pulex) were submitted to Swiss model in the automated mode 
for the creation of 3D protein models. The models were based on a known crystallized 
molecular structure of sheep COX2 PDB 1PXX obtained from RCSB protein data bank. 
The resulting structures were saved in the PDB format needed for molecular docking. 
4.3.4 Molecular Docking 
 The PDB files for diclofenac and ibuprofen were docked using AutoDock 4.0 
with the five protein models hCOX2, zCOX2, sCOX2, dCOX2 and tCOX2. The 
following procedure was used: 
 Preparing the ligand and macromolecule files for AutoDock:  
The PDB files created in Swiss model were prepared using the GUI (graphic user 
interface) of ADT in order to limit imperfections in the PDB files e.g. missing 
hydrogen atoms, multiple molecules and added water. First all the hydrogen 
atoms were removed from the macromolecule files (hCOX2, zCOX2, sCOX2, 
dCOX2 and tCOX2). Then polar hydrogen’s were restored. ADT then checked 
whether the molecule had charges, if not ADT checked whether the molecule was 
a peptide. If the molecule was found to be a peptide, Kollman charges were 
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added, otherwise Gasteiger charges were added. Finally solvation parameters 
were added and the files saved with .pdbqs extension (where ‘q’ and ‘s’ represent 
charge and solvation, respectively). 
The ligand files for diclofenac and ibuprofen were also read in ADT, all the 
hydrogens and  charges were added and the non-polar hydrogens merged and 
saved with .pdbqs extension. ADT then automatically determined the best root, 
which is defined as the fixed portion of the ligand from which rotatable branches 
sprout. Next the rotatable bonds in the ligand were defined, making all amide 
bonds non-rotatable and the number of active torsions was set to fewest atoms. 
The ligand file was then saved with ligand out .pdbq extension (q representing 
charge). 
 Preparing the grid parameter file: 
 For the calculation of docking interaction energy, a three-dimensional box (grid) 
was created in which the target location (suspected enzyme active binding site) of 
the protein molecule was enclosed. The grid volume was large enough to allow 
the ligand to rotate freely, even with its most fully extended conformation. The 
grid box size was set to 64000 total grid points, with 40 points in each of the x, y, 
z directions. The spacing was set to 0.375 Angstrom.  
The location of the suspected enzyme binding site on the human COX enzyme 
model were obtained by opening the hcox pdb file in text pad and finding the co-
ordinates for amino acid residues SER530 and TYR385, thought to be involved 
in binding diclofenac (Rowlinson et al., 2003). The multiple sequence alignment 
program Clustalw was used to locate these conserved residues on the homologues, 
zCOX2, sCOX2, dCOX2 and tCOX2. Once identified the co-ordinates of the 
residues involved were found by opening the PDB files in text pad. The 
parameters required to create the grid were stored in the grid parameter file with 
molecule .gpf extension. 
 Preparing the docking parameter file:  
The docking parameter file, which instructs AutoDock about the ligand to move, 
the map files to use, and other properties defined for the ligand was created. 
AutoDock’s Lamarckian genetic algorithm (LGA) was the algorithm used for the 
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docking file, which was stored with the .dpf extension. Finally, the AutoDock job 
was run from the GUI (graphical user interface) created at the University of 
Westminster. Each docking experiment was run 102 times and the results stored 
in docking log files with the .dlg extension. The best 10 dlg docking files, i.e. 
those with the lowest energy binding scores in docked ligand complexes were 
chosen. These were then read in the ADT viewer. A conformation instance was 
created for each docked result found in the docking log. A conformation 
represents a specific state of the ligand and has either a particular set of state 
variables from which all the ligand atoms’ co-ordinates can be computed or the 
co-ordinates themselves. Conformations also have energies: docked energy, 
binding energy, and possibly per atom electrostatic and van der waals energies. 
AutoDock 4 computes the free energy of binding and reports a detailed energy 
breakdown. 
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4.4  Results 
4.3.1  Drug targets and modes of action  
A total of twenty FASTA protein sequences were collected to enter into separate 
BLAST sequence homology searches (Table 4.3-4.6). The results of the BLAST search 
are presented as percent sequence identity (I) and probability of this identity occurring by 
chance (E value). The lower the E value the less likely that the sequence similarity could 
occur by chance, zero being the best result.  
Several of the drugs were found to share the same mode of action and drug target 
protein (Table 4.3 & 4.4). This is not surprising for pharmaceuticals in the same 
therapeutic class. Ibuprofen, diclofenac and paracetamol are all analgesics and all bind to 
the same target proteins, the COX 1 and COX 2 enzymes (Table 4.4). The oestrogen 
receptor was the primary drug target for the synthetic hormone contraceptive ethinyl 
estradiol (EE2) and also the anti-cancer drug tamoxifen (Table 4.3). The other 
pharmaceuticals investigated had different protein drug targets determined by their 
therapeutic class. Propranolol is a beta blocker, gemfibrozil is a lipid regulator and 
carbamazepine is an anti-convulsive.  Fluoxetine has the same mode of action and drug 
target as other selective serotonin reuptake inhibitors (SSRIs) such as citalopram, 
escitalopram, zimelidine but these were outside the scope of this study (Table 4.6).  
The BLAST homology data was also evaluated against relevant ecotoxicity data 
in the literature for drug receptor mediated MoA responses (Tables 4.3 – 4.6). Chronic 
MoA ecotoxicity data was found to be extremely limited for most pharmaceuticals with 
most organisms selected in the BLAST homology search. Due to the fact that only one 
aquatic organism (D.rerio) had a complete genome sequenced it was not possible to 
determine whether other aquatic organisms lack the primary drug receptor and hence may 
be less sensitive to exposure.  
4.4.2 Drug target sequence homology  
 The results of the BLAST homology search show that lower vertebrates such as 
fish and frogs have significant protein sequence homology with human drug target 
proteins. There was much less sequence homology with invertebrates. Algae never 
appeared in the results of the blast sequence homology search for any of the twenty drug 
187 
 
target proteins of any the pharmaceuticals investigated. Daphnia (water flea), regularly 
used in ecotoxicological testing only rarely showed significant sequence homology with 
human drug target proteins. It is unknown at present whether this is due to a lack of 
sequence homology or that a limited number of genomes are fully sequenced. All of the 
human drug targets showed significant sequence homology with several fish and often 
with Xenopus laevis (African clawed frog) and Xenopus tropicalis (western clawed frog) 
(Table 4.3-4.6). 
188 
 
Table 4.3 17α ethinylestradiol and tamoxifen drug target sequence homology results  
I: percent sequence identity; E value: the probability of this identity occurring by chance; Ecotoxicity, 
YES = relevant literature to support mode of action (MoA) effects of the particular pharmaceutical on the 
primary drug target receptor; NA: Ecotoxicity data not available. (Urbatzka et al., 20071; Pettersson et al., 20062; 
Velasco-Santamaría et al., 20093; Salierno & Kane, 20094; Schwaiger et al., 20005; Solé et al., 20005; Pérez et al., 
20127; Mortensen & Arukwe, 20078; Notch & Mayer, 20119) 
Pharmaceutical Drug 
Target 
Organism I E value Ecotoxicology 
ethinyl estradiol 
tamoxifen 
 
estrogen 
receptor 
Pseudemys nelson (Red Belly turtle) 
Leidochelys olivacea (Olive Ridley turtle) 
Crocodylus niloticus (Crocodile) 
Alligator mississippiensis (Alligator) 
Taeniopygia guttata (Zebra Finch) 
Anas platyrhynchos (Mallard duck) 
Xenopus laevis (African clawed frog) 
Xenopus tropicalis (Western clawed frog) 
Pleurodeles walt (Spanish ribbed newt) 
protopterus annectens (West African lungfish) 
Atractosteus tropicus (Tropical gar) 
Acipenser schrenckii (Sturgeon) 
Zoarces viviparus (Eelpout) 
Pimephales promelas (Fathead minnow) 
Tanichthys albonubes (Mountain minnow) 
Cyprinus carpio (Common carp) 
Odontesthes bonariensis (Peejerry fish) 
Salmo salar  (Atlantic salmon) 
 Danio rerio (Zebra fish) 
79 
78 
78 
77 
78 
80 
69 
69 
68 
59 
58 
59 
54 
57 
58 
55 
51 
52 
58 
0.0 
0.0 
0.0 
0.0 
0.0 
0.0 
0.0 
0.0 
0.0 
0.0 
0.0 
7.0e-168 
3.0e-148 
6.0e-148 
2.0e-147 
3.0e-146 
4.0e-146 
2.0e-145 
2e-170 
NA 
NA 
NA 
NA 
NA 
NA 
YES1 
YES2 
NA 
NA 
NA 
NA 
YES3 
YES4 
NA 
YES5,6 
YES7 
YES8 
YES9 
ethinyl estradiol orphan 
nuclear 
receptor 
 Danio rerio (Zebra fish) 
 Xenopus laevis (African clawed frog) 
 Xenopus tropicalis (Western clawed frog) 
 Fundulus heteroclitus (Mummichog) 
 Oncorhynchus mykiss (Rainbow trout) 
 Tetraodon nigroviridis (Pufferfish) 
 Oryzias latipes (Medaka fish) 
 Paralichtys olivaceus (Bastard halibut) 
 Salmo salar (Atlantic salmon) 
 Cyprinus carpio (Common carp) 
 Petromyzon marinus (Sea Lamprey) 
 Callorhinus ursinus (Seal) 
Pimephales promelas (Fathead minnow)  
51 
49 
51 
44 
45 
43 
42 
42 
42 
42 
41 
40 
47 
4.0e-105 
4.0e-104 
3.0e-103 
8.0e-97 
2.0e-95 
3.0e-86 
6.0e-86 
4.0e-85 
2.0e-83 
6.0e-82 
7.0e-81 
8.0e-76 
7.0e-73 
 
tamoxifen estrogen 
receptor 
beta 
Taeniopygia guttata  (Zebra Finch) 
Xenopus tropicalis (Western clawed frog) 
Xenopus laevis (African clawed frog) 
Ornithorhynchus anatinus (Platypus) 
Protopterus annecten  (African lugfish) 
Protopterus dolloi (Spotted lugfish) 
Squalus acanthias (Spiny dogfish) 
74 
69 
69 
66 
64 
63 
63 
0.0 
0.0 
0.0 
0.0 
0.0 
0.0 
0.0 
 
tamoxifen 
 
multidrug 
resistance 
protein 1 
Xenopus laevis (African clawed frog) 
Ornithorhynchus anatinus (Platypus) 
Platichthys flesus (Flounder) 
Danio rerio (Zebra fish) 
Xenopus tropicalis (Western clawed frog) 
Branchiostoma floridae (Lancelet) 
Trioplax adhaerens (Placozoa) 
Taeniopygia guttata (Zebra Finch) 
Raja erinacea (Little skate) 
68 
66 
63 
57 
56 
59 
53 
51 
50 
0.0 
0.0 
0.0 
0.0 
0.0 
0.0 
0.0 
0.0 
0.0 
 
tamoxifen 
 
epoxide 
hydrolase 
Xenopus tropicalis (Western clawed frog) 
Xenopus laevis (African clawed frog) 
Ornithorhynchus anatinus (Platypus) 
Danio rerio (Zebra fish) 
Salmo salar (Atlantic salmon) 
Trioplax adhaerens (Placozoa) 
Strongylocentrotus purpuratus) (Sea Urchin) 
Tetraodon nigroviridis) (Pufferfish) 
Ciona intestinalis) (Sea squirt) 
Nematostella vectensis) (Sea anaemonae) 
Branchiostoma floridae (Lancelet) 
56 
56 
60 
50 
47 
42 
44 
46 
45 
39 
42 
0.0 
0.0 
1.0e-174 
3.0e-162 
9.0e-158 
2.0e-138 
1.0e-135 
3.0e-134 
2.0e-123 
5.0e-111 
3.0e-61 
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The oestrogen receptor primary protein drug target for the anti-cancer drug 
tamoxifen and the synthetic hormone EE2 showed very high sequence identity with a 
number of non target organisms (Table 4.3). Fish species included: Commercially 
relevant fish Oncorhynchus mykiss (rainbow trout) and Salmo salar (Atlantic salmon), 
British freshwater fish Cyprinus carpio (Common carp) and Rultilus rutilus (Roach) and 
ecotoxicological test fish Danio rerio (zebra fish) and Pimephales promelas (fathead 
minnow). Other organisms that have an oestrogen receptor with significant sequence 
identity to the human form included turtles, frogs, newt and crocodile. 
The COX 1 and 2 target proteins for the analgesics diclofenac, ibuprofen and 
paracetamol were found to have significant similarity to the human forms including 
Oncorhynchus mykiss (rainbow trout), Salmo salar (Atlantic salmon), Micropogonias 
undulates (Atlantic croaker), Danio rerio (zebra fish), Tetraodon nigroviridis (pufferfish), 
Ornithorhynchus anatinus (platypus) and the frogs, Xenopus laevis (African clawed frog) 
and Xenopus tropicalis (Western clawed frog) (Table 4.4). A COX enzyme or protein 
with sequence homology was not found for the Pimphales promelas (fathead minnow), 
one of the species of fish regularly used in ecotoxicology. Daphnia pulex also produces a 
COX2 enzyme with 46% sequence homology with the COX2 human enzyme.  
The primary drug target for gemfibrozil showed a high sequence homology with 
several fish including the British freshwater fish Cyprinus carpio (common Carp) and the 
ecotoxicological test relevant fish D.rerio (Table 4.5). Other organisms with high 
sequence homology included the frog X. laevis and Anas platyrhynchos (Mallard duck), 
Ornithorhynchus anatinus and Crocodylus niloticus (crocodile). 
 Propranolol had five identified drug target proteins. The primary target beta 1-
adrenergenic receptor had significant sequence identity with several proteins in other 
species including the British freshwater fish, C. carpio, commercially relevant fish 
S.salar and O.mykiss and the ecotoxicological test fish P.promelas and D.rerio (Table 
4.5). High sequence identity was also found with O.anatinus (Platypus) and X.laevis 
(African clawed frog). 
The sodium channel protein drug target for carbamazepine showed a high 
sequence homology with O.mykiss (72%) and D.rerio (64%) but not with the S.salar or 
P.promelas (Table 4.6), indicating a strong possibility that a similar mode of action may 
190 
 
be occurring in some fish but not others (see discussion). The frog X.laevis also had a 
protein with 52% similarity (Table 4.6). It appears possible that frogs may be responding 
to this recalcitrant (section 2) anti- convulsive in the environment.  
The anti-depressant fluoxetine drug target the sodium dependant serotonin 
transporter showed high sequence homology with several fish and both the frogs that 
have genome sequences available, X.tropicalis and X.laevis (Table 4.6). Therefore 
environmental exposure to fluoxetine will probably cause disruption in serotonin 
metabolism and function in these organisms. 
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Table 4.4 Analgesic drug target sequence homology results 
(I: percent sequence identity; E value: the probability of this identity occurring by chance; Ecotoxicity, 
YES = relevant literature to support mode of action (MoA) effects of the particular pharmaceutical on the 
primary drug target receptor, references: David & Pancharatna, 2009
1
; Han et al., 2010
2
; Heckmann et al., 
2007
3
; Mehinto et al., 2010
4
; NA: Ecotoxicity data not available). 
 
 
 
Pharmaceutical Drug 
Target 
Organism I E 
value 
Ecotoxicity 
diclofenac 
ibuprofen 
paracetamol 
Prostaglan-
din G/H 
synthase 1 
precursor 
(COX1) 
Ornithorhynchus anatinus (Platypus) 
Taeniopygia guttata  (Zebra Finch) 
Xenopus laevis (African clawed frog) 
Micropogonias undulates (Atlantic croaker) 
Fundulus heteroclitus (Mummichog) 
Myoxocephalus octodecemspinosus (Longhorn sculpin) 
Salvelinus fontinalis (Brook trout) 
Salmo salar (Atlantic salmon) 
Danio rerio (Zebrafish) 
Squalus acanthias (Spiny dogfish) 
Tetraodon nigroviridis (Pufferfish) 
 Xenopus tropicalis (Western clawed frog) 
Oryzias latipes (Medaka fish) 
Dapnnia.magna 
Daphnia pulex 
76 
76 
74 
69 
68 
68 
72 
69 
68 
67 
67 
63 
64 
31 
32 
0.0 
0.0 
0.0 
0.0 
0.0 
0.0 
0.0 
0.0 
0.0 
0.0 
0.0 
0.0 
0.0 
3.2 
8.6 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
YES1 
NA 
NA 
NA 
YES2 
YES3 
NA 
diclofenac 
ibuprofen 
paracetamol 
Prostaglan-
din G/H 
synthase 2 
precursor 
(COX2) 
Ornithorhynchus anatinus (Platypus) 
 Xenopus tropicalis (Western clawed frog) 
Xenopus laevis (African clawed frog) 
Taeniopygia guttata (Zebra Finch) 
Danio rerio (Zebrafish) 
Fundulus heteroclitus (Mummichog) 
Oncorhynchus mykiss (Rainbow trout) 
Myoxocephalus octodecemspinosus (Longhorn sculpin) 
Micropogonias undulates (Atlantic croaker) 
Salvelinus fontinalis (Brook trout) 
Dicentrarchus labrax (European Seabass) 
Myxine glutinosa (Hagfish) 
Squalus acanthias (Spiny dogfish) 
Salmo salar (Atlantic salmon) 
Oryzias latipes (Medaka fish) 
Daphnia pulex 
86 
74 
74 
81 
75 
72 
72 
71 
71 
71 
73 
63 
62 
67 
73 
46 
0.0 
0.0 
0.0 
0.0 
0.0 
0.0 
0.0 
0.0 
0.0 
0.0 
0.0 
0.0 
0.0 
0.0 
0.0 
0.0 
NA 
NA 
NA 
NA 
YES1 
NA 
YES4 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
YES2 
NA 
diclofenac Transthyre-
tin 
precursor 
Ornithorhynchus anatinu) (Platypus) 
Anas platyrhynchos (Mallard Duck) 
Xenopus laevis (African clawed frog) 
Taeniopygia guttata (Zebra Finch) 
Rana catesbeiana (Bullfrog) 
Xenopus tropicalis (Western clawed frog) 
Perca flavescens (Yellow perch) 
Cyprinus carpio (Common carp) 
Sparus aurata (Gilt-Head bream) 
Danio rerio (Zebrafish) 
Epinephelus coioides Orange spotted grouper) 
65 
70 
58 
68 
56 
59 
54 
51 
51 
48 
50 
7.0e-53 
4.0e-56 
2.0e44 
4.0e-52 
8.0e-41 
7.0e-39 
1.0e37 
2.0e-35 
4.0e-35 
6.0e-34 
1.0e-33 
 
ibuprofen Serum 
albumin 
precursor 
Ornithorhynchus anatinus (Platypus0 
Taeniopygia guttata (Zebra Finch) 
Bombina maxima (Giant fire bellied toad) 
Ambystoma maculatum (Salamander) 
Xenopus tropicalis (Western clawed frog) 
Xenopus laevis (African clawed frog) 
Oncorhynchus mykiss (Rainbow trout) 
61 
44 
40 
40 
39 
39 
35 
4.0e-
150 
1.0e-
147 
5.0e-
138 
9.0e-
136 
2.0e-
130 
2.0e-
127 
7.0e-24 
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Table 4.5 Gemfibrozil and propranolol drug target sequence homology results 
(I: percent sequence identity; E value: the probability of this identity occurring by chance; Ecotoxicity: 
YES = Ecotoxicity data available in the literature to support mode of action effects of the particular 
pharmaceutical on the primary drug target receptor: Finn et al., 2012
1
; Bartram et al., 2012
2
; Petersen et al., 
2013
3
; NA: ecotoxicity data not available). 
Pharmaceutical Drug Target Organism I E value Ecotoxicity 
Propranolol 
 
Beta- 1- 
adrenergenic 
receptor  
Ornithorhynchus anatinus (Platypus) 
Xenopus laevis (African clawed frog) 
Tetraodon nigroviridis (Pufferfish) 
Danio rerio (Zebra fish) 
Oncorhynchus mykiss (Rainbow trout) 
Salmo salar (Atlantic salmon) 
Pimphales promelas (Fathead minnow) 
Cyprinus carpio (Common carp) 
65 
61 
61 
55 
51 
51 
58 
50 
4.0e-157 
4.0e-138 
2.0e-127 
5.0e-127 
5.0e-109 
1.0e-104 
9e-156 
5e-120 
NA 
NA 
NA 
YES1 
YES2,3 
NA 
NA 
NA 
Propranolol 
 
5-
hydroxytryptam
ine 1A receptor 
Taeniopygia guttata (Zebra Finch)  
Danio rerio (Zebra fish) 
Platichthys flesus (European flounder) 
Tetraodon nigroviridis (Pufferfish) 
Opsanus beta (Gulf Toad fish) 
Xenopus laevis (African clawed frog) 
Lates calcarifer (Barramundi)  
Branchiostoma floridae (Lancelet) 
Mizuhopecten yessoensis (Scallop) 
Aplysia californica (Sea slug) 
Helisoma trivolvis (Freshwater snail) 
Procambarus clarkii (Freshwater crayfish) 
Panulirus interruptus (California spiny lobster) 
Macrobrachium rosenbergii (Giant prawn) 
79 
75 
76 
69 
70 
70 
67 
44 
39 
41 
40 
38 
39 
39 
0.0 
1.0e-173 
9.0e-169 
6.0e-164 
1.0e-163 
7.0e-155 
4.0e-109 
2.0e-88 
7.0e-84 
5.0e-82 
8.0e-79 
9.0e-76 
2.0e-71 
4.0e-68 
 
propranolol β-2 adrenergenic 
receptor 
 Galemys pyrenaicus (Pyrenean Desman) 
 Sylvilagus floridanus (American Beaver) 
94 
93 
2.0e-153 
8.0e-152 
 
Propranolol 
 
5-
hydroxytryptam
ine 1B receptor 
 Taeniopygia guttata (Zebra Finch) 
 Tetraodon nigroviridis (Pufferfish) 
 Danio rerio (Zebra fish) 
 Ornithorhynchus anatinus (Platypus) 
Branchiostoma floridae (Lancelet) 
87 
69 
64 
58 
43 
0.0 
3.0e-146 
3.0e-138 
6.0e-111 
 
 
propranolol beta- 3- 
adrenergenic 
receptor 
Oncorhynchus mykiss (Rainbow trout) 
Salmo salar (Atlantic salmon) 
Xenopus laevis (African clawed frog) 
Ornithorhynchus anatinus (Platypus) 
53 
53 
52 
53 
4.0e-95 
2.0e-91 
2.0e-90 
3.0e-90 
 
Gemfibrozil 
 
Peroxisome 
proliferator- 
activated 
receptor alpha 
 Taeniopygia guttata (Zebra Finch) 
 Anas platyrhynchos (Mallard duck) 
 Xenopus laevis (African clawed frog) 
Ornithorhynchus anatinus (Platypus) 
 Pagrus major (Red seabream) 
 Lateolabrax japonicas (Sea perch) 
 Salmo salar (Atlantic salmon) 
 Ctenopharyngodon idella (Grass carp) 
 Danio rerio (Zebra fish) 
 Tetraodon nigroviridis (Pufferfish) 
 Crocodylus niloticus (Crocodile) 
 Sparus aurata (Sea bream) 
 Dentex dentex (Dentex fish) 
Rachycentron canadum (Cobia fish) 
 Pleuronectes platessa ( Plaice) 
Orizias latipes (Medaka fish) 
 Sparus aurata (Gilthead bream) 
Cyprinus carpio (Common Carp) 
88 
88 
81 
90 
73 
73 
73 
72 
71 
77 
92 
65 
64 
64 
64 
59 
65 
67 
0.0 
0.0 
0.0 
0.0 
0.0 
0.0 
0.0 
0.0 
0.0 
0.0 
7.0e-180 
2.0e-177 
1.0e-174 
1.0e-174 
1.0e-168 
6.0e-164 
1.0e-155 
6e-96 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
gemfibrozil Lipoprotein 
lipase precursor 
Ornithorhynchus anatinus (Platypus) 
Anas platyrhynchos (Mallard duck ) 
Danio rerio (Zebra fish) 
Ctenopharyngodon idella (Grass carp) 
Cyprinus carpio (Common carp) 
Oncorhynchus mykiss (Rainbow trout) 
 Dicentrarchus labrax (Seabass) 
Sparus aurata (Gilthead bream) 
Thunnus niloticus (Bluefin Tuna) 
Xenopus laevis (African clawed frog) 
85 
76 
61 
62 
63 
62 
63 
62 
56 
50 
0.0 
0.0 
1.0e-177 
2.0e-175 
1.0e-173 
2.0e-172 
3.0e-172 
2.0e-170 
2.0e-148 
6.0e-126 
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Table 4.6 Fluoxetine and carbamazepine drug target sequence homology results  
(I: percent sequence identity; E value: the probability of this identity occurring by chance; Ecotoxicity: 
YES = Ecotoxicity data available in the literature to support mode of action (MoA) effects of the particular 
pharmaceutical on the primary drug target receptor, references: Lister et al., 2011
1
; Painter et al., 2009
2
; 
Schultz et al., 20113; Conners et al., 2009
4
; Li et al., 2009
5
; NA: Ecotoxicity data not available) 
 
 
4.4.3 Multiple sequence alignment (COX2) 
Two drugs were chosen to test the potential for using molecular docking as an aid 
in ecotoxicology tests of pharmaceuticals. These were diclofenac and ibuprofen (for drug 
choice rationale see Section 4.1.4). Sequence alignment is useful for locating conserved 
regions in the amino acid sequence of proteins. Conserved regions often form the binding 
sites of enzymes. The homologues of five species were compared to the primary drug 
target for diclofenac and ibuprofen, the COX 2 enzyme.  These species were: Ovis aries 
(sheep), because it was this species that was used to obtain the crystal structure of COX2 
(Rowlinson et al., 2004), O.mykiss (used in several ecotoxicological studies (Hoeger et 
al., 2004; Schwaiger et al., 2004), S.salar, D.rerio and D.pulex (regularly used in 
ecotoxicity tests). As a COX2 homologue for P.promelas was not found in the BLAST 
search, this ecotoxicological test species was not included. The CLUSTAL W multiple 
sequence alignment for the H.sapiens, (human), D.rerio, O.mykiss, S.salar and D.pulex 
and O.aries (sheep) COX2 homologues are displayed (Fig 4.2). The multiple sequence 
alignment shows the differences in numbering of amino acid residues that can occur 
when aligning sequences. The amino acid residues found to be important for binding of 
diclofenac in the crystal structure (Rowlinson et al., 2004) and other NSAIDs (Pouplana 
et al., 2002) by hydrogen bonding are highlighted in red. The amino acid residues 
Pharmaceutical Drug Target Organism I E value Ecotoxicity 
fluoxetine 
citalopram 
escitalopram 
zimelidine 
Sodium 
dependant 
serotonin 
transporter 
 Oncorhynchus mykiss (Rainbow trout) 
 Salmo salar (Atlantic salmon) 
 Danio rerio (Zebra fish) 
 Pimphales promelas (Fathead minnow) 
 Xenopus laevis (African clawed frog) 
 Xenopus tropicalis (Western clawed frog) 
34 
44 
69 
53 
44 
42 
8.4 
2.0e-137 
0.0 
1.0e-40 
4.0e-142 
1.0e-139 
NA 
NA 
YES1 
YES2,3 
YES4 
NA 
carbamazepine Sodium 
chanel 
protein type 
5 subunit 
alpha 
 
Oncorhynchus mykiss (Rainbow trout) 
Salmo salar (Atlantic salmon) 
Daphnia magna 
Danio rerio (Zebra fish) 
Pimphales promelas (Fathead minnow) 
 Takifugu rubripes (Japanese killifish) 
 Xenopus laevis (African clawed frog) 
 Hydra vulgaris (Freshwater hydroid) 
 Lymnaea stagnalis (Pond snail) 
72 
24 
35 
64 
22 
19 
52 
33 
32 
0.0 
3.0e-07 
6.8 
0.0 
3.8 
4.0e-06 
2.0e-159 
2.0e-60 
1.0e-86 
YES5 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
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arginine (R), tyrosine (Y), and serine (S) are contained in highly conserved regions of the 
protein sequence and form part of the binding pocket. The molecular docking 
experiments with ibuprofen and diclofenac with the D.pulex COX2 homologue were 
unsuccessful potentially due to a difference in amino acid at residue 525 from leucine to 
isoleucine (highlighted in blue) (Fig 4.2).  
 
 
Ovis aries             SRSHLIESPPTYNVHYSYKSWEAFSNLSYYTRALPPVPDDCPTPMGVKGRKELPDSKEVV 163 
Homo sapiens           SRSHLIDSPPTYNADYGYKSWEAFSNLSYYTRALPPVPDDCPTPLGVKGKKQLPDSNEIV 164 
Danio rerio            SRAHLIDSPPTFNADYGYKSWEAYSNLSYYTRTLPPVPRDCPTPMGVAGKKELPDVKMLA 166 
Oncorhynchus mykiss    PRSHLVDSPPTYNADYGYKSWEAYSNLFYYTRTLPPLPKDCPTPMGTAGRAVLPDVKLVV 167 
Salmo salar            VRSNLIPSPPTFNSKYGYLSWESYSNVSYYTRILPPVPEDCPTPMGTKGKSVLPDPKLVV 178 
Daphnia pulex         SRGAAIQSPPRFNSGHDYITTQSHFNTSYYARSLPPVPQHCPTPMGVAGHGELPDIDELA 171 
 
Ovis  aries  FKLKFDPELLFN-QQFQYQNRIAAEFNTLYHWHPLLPDVFQIDGQEYNYQQFIYNNSVLL 400 
Homo sapiens            FKLKFDPELLFN-KQFQYQNRIAAEFNTLYHWHPLLPDTFQIHDQKYNYQQFIYNNSILL 401 
Danio rerio  FKLKFDPELLFN-ERFQYQNRISSEFNTLYHWHPLMPDDFHIQDEVYNYQQFLFNTSILT 403 
Oncorhynchus mykiss  FQLKFDPELLFN-QRFQYQNRIAAEFNTLYHWHPLMPETFSIEDRAYTYPQFVFNNSLVT 404 
Salmo salar  LDLKFDPVLLFK-STFQYRNRIAVEFKQLYHWHPLMPDSFHIDGDVVPYSQFMFNTSIVT 415 
Daphnia pulex  VKLSYDPELLRDEPQFQFSNRIHVEFAHLYHWHPMAPEAITLGNNTYTLEQMSFSTKTVA 410  
 
Ovis aries              ESFEELTG-EKEMAAELEALYGDIDAMELYPALLVEKPAPDAIFGETMVEAGAPFSLKGL 519 
Homo sapiens             ESFEELTG-EKEMSAELEALYGDIDAVELYPALLVEKPRPDAIFGETMVEVGAPFSLKGL 520 
Danio rerio              RSFEEMTG-EKEMAAELEEMYGDVDAVELYAGLLVEKPRSNAIFGETMVEMGAPYSLKGL 522 
Oncorhynchus mykiss       TSFEDLTG-ETELAAELESLYGDVDAVELYPGLLVERPRPNAVFGETMVEMGAPYSLKGL 523 
Salmo  salar             TSFSDFTG-EEEIARELEELYGDIDALEFYPAIMLEKTRPNAIFGESMVEMGAPFSLKGL 534 
Daphnia pulex            TSFMELTGGDVDLSRQLDKLYGDIDALEFYPGMLLEKS-DSSVTPFTMVNIGGPYAIKGM 528 
 
Ovis aries   MGNPICSPEYWKPSTFGGEVGFKIINTASIQSLICSNVKG--CPFTSFSVQDA----HLT 573                   
Homo sapiens  MGNVICSPAYWKPSTFGGEVGFQIINTASIQSLICNNVKG--CPFTSFSVPDP----ELI 574 
Danio rerio  MGNPICSPEYWKPSTFGGKVGFEIVNSASLQNLVCNNVNGP-CPMASFYVPNV----KDS 577 
Oncorhynchus mykiss  LGNPICSPEYWMPSTFGGSVGFDILNTASLERLVCNNVKGS-CPMVSFQVPDF----LRA 578 
Salmo  salar  LGNPICSPEYWKPSTFGGQTGFDIVNSASLERLVCLNTNW--CPYVAFNVPPA----GQE 588 
Daphnia pulex  MANPISSPHYWKPSTFGGPVGFDIVKSTTIKDLFCRNMKPGECGHIAFHLPTTEGQSQQQ 588 
 
Fig 4.2 CLUSTAL W multiple sequence alignment of COX 2 enzymes 
(Conserved residues involved in binding of diclofenac and ibuprofen arginine, tyrosine and serine 
highlighted red; mutation in leucine to isoleucine in Daphnia pulex highlighted blue) 
 
 
4.4.4 Molecular docking 
Molecular docking experiments were then performed for the human, O.mykiss, 
S.salar, D.rerio and D.pulex COX2 homologues with diclofenac and ibuprofen. All of the 
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dockings were successful except D.pulex. Diclofenac and ibuprofen failed to bind to the 
D.pulex COX2 homologues. This suggests that although the protein was of high 
similarity to the human form, some change in the residue sequence must prevent it from 
binding diclofenac or ibuprofen. This could be due to a change in the leucine residue at 
position 525 (Fig 4.2). This leucine residue can be seen in the binding pocket very close 
to the location of the docked diclofenac and ibuprofen molecules (Leu525 in Fig 4.13; 
Leu 531 in Fig 4.15; Leu 522 in Fig 4.17; Leu 517 in Fig 4.19; Leu521 in Fig 4.21). 
For each of the eight separate successful docking experiments the ten best (i.e. the 
ten lowest binding energies) docked molecules (COX2) and ligands (diclofenac and 
ibuprofen) all docked in the same binding pocket (Fig 4.3-4.10). The results show that in 
each case the ten best docked drugs were positioned in the same orientation directly on 
top of one another. This indicates the reliability and the reproducibility of the results. The 
free energy of binding for each of the separate experiments ranged from -7.62 to -5.9 
kjmol
-1 
(Table 4.7). The free energy of binding for each of the drugs to each COX 2 
homologue was very similar within each separate experiment. Ibuprofen had a lower free 
energy of binding than diclofenac for all the COX2 homologues apart from D.rerio. The 
reason for this is unknown. 
Three amino acid residues were identified as important for binding of diclofenac 
and ibuprofen in the COX 2 binding pocket. Hydrogen bonding between occurred 
between either arginine, tryrosine or serine and the drug molecules diclofenac or 
ibuprofen. In all the dockings hydrogen bonding occurred between one or more of these 
residues and the drugs. An example of the hydrogen bonding between each of the docked 
drugs and the different COX homologues are displayed (Fig 4.11, 4.13, 4.15, 4.17, 4.19, 
4.21, 4.23, and 4.25). The positioning of the drug binding site for each drug and COX 2 
homologue is also shown (Fig 4.12, 4.14, 4.16, 4.18, 4.20, 4.22, and 4.24). The results of 
the docking experiments (Fig 4.11-4.24) show that binding between the human COX 2 
enzyme and diclofenac and ibuprofen are in the same binding pocket. The hydrogen 
bonding that occurs is similar for all these experiments indicating a strong possibility that 
these three fish would all respond to diclofenac and ibuprofen in the same way as humans. 
These dockings also show that ibuprofen and diclofenac are bound to the same amino 
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acid residues in the same binding pocket of the COX 2 enzyme indicating a likelihood 
that these two drugs could have a concentration addition effect.   
 
Table 4.7 The ten best free energy of binding (kjmol
-1
) for diclofenac and ibuprofen 
to COX 2 enzymes 
 
 
 
 
Organism Diclofenac Ibuprofen   Organism Diclofenac Ibuprofen 
H.sapiens -5.16 -7.58   S.salar -6.26 -7.36 
  -4.99 -7.59 
 
  -6.23 -7.33 
  -4.79 -7.565 
 
  -6.19 -7.34 
  -4.65 -7.57 
 
  -6.15 -7.37 
  -4.62 -7.56 
 
  -6.15 -7.35 
  -4.61 -7.56 
 
  -6.13 -7.38 
  -4.6 -7.56 
 
  -6.12 -7.34 
  -4.56 -7.59 
 
  -6.08 -7.34 
  -4.47 -7.57 
 
  -6.07 -7.35 
  -4.47 -7.56     -6.07 -7.45 
O.mykiss -6.62 
 
-5.88   D.rerio -5.13 -7.59 
  -6.6 -5.88     -5.08 -7.59 
  -6.57 -5.88     -4.91 -7.58 
  -6.52 -5.89     -4.9 -7.58 
  -6.51 -5.88     -4.86 -7.58 
  -6.47 -5.88     -4.85 -7.58 
  -6.47 -5.9     -4.84 -7.62 
  -6.47 -5.9     -4.81 -7.59 
  -6.45 -5.88     -4.79 -7.61 
  -6.44 -5.9     -4.74 -7.58 
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Fig 4.3 Results of the ten lowest energy dockings of human COX 2 and diclofenac (COX 2 shown in pink) 
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Fig 4.4   Results of the ten best lowest energy dockings of O.mykiss COX 2 and diclofenac (COX 2 shown in pink) 
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Fig 4.5 Results of the ten lowest energy dockings of S.salar COX 2 and diclofenac (COX 2 shown in pink) 
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Fig 4.6 Results of the ten lowest energy dockings of D.rerio COX 2 and diclofenac (COX 2 shown in pink) 
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Fig 4.7 Results of the ten lowest energy dockings for human COX 2 and ibuprofen (COX2 shown in pink) 
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Fig 4.8 Results of the ten lowest energy dockings for O.mykiss COX 2 and ibuprofen (COX 2 shown in pink) 
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Fig 4.9 Results of the ten lowest energy dockings for S.salar COX 2 and ibuprofen (COX 2 shown in pink)                           
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Fig 4.10 Results of the ten lowest energy dockings for D.rerio COX 2 and ibuprofen (COX 2 shown in pink) 
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Fig 4.11 Hydrogen bonding of human COX 2 and diclofenac  
(hydrogen bonds shown in green, diclofenac shown in blue) 
                             
Fig 4.12 Positioning of diclofenac and human COX 2 
                                  (human COX 2 coloured by residue)
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Fig 4.13 hydrogen bonding of O.mykiss COX 2 and diclofenac 
(hydrogen bonds shown in green, diclofenac shown in blue) 
 
                  
Fig 4.14 Positioning of diclofenac and O.mykiss COX 2 
(O.mykissCOX 2 coloured by residue)  
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Fig4.15 Hydrogen bonding of S.salar COX 2 and diclofenac 
(hydrogen bonds shown in green; diclofenac shown in blue) 
 
 
 
Fig 4.16 Positioning of diclofenac and S.salar COX 2  
(COX 2 coloured by residue) 
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Fig4.17 Hydrogen bonding of D.rerio COX 2 and diclofenac 
(Hydrogen bonds shown in green; diclofenac shown in blue) 
 
 
 
Fig 4.18 Positioning of diclofenac and D.rerio COX 2 
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Fig 4.19 Hydrogen bonding of human COX 2 and ibuprofen 
(Hydrogen bonds shown in green; ibuprofen shown in blue) 
                
                                  
Fig 4.20 Positioning of ibuprofen and human COX 2  
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Fig 4.21 Hydrogen bonding of  D.rerio COX 2 and ibuprofen 
(Hydrogen bonds shown in green; ibuprofen shown in blue) 
 
Fig 4.22 Positioning of ibuprofen and D.rerio COX 2  
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Fig 4.23 Hydrogen bonding of S.salar COX 2 and ibuprofen 
(Hydrogen bonds shown in green; ibuprofen shown in blue) 
 
 
Fig 4.24 Positioning of ibuprofen and S.salar COX 2  
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Fig 4.25 Hydrogen bonding of D.rerio COX 2 and ibuprofen 
(Hydrogen bonds shown in green; ibuprofen shown in blue) 
 
 
Fig 4.26 Positioning of ibuprofen and D.rerio COX 2  
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4.5  Discussion 
 Aquatic organisms have a high degree of human drug target conservation and may be 
susceptible to a similar MoA occurring when exposed to pharmaceuticals. 
4.5.1 Drug target conservation in aquatic wildlife 
The BLAST search revealed that aquatic vertebrates have the highest degree of sequence 
homology with the human drug targets investigated. Fish and frogs were the organisms found to 
have the most homologues with the highest percentage of similarity (Table 4.3-4.6). It is, 
therefore, probable that human drugs would exhibit a similar mode of action in these organisms.  
Organisms such as aquatic invertebrates and algae were found to lack similar drug target 
receptors. This could be because the genomes for these organisms have yet to be sequenced; 
however, if this is not the case, it is therefore unlikely that they would show a similar effect to 
humans when exposed to the selected drugs. Ankley et al., (2007) suggest that ecotoxicity testing 
should be focused in two ways (1) identification of drugs with the most potential to elicit adverse 
effects and (2) determination of which species and end points should be used for testing. The 
results of the homology BLAST search and molecular docking experiments performed here can 
provide important and useful information for both of these tasks. 
Fish were found to have a degree of protein sequence conservation of drug targets for all 
of the nine pharmaceuticals investigated.  D.rerio, the only fish so far to have its whole genome 
sequenced was found to have some protein sequence conservation of the target proteins for all 
the drugs investigated. D.rerio drug target homologues regularly had over 60% identity (Table 
4.3-4.6). This indicates a high potential for D.rerio to exhibit similar metabolic responses to 
humans when exposed to these pharmaceuticals. This is significant when considering what end 
points should be used in sub chronic early life stage tests performed as part of an ERA. 
Intelligent testing would incorporate the mode of action of these compounds which is likely to 
occur in fish.  
The frogs Xenopus laevis and Xenopus tropicalis regularly appeared in the homology 
search (Table 4.3-4.6). They often had an even higher percentage sequence homology than that 
of the fish homologues. This could be an important finding with regards to ERA of human 
pharmaceuticals because amphibians are not covered in the current guidelines for ecotoxicity 
testing. It is known that exposure to EE2 can cause persistent sex reversal in X.tropicalis 
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(Petterson et al., 2006; Gyllenhammar et al., 2009). Exposure of frogs to sewage effluent can 
disrupt the production and bioactivity of protective peptides which are a critical part of 
amphibian resistance to pathogens such as the chytrid fungus (Gibble & Baer, 2011). The 
antidepressant sertraline has been shown to disrupt the neuroendocrine system in tadpoles 
causing developmental toxicity at environmentally relevant concentrations (Conners et al., 2009). 
Amphibians have declined dramatically in many areas of the world. These declines seem to have 
worsened over the past 25 years and amphibians are now more threatened than either mammals 
or birds (Beebee & Griffiths, 2005). Currently, the highest trophic level used for ecotoxicity tests 
is a fish. Although not an issue in the UK, crocodiles and alligators were also identified as 
having high conservation of drug target proteins for tamoxifen, EE2 and gemfibrozil. This could 
be an environmental problem for other countries outside the UK such as the USA and Australia. 
Two species of birds appeared several times in the homology BLAST results. The zebra 
finch (Taeniopygia guttata) had similar targets for the drugs diclofenac, paracetamol, ibuprofen, 
propranolol, gemfibrozil, tamoxifen and EE2 (Table 4.3-4.6). The mallard duck (Anas 
platyrhynchos) had homologues for targets of diclofenac, EE2, tamoxifen and gemfibrozil. 
Although it is not immediately thought of as an aquatic species it does spend the majority of its 
life associated with the water and feeds on aquatic plants. Aquatic birds such as ducks that feed 
and drink from rivers could represent an exposure pathway that has not been considered with 
regards to ERA of human pharmaceuticals but potentially should be included. Although it may 
seem unlikely, the massive decline of vultures in India and Pakistan was not an exposure 
pathway that had been considered (Oaks et al., 2004). The exposure pathway is more likely to 
occur if the pharmaceutical compound has a tendency to bioaccumulate in fish or aquatic 
invertebrates, which is the case with diclofenac and fluoxetine (Mennigen et al., 2011; Kallio et 
al., 2010).  All new medicines that have an octanol partition coefficient (Kow) >4.5 must undergo 
a test for persistence, bioaccumulation and toxicity during the ERA. However Kow has been 
shown to be a poor indicator of bioaccumulation for some compounds such as diclofenac and 
ibuprofen (Schnell et al., 2009). 
 Molluscs and mussels have been highlighted as a species that should be covered by 
ecotoxicity testing of chemicals and pharmaceuticals but which are not currently (Rittschof & 
McClellan-Green, 2005). The homology research results revealed some conservation of drug 
targets in molluscs. The Pond snail (Lymnaea stagnalis) has a protein with 32% identity to the 
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carbamazepine drug target and the scallop (Mizuhopecten yessoensis) had 39% sequence identity 
with the propranolol drug target (Table 4.5 & 4.6). It is worth noting that although the sequence 
homology is quite low, generally speaking any protein with above 30% sequence identity 
probably has the same function because it is the binding motifs that are particularly important in 
conservation (Palowski et al., 2000). It is possible, therefore that these proteins may bind the 
drugs and react in the same way. Mollusks may be very sensitive to propranolol and fluoxetine 
(Lazzara et al., 2012; Bringolf et al., 2010; Ericson et al., 2010).  
Daphnia showed some sequence homology with the COX enzyme targets for 
paracetamol, diclofenac and ibuprofen. This organism showed no significant sequence homology 
with any of the other drug targets, making it is less likely that these drugs would produce a 
similar effect in Daphnia species as in humans. Again this could be because the whole genome 
has yet to be sequenced. The same was true for algae which also showed little sequence 
homology with the drug targets. So far, little is known about their potential detrimental effects of 
pharmaceuticals on algae. In a recent study on the effects of a mixture of 13 pharmaceuticals on 
the microalga, Pseudokirchneriella subcapitata the findings were that the cells could absorb the 
drugs and whilst no genotoxic effect was detected, proteomic analysis showed that algae are 
sensitive to the presence of drugs and that, in particular, the chloroplast is affected. 
  These organisms represent two of the three trophic levels required in the toxicological 
assessment of pharmaceuticals for an ERA. If human drug targets are not conserved in these 
species then any effect produced from chronic pharmaceutical exposure is more likely to be 
general toxic effect rather than that related to a specific mode of action. A search of the literature 
revealed that adverse effects of pharmaceuticals on daphnids are unlikely at concentrations 
below 1 mgl
-1 
(Santos et al., 2009). This lack of likely toxicological effects on the Daphnia 
genus at environmentally relevant concentrations brings into question its use in ERAs. However, 
another crustacean, Gammurus pulex has been shown to exhibit changes in behaviour with 
exposure to concentrations of fluoxetine, ibuprofen and carbamazepine at concentrations as low 
as 10 ngl
-1
 (De-Lange et al., 2005).  Behavioral changes in the marine amphipod, 
Echinogammarus at concentrations of 100 ngl
-1
 have also been reported (Guler & Ford, 2010). It 
has also been shown that G.pulex can bioconcentrate the pharmaceuticals fluoxetine and 
carbamazepine, which may have implications for fish that use amphipods as their food source 
(Meredith-Williams et al., 2012). These findings suggest that subtle chronic toxicological effects 
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may be occurring in these species when exposed to pharmaceuticals. It is unknown whether these 
toxicological effects are related to evolutionary conservation of drug targets because at present, 
the entire genomes of these organisms have yet to be sequenced. In order to increase the amount 
of information that ecotoxicology tests reveal, they need to be made more relevant to the actual 
environmental situation. The choice of end points for chronic tests needs to be connected to the 
mode of action of the drug and the presence of a functional gene target in the organism you are 
testing. In order to achieve this more intelligent approach it is suggested that sequencing the 
genomes of species regularly used in ecotoxicology tests is made a priority. 
4.5.2 Lack of protein target homology 
If a protein homologue of the drug target does not exist in a particular species it does not 
mean that toxicity effects from human drugs does not occur. They may exhibit a different mode 
of action and affect differing pathways to humans through acting upon target proteins that are 
present in other organisms but not humans. Functional interactions between a drug and non-
orthologous proteins are also possible (Gunnarsson et al., 2008). For example EE2 can induce 
reproductive responses in molluscs (Jobling et al., 2004) although the oestrogen receptor 
described in molluscs is not activated by this synthetic hormone (Thornton et al., 2003). 
Although impossible at the moment, in the future molecular docking packages may be developed 
which could screen a vast number of proteins (entire genomes) for potential interactions with 
pharmaceuticals or in fact any small molecule.  
A COX enzyme homologue was not found in the BLAST search for P.promelas although 
COX or COX like proteins with significant sequence homology were found for several other fish 
including O.mykiss, Salmo salar, Atlantic croaker (Micropogonias undulates) and Danio rerio 
(Table 4.4). Another example of inconsistencies in the drug target homologue results was found 
for carbamazepine. The drug target for carbamazepine, a sodium transport protein also showed 
no sequence homology with P.promelas or S.salar, but did with several other fish. A similar 
protein with 72% identity was found for O.mykiss (Table 4.6) which is an evolutionary similar 
fish to S.salar. This is a surprising finding because it would seem logical that these fish would 
have very similar molecular pathways and processes and therefore express similar enzymes. The 
reason for this could be that the proteins have yet to be sequenced because the genome for these 
organisms is not yet complete, however, a great number of the proteins have been characterised 
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and a substantial quantity of genomic information has been assembled for P.promelas; probably 
because it is frequently used in ecotoxicity testing. If they do not posses the protein target, then 
this is very important information from an ecotoxicological and ERA stance. If an organism does 
not possess the drug target protein then the organism cannot react to a drug by a similar mode of 
action and would only respond through any non-specific general toxicity effects or through 
possible binding to non-target proteins. Thus choice of test species is particularly important for 
drugs that have functional receptor drug targets in other organisms (Gunnarsson et al., 2008). 
Bioinformatics databases can provide this kind of information which may be crucial for 
identifying and selecting vulnerable species for ecotoxicology testing.  
4.5.3 Presence of homologous drug receptors and present ecotoxicology knowledge 
One of the findings of this study was that human drugs may have multiple targets. 
Tamoxifen, a drug used in the treatment of breast cancer had several drug target proteins the first 
of which was listed as the oestrogen receptor (Table 4.3). The order of targets listed in drug bank 
reflects their importance regarding therapeutic indication or physiological effect (Wishart et al., 
2008). This drug target is the same as the highly potent EE2 known to cause intersex changes in 
fish and frogs downstream of sewage outfalls (Jobling et al., 2004). The BLAST results revealed 
a high sequence homology of the oestrogen receptor with several aquatic species (Table 4.3). 
The data analysis results show that tamoxifen has been detected in surface waters in the UK and 
France at concentrations of up to 210 ngl
-1
 (Roberts and Thomas, 2006), (Section 2) and if it is as 
potent as EE2 it could potentially be a problem for aquatic species. Tamoxifen has a high 
estrogenic potential and can inhibit the proliferation of yeast cells (Isidori et al., 2010). Therefore 
the potential for adverse reproductive effects on fish would seem likely. However a NOEC of 5.1 
mgl
-1
for a full lifecycle study on reproductive effects of tamoxifen on P.promelas has been 
reported (Williams et al., 2007) which is considerably higher than concentrations reported in 
surface water, indicating that despite P.promelas having a protein with high sequence homology 
with the human oestrogen receptor (Table 4.3) tamoxifen has a low potential for adverse effects 
at environmentally relevant concentrations on this fish. However, this was one of the only 
chronic ecotoxicity studies for this drug. Tamoxifen has a high log Kow (Table 2.1), 
(unfortunately a pH corrected log Kow value was not available) therefore the potential for 
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bioaccumulation exists. Tamoxifen also scores highly for PBT potential (Roos et al., 2012). 
Clearly the potential for adverse effects of this pharmaceutical cannot be excluded. 
The beta blocker propranolol mainly targets beta adrenoreceptor proteins in humans. The 
bioinformatics results showed a high degree of conservation of these proteins in lower 
vertebrates and fish (Table 4.5). Nickerson et al., (2001) also found beta adrenoreceptors in 
O.mykiss and a high degree of sequence conservation in lower vertebrates. Propranolol can cause 
cell membrane stabilization and known side effects include broncho-constriction and disturbed 
peripheral circulations in humans. It can pass the blood brain barrier and act in the central 
nervous system (Giltrow et al., 2009). If these conserved proteins in aquatic species act in the 
same way when bound to propranolol, similar effects could be taking place. In a study by Owen 
et al., (2009) it was concluded from chronic ecotoxicology studies that effects of propranolol 
were unlikely at environmentally relevant concentrations on O.mykiss but found that responses 
of O.mykiss supported the use of mammalian toxicology data to determine responses in fish. 
These findings (Table 4.5) are also supported by a recent study by Giltrow et al., (2011) that 
confirms that the beta-adrenergic homologue found in P.promelas (Table 4.5) contains the 
molecular signatures required for propranolol binding and can alter the expression profile. The 
authors concluded that characterization of the molecular targets for beta-blockers in fish will aid 
informed environmental risk assessments of these drugs.  
Although no homologues of the human beta adrenergic receptor were found in algae or 
mussels (Table 4.5), beta blockers such as propranolol may also adversely affect mechanisms 
that are not present in mammals such as photosynthesis in algae (Escher et al., 2006) or immune 
systems in mussels (Canesi et al., 2007). As a consequence further investigation into interactions 
between non specific receptors and propranolol in non target species are recommended. 
Molecular docking programs may offer a method for this investigation. 
Fluoxetine (Prozac) is an antidepressant belonging to a group of compounds called 
selective serotonin reuptake inhibitors (SSRIs) it blocks the reuptake of serotonin at the serotonin 
reuptake pump of the neuronal membrane, enhancing the actions of serotonin on the serotonin 
receptor. This is a neurotransmitter involved in hormonal and neuronal mechanisms. It is 
important in food intake and sexual behaviour and mediates endocrine functions in aquatic 
organisms (Pery et al., 2008). The bioinformatics results revealed a high degree of homology 
between the sodium dependant serotonin transporter protein target in humans with those found in 
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S.salar, D.rerio, and X.tropicalis (Table 4.6). This is in agreement with Fong, (1998) who found 
serotonin in lower vertebrates and invertebrates.  Several fish species possess serotonin receptors 
making it possible to predict that SSRIs can modulate serotonin levels in these animals (Brooks 
et al., 2005). There are several reports of ecotoxicity of fluoxetine on aquatic organisms, some of 
which are clearly related to the mode of action of this drug supported by the high degree of 
homology in target proteins (Table 4.6). Fluoxetine exposure has been shown to affect the 
serotonin receptor and cause sub lethal changes in the serotonergic pathway in the sheepshead 
minnow (Cyprinodon variegatus) which may result in behavioral changes that could, in turn, 
have implications for the ecological response of populations to additional environmental 
stressors (Winder et al., 2009). This supports observations of behavioral changes in non target 
organisms reported by other authors. For instance, inhibition of innate C start predator avoidance 
in fathead minnows (Painter et al., 2009) and disrupted feeding behaviour goldfish (Carassius 
auratus) (Mennigen et al., 2010). Reproductive disturbances have also been reported.These 
include reduction of the number of neonates and induced spawning of zebra mussels (Fong & 
Molar, 2008), changes in and reduced and changes in reproductive patterns of the invertebrate 
Ceriodaphnia dubia (Henry et al., 2004), and reproductive changes in goldfish (Mennigen et al., 
2010b). Brooks et al., (2005) found fluoxetine and its metabolite norfluoxetine bioaccumulates 
in all tissues of fish. 
At present the human serotonin receptor protein has not been crystallized. This is 
probably due to the fact that membrane proteins are often difficult to characterise (Celik et al., 
2008). This poses a problem when creating a reliable model of this protein or the homologues 
found in this study for molecular docking purposes. It would be beneficial to be able to model 
interactions of fluoxetine with serotonin receptor homologues in light of the mounting evidence 
of potential chronic effects on non target organisms (see above). Oakes et al., (2010) concluded 
that fluoxetine may pose an environmental risk to the aquatic compartment and has a risk 
quotient (RQ) of greater than 1. There is also the distinct possibility of additive and synergistic 
effects of fluoxetine with other SSRIs (section 4.4.6). Further characterization of the serotonin 
receptor would aid computational molecular docking simulations which may prove beneficial for 
ERA by providing evidence of potential interactions between protein homologues and fluoxetine 
as well as other SSRIs. 
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 Gemfibrozil acts by increasing the synthesis of lipoprotein lipase, thereby increasing the 
clearance of lipoproteins (DrugBank, 2012). A high sequence homology (73%) was found 
between the human peroxisome proliferator-activated receptor alpha drug target for gemfibrozil, 
with the protein in O.mykiss (Table 4.5). This indicates the potential that this pharmaceutical 
may act similarly in fish as it does in humans. This theory is supported by a study by Prindiville 
et al., (2011) in which it was demonstrated that gemfibrozil reduced lipoprotein concentration as 
dramatically in trout as it does in mammals.  
  Carbamazepine targets the human sodium channel receptor protein SCN5A, its mode of 
action is still not fully understood. Significant homology was found with the proteins of D.rerio 
and O.mykiss (Table 4.6) indicating that a similar mode of action may be occurring in aquatic 
species. Chronic ecotoxicity studies involving the MoA of carbamazepine were not found in the 
literature representing a research need. However ecotoxicity testing of carbamazepine has shown 
that it can have a negative effect at environmentally significant concentrations. Long term 
exposure to carbamazepine could cause low level oxidative stress inducing adaptive responses in 
antioxidant enzymes and serious oxidative damage in fish brain (Li et al., 2010) and 
carbamazepine is able to alter expression of fish genes associated with development, regulation 
and differentiation of synapses, neurons and neurotransmitters (Thomas et al., 2012). 
4.5.4 Evaluation of BLAST search against available ecotoxicity data 
Unfortunately the evidence for an organism having a functional drug receptor being more 
sensitive to exposure than an organism which does is very limited. Chronic ecotoxicity data is 
quite limited for human pharmaceuticals and even scarcer for chronic mode of action related 
toxicity tests (Table 4.3-4.6). A study investigating chronic MoA toxicity in organisms 
containing a functional drug receptor and organisms without is a research need. This type of 
information would provide valuable support for inclusion of identification of gene conservation 
of drug targets in ecotoxicity tests as well as molecular modelling and docking. It may of course 
transpire that the opposite is true; nevertheless it is important to establish whether in silico 
investigations might provide a valuable tool in ecotoxicity testing. 
One of the key problems in identification of organisms that lack the relevant drug target 
gene is that as yet limited organisms have been fully sequenced. This means that if the gene is 
not found during a BLAST homology search for a particular organism it is not known whether 
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the organism actually lacks that gene or it has simply not been sequenced yet. Sequencing of the 
genomes of organisms regularly used in ecotoxicity tests in particular needs to be made a priority. 
4.5.5 Molecular docking of drugs with proteins in non-target species 
The presence of a drug target homologue in a species does not guarantee that a functional 
interaction with the drug will occur (Gunnarsson et al., 2008). A more precise prediction of 
potential drug target interaction might be possible with better knowledge about drug binding 
domains and three dimensional structures of the target proteins (Gunnarsson et al., 2008). 
Molecular modelling programmes and databases such as Swiss Model and RCSB can help 
provide this type of information. The molecular docking experiments using ibuprofen and 
diclofenac with the COX2 enzyme performed here show that this can be done.  
The analgesics diclofenac and ibuprofen act by inhibiting (reversibly or irreversibly) the 
COX enzyme which catalyze the synthesis of prostaglandins (Vane & Botting, 1998). 
Prostaglandins are involved in inflammation, pain regulation, and regulation of blood circulation 
especially in the kidney, coagulation processes, and synthesis of gastric mucosa, vascular 
permeability and kidney function including ion retention (Sali, 2005; Mutschler, 1996; Fent et al., 
2003). Nephropathy is thought to be directly related to inhibition of prostaglandin production 
(Sanchez et al., 2002). COX mediated production of prostaglandins is important for ovulation in 
mammals (Gaytan et al., 2006) and fishes (Mercure and Van Der Kraak, 1996; Sorbera et al., 
2001). COX like proteins with significant similarity to the human forms were identified in 
several aquatic species including: O.mykiss, brook trout (Salvelinus fontinalis), S.salar, M. 
undulates, D.rerio, puffer fish (Tetraodon nigroviridis), platypus (Ornithorhynchus anatinus), 
X.tropicalis, and D. pulex (Table 4.4). The COX enzymes are part of the cytochrome P450 (CYP) 
family of enzymes particularly important in most drug metabolism (Dorne et al., 2007). The 
amino acids Ser-530 and Tyr-385 in COX 2 enzymes have been identified as important in the 
binding diclofenac in sheep (Rowlinson et al., 2003). The amino acid residue Arg-120 in human 
COX2 has also been identified as important for hydrogen bonding of NSADs (Pouplana et al., 
2002). All three of these residues were present on the COX enzymes identified in these aquatic 
organisms (Fig 4.2). This indicates a high probability that the COX enzymes in fish and other 
aquatic organisms will bind and react to diclofenac in the same or a similar way as humans. 
These findings are supported Wallace et al., (2000) who showed that rat COX enzymes will bind 
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and be inhibited by diclofenac, ibuprofen and paracetamol and Zou et al., (1999) who found a 
fish inducible COX 2 homologue in rainbow trout, the translation product of which had a high 
homology of 83-84% to its human counterpart.  
Ecotoxicity data indicates a low risk of acute toxicity on aquatic organisms for diclofenac 
and ibuprofen (Ferrari et al., 2003; Schwaiger et al., 2004). Chronic toxicity data is generally 
lacking for most pharmaceuticals but there is a growing body of knowledge for diclofenac. 
Diclofenac has been found to cause serious adverse effects in vertebrate species at much lower 
concentrations than suggested by acute or sub chronic toxicity tests with invertebrate species 
(Hoeger et al., 2005). This indicates that traditional ecotoxicity studies and sub chronic fish 
studies recommended in the EMEA, 2006 guidelines for ERA of pharmaceuticals may miss 
whole lifecycle chronic effects and underestimate potential adverse effects in the environment. 
The molecular docking results in this study show that COX2 homologues in O.mykiss, 
S.salar, and D.rerio would all bind diclofenac and ibuprofen (Fig 4.3-4.26). The docking results 
show that the free energy of binding for diclofenac and ibuprofen is similar in these fish 
homologues as the human form (Table 4.7). The hydrogen bonding highlighted as critical for 
diclofenac binding to residues Ser-530 and Tyr-385 for the sheep COX 2 crystalline structure 
(Rowlinson et al., 2003) and residue Arg-120 for the binding of NSAIDs generally (Pouplana et 
al., 2002) also occurred in the fish docking simulations (Fig 4.11, 4.13, 4.15, 4.17, 4.19, 4.21, 
4.23, 4.25). The fact that binding occurs suggests that fish would react in a similar way when 
exposed to these pharmaceuticals as humans, and in all probability that prostaglandin production 
in these fish would be inhibited. This finding is supported by Hoeger et al., (2005) which 
reported that diclofenac provokes the same mechanism of action in brown trout (Salmo trutta) 
(i.e. inhibition of prostaglandin synthesis) as mammalian species at environmentally relevant 
concentrations of 500 ngl
-1
. Lack of prostaglandin production may lead to renal failure in fish, 
the established cause of the death of exposed vultures (Taggart et al., 2007). Renal complications 
are a known side effect of NSAIDs in humans (Banks et al., 1995). This effect may be further 
reinforced by the accumulation of diclofenac in the liver and kidneys of fish by factors of up to 
2700 (Schwaiger et al., 2004) and in the bile by a factor of over 600 (Mehinto et al., 2010). 
Cytological alterations in liver, kidneys and gills have been observed in rainbow trout following 
exposure to diclofenac for 28 days at a concentration of 1 µgl
-1
. Other toxicological effects 
include reduced haematocrit levels, increased monocyte concentration in the liver, telangiectasis 
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in gills and mild tubular necrosis in trunk kidney (Schwaiger et al., 2004 Mehinto et al., 2010; 
Hoeger et al., 2004). Further evidence to support accuracy of the docking results is that 
expression levels of both COX1 and COX2 in the liver gills and kidney of rainbow trout were 
significantly reduced by diclofenac exposure of 1 µgl
-1
 (Mehinto et al., 2010). This study 
concluded that sub-chronic exposure of environmental concentrations of diclofenac can interfere 
with the biochemical functions of fish and lead to tissue damage.   
Daphnia is a common invertebrate model organism for freshwater systems and plays a 
central role as an algal grazer and important food source for fish (Dietrich et al., 2010). High 
sequence homology was found for COX2 proteins in Daphnia pulex. A percent identity of 46% 
was found with the human form (Table 4.4). The CLUSTAL W multiple alignment also shows a 
high sequence homology especially in the regions where the amino acid residues, Ser530, 
Tyr385 and Arg-120 identified as important in binding diclofenac, were present (Fig 4.2). 
However molecular docking experiments with the D.pulex homologue were unsuccessful. This 
could be due to the presence of mutations or differences in the amino acid sequence in the 
homologue protein leading to a different secondary and tertiary protein structure preventing 
binding of diclofenac. The Daphnia homologue has a different amino acid at position 525 (Fig 
4.2). In Daphnia this residue is an isoleucine but in the human, D.rerio, O.mykiss, S.salar and 
sheep homologues, this residue is a leucine. Pouplana et al., (2002) found that an isoleucine in 
this position could severely restrict access of the active site of cyclooxygenase. Further docking 
experiments should be run using a mutant D. pulex model with the isoleucine changed to a 
leucine and re modelled in Swiss model to test that there is a similar effect in Daphnia. The 
molecular docking results then suggest that diclofenac would not have an impact through its 
mode of action on Daphnia; this is supported by ecotoxicological studies. Chronic 
multigenerational toxicity of diclofenac on D.magna was observed at concentrations of 40 mgl
-1 
 
(Dietrich et al., 2010), it did not appear to be due to any obvious mode of action related cause. 
This concentration is considerably higher than concentrations detected in the environment 
(Section 2).  
Ibuprofen is a nonspecific COX inhibitor and is shown to inhibit both COX 1 and COX 2 
(Van Hecken et al., 2000). Ecotoxicological assessment of ibuprofen is somewhat lacking in the 
scientific literature. Effect concentrations have been reported for Daphnia species at between 10 
and 108 mgl
-1 
for immobilization, 13.4 mgl
-1 
for reproduction, a NOEC for survival of 20 mgl
-1
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and a LOEC for population growth of 20 mgl
-1
 (Heckamann et al., 2007; Cleuvers, 2003). These 
concentrations are far greater than that detected in raw sewage let alone surface waters (section 
2). However, behavioural changes in Gammurus pulex have been reported at 10 ngl
-1
 (De Lange 
et al., 2006). Toxicological studies of ibuprofen on fish are also sparse. Acute assessment 
indicates a LC50 (50% lethal dose) on Oryzias latipes (Japanese medaka) of   >100 mgl
-1
 (Pounds 
et al., 2008). Kim et al., (2009) also reported a lack of acute affects of ibuprofen on O.latipes and 
also the crustacean Thamnocephalus platyurus. Further investigation on toxicological effects on 
O.latipes with ibuprofen exposure found no acute effects but did highlight changes in timing of 
reproduction, less frequent reproduction and more eggs per reproductive event (Flippin et al., 
2007). This is not surprising since COX 1 activity is important for ovulation in fish. However 
although some stabilization in COX activity in female fish was recorded no overall reduction 
was found. Overturf et al., (2011) found no chronic effects of ibuprofen on survival or growth of 
P.promelas. The reasons for this are unknown but it could be because the organism lacks the 
COX protein as this enzyme was not detected in the BLAST results (Table 4.4).  
These docking experiments could help direct ecotoxicity tests by selecting chronic test 
endpoints that are related to the MoA of the drug. The selection of organisms is also important. 
Daphnia is regularly used in ecotoxicity tests but in this case it appears that this organism does 
not have a functional drug target receptor for ibuprofen or diclofenac. This sort of information 
would be highly relevant to the ERA procedure. 
4.5.6 Additive effects 
There is clearly potential for synergistic and additive effects for ibuprofen, diclofenac and 
paracetamol on aquatic species as our findings show these three pharmaceuticals commonly 
occur as a mixture in surface waters (Section 2) and act upon the same drug target (this Section). 
The results of the molecular docking experiments show that ibuprofen and diclofenac both bind 
to the same active site on the COX2 enzyme (Figs 4.3-26). Ecotoxicological effects may not be 
invoked when a single pharmaceutical concentration is too low (Pomati et al., 2008). However, 
the combined effect may be significant. In toxicity studies mixtures of diclofenac and ibuprofen 
have been shown to exhibit combined toxicity following a concentration addition concept 
(Schneel et al., 2009). Considerable mixture toxicity for NSAIDs has been reported at 
concentrations where a single compound showed no effect (Cleuvers, 2003). Significant sub 
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lethal effects have been found for the zebra mussel (Dreissena polymorpha) when exposed to a 
mixture of diclofenac, ibuprofen and paracetamol (Parolini & Binelli, 2011). This has also been 
shown for other pharmaceuticals when they are in the same therapeutic class (Schnell et al., 
2009). Fluoxetine is one of five selective serotonin reuptake inhibitors (SSRI) available on the 
market (Johnson et al., 2007). The drug target protein for fluoxetine SL6A4, for example, is also 
the drug target receptor for 3 other SSRIs; citalopram, escitalopram and zimelidine (Table 4.6). 
Thus synergistic, additive or antagonistic effects are also likely to occur because these 
compounds are probably present in mixtures in surface waters (Styrishave et al., 2011).  
Accurate prediction of mixture toxicity is indispensible for ERA (Cleuvers, 2004). The 
current ERA does not include additive, synergistic or antagonistic effects of mixtures of 
pharmaceuticals when calculating PECs, PNECs and risk quotients, some revision of ERAs is 
needed in this respect to reduce scientific uncertainties related to pharmaceutical effects on 
aquatic species. In addition the retrospective toxicology assessment used to set the 10 ngl
-1
 
trigger limit used in the EMEA, (2006) ERA did not account for mixtures of pharmaceuticals 
bringing into question sound ecotoxicological evidence in its calculation (Montforts, 2003). 
Molecular docking may offer a way of establishing synergistic/additive effects.  
4.5.7 Choice of chronic toxicology end points 
Bioinformatics and molecular docking might be a valuable aid in ecotoxicity tests 
directing the choice of suitable endpoints in chronic ecotoxicity testing. These tests could be 
made relevant to organisms that are likely to be exposed to a pharmaceutical and have been 
shown in molecular docking experiments to have target proteins that bind a pharmaceutical. 
Ecotoxicity tests have shown that the mode of action for diclofenac is similar in fish species and 
that a reduction of prostaglandin synthesis occurs. The molecular docking experiments for 
D.rerio, O.mykiss and S.salar clearly showed that the drugs ibuprofen and diclofenac bound to 
COX2 proteins in these organisms suggesting the inhibition of the enzyme and possible end 
points for ecotoxicity testing. Chronic test end points, therefore, could be selected on the basis of 
the function of that protein and the known mode of action of the drug. 
4.5.8 Increasing the number of species used in ERA 
Molecular docking provides a means of increasing the number of trophic levels and 
quantity of species tested without doing any further testing on animals. AutoDock or other 
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molecular docking software could guide the ecotoxicity tests performed by selecting organisms 
which could be exposed and identifying organisms with conserved proteins that would probably 
be affected through the mode of action of the drug.  In-silico studies would effectively extend the 
range of test organisms with no ‘wet’ laboratory work and no need to sacrifice organisms. 
4.5.9 Choice of sensitive organisms 
Choice of sensitive organisms is important for risk assessment. Some organisms may be 
more sensitive that others. The dramatic decline of Gyps vultures in India, Nepal and Pakistan 
caused by the veterinary drug diclofenac is one example of this. Sensitivity varies substantially 
with species. Birds such as the pied crow (Corvus albus), an organism recently evaluated for 
toxicity testing of NSAIDS, was found to be unaffected by concentrations of 10 mgKg
-1
 of 
diclofenac. Sensitivity varies considerably even across vultures, the Gyps showing very high 
sensitivity to diclofenac and other species showing no toxicity at all (Rattner et al., 2008).  It is 
not yet known why the Gyps vultures are more sensitive to diclofenac as yet the full genome 
sequences are not available for all these birds, but eventually may give the clue through 
bioinformatics and molecular docking to the mechanisms for these differences.  
4.5.10 Bioinformatics as a potential tool in environmental risk assessment 
As the data on genomes increases, so too does its potential application in ecotoxicological 
assessments. The potential for use in bioinformatics and molecular docking as a tool in ERA is 
clear from the work described above. As genome sequencing becomes faster, however, it is 
conceivable that full genome sequences may become available for all UK fish species. New drug 
targets are continually being added to the DrugBank database as the mechanisms and modes of 
actions of pharmaceuticals are elucidated. This is true even for some older long established 
pharmaceuticals where the mode of action was often not well understood. It is important that the 
potential of this new knowledge forms a part of ecotoxicology data for ERA. Gunnarsson et al., 
(2008) concluded in a similar study on homologue drug targets in aquatic organisms’ that a more 
comprehensive understanding of the mechanisms of actions of drugs in wildlife was required. In-
silico molecular docking experiments performed here may provide an insight into this, and will 
certainly provide a tool to inform and direct chronic ecotoxicological experiments. 
The findings of the homology search suggest that some lower vertebrates and 
invertebrates have a degree of conservation in proteins that are drug target receptors in humans. 
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Organisms with these similar or conserved proteins may bind pharmaceuticals with possible 
physiological effects. Bioinformatics databases and analysis tools could indeed potentially be 
useful in identifying species that may be more susceptible to a pharmaceutical for 
ecotoxicological tests. This could help make chronic ecotoxicology tests more appropriate by 
improving the selection of species used and choosing more realistic end points better fitted to the 
drug being tested. It is not possible to test all the species likely to be exposed to a compound 
including all potential toxicological endpoints as well as taking into account all routes of 
exposure such as aquatic, terrestrial and food chain pathways. It is imperative that toxicologists 
use all of the available data including that from in vivo experiments (Winter et al., 2009) and in 
the case of bioinformatics in silico work. 
Increasing life expectancy is likely to lead to a greater consumption of pharmaceuticals 
and hence increased presence in the environment (van den Brandhof & Montforts, 2010). Due to 
the low level chronic nature of the exposure to pharmaceuticals there is a possibility that adverse 
effects may go undetected and that these effects could accumulate slowly leading to an 
irreversible change (Schnell et al., 2009) reflected at species, population and ultimately 
community level. The idea of intelligent testing in environmental toxicology has been suggested 
as a way to address this problem (Lange & Dietrich, 2002). This includes the use of information 
on the mode of action of a substance to predict or anticipate effects in a range of species and 
based on this tailor the tests and select species as part of ERA (Fent et al., 2006; Sumpter, 2007; 
Montforts et al., 2007). There are clear legislative, economic and ethical advantages to 
maximising the use of existing data and minimising inappropriate testing. However data to 
support this approach is lacking with few published studies testing theses concepts 
experimentally (Winter et al., 2009).  
Molecular docking software such as AutoDock could also be used to select organisms 
that may be more susceptible to a particular mode of action of the drug. The experiments 
performed here show that S.salar, D.rerio and O.mykiss are more sensitive to diclofenac than 
Daphnia and this is supported by actual ecotoxicology results. This information could be 
invaluable for toxicology tests.   
 The work carried out in this section has led to the development of a flow chart which 
indicates how drug target information, molecular modelling and molecular docking could be 
used as part of the ERA (Fig 4.27). The proposed revisions to the ERA include early 
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identification of drug target conservation in aquatic species. This should be done using the NCBI 
BLAST database. The results of this search can then be used to perform molecular modelling and 
docking studies to ascertain the likelihood of non target organisms producing a functional drug 
target receptor protein. It is proposed that organisms which have potentially functional target 
receptors should then be selected for chronic ecotoxicology tests incorporating the MoA of the 
pharmaceutical. Standard ecotoxicological tests would still be required. The lowest PNEC should 
then be selected from both the chronic MoA tests and standard tests and the ERA continues as in 
the 2006 EMEA guidelines. 
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Fig 4.27 Proposed environmental risk assessment flow chart  
230 
 
4.5  Conclusion 
 
Although bioinformatics databases at present are not capable of replacing ecotoxicology 
tests they may be a useful tool in ERAs. There is a need to focus on long term exposure 
assessment regarding specific modes of action of pharmaceuticals to better judge the 
implications of pharmaceutical residues in aquatic systems (Fent et al., 2003). Some of these 
specific modes of action can be identified using bioinformatics databases. If a similar mode of 
action occurs in other organisms, existing human toxicology data which is held by the 
pharmaceutical companies may be useful (Winter et al., 2009). This may provide information on 
the MoA, therapeutic plasma concentrations or potential adverse side effects which could aid a 
more thorough ecotoxicological assessment. 
Bioinformatics data reveals that a drug target protein sequence may not occur in all 
species of fish suggesting that selection of species known to carry a target gene or protein for 
testing sequence could be beneficial. Bioinformatics databases may provide useful indications of 
vulnerable species for ecotoxicological tests or environmental monitoring. Knowledge about 
what affects a drug is likely to have on an organism could help identify which effects to monitor. 
The advantages of using computer models include the reduction of animal testing and costs. In 
the current regulatory environment, there is a clear need to develop and validate alternatives to 
existing in vivo ecotoxicity test methods, without increasing the uncertainty in risk assessment 
(Embry et al., 2010).  
Some of the problems with the current ERA, e.g. that the range of species used to support 
the action limit is inadequate and that acute toxicity data are predominantly used (see Section 3), 
might be addressed by the use of bioinformatics. The toxicity data sets used to calculate the 
action limit should include chronic toxicity data for the entire lifecycle exposure of a large range 
of species to make more accurate predictions about environmental effects of pharmaceuticals on 
aquatic organisms. Bioinformatics databases could help identify vulnerable species which should 
be included and the types of chronic toxicity tests and endpoints which should be employed. The 
experiments undertaken in this work show that molecular docking could be used as a tool to aid 
and direct ERA by predicting potential reactions between human drugs and conserved drug 
targets in other organisms. The advantages of this are that ERA could be made more 
precautionary by incorporating predictions of sensitive species. There is a strong societal and 
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regulatory pressure that alternatives to vertebrate testing are developed (van den Brandhof & 
Montforts, 2010) and bioinformatics represents a means by which this could possibly be 
achieved. 
The limitations of using molecular docking for toxicity testing are that a limited number 
of genomes have been sequenced. Often proteins that have been sequenced have not been 
crystallized and there is limited information about the three dimensional structure and folding of 
proteins. This is especially true for membrane proteins which are difficult to isolate. For instance 
it was found that there is no human crystal structure known for the serotonin receptor protein and 
currently modelling of this protein is based on a microbial homologue with only 20% homology 
(Celik et al., 2008). This means that a reliable or similar enough template is not yet available on 
which to base a protein model. Another limitation is that sometimes the mode or mechanism of 
action is not well known for a drug, with insufficient information available on which proteins 
interact with or where a drug binds when a protein receptor is identified. New drugs however are 
usually quite well characterised before release. Drug discovery uses molecular modelling and 
docking much more frequently today than in the past. The modes of action are usually well 
understood for new pharmaceuticals for human health and safety reasons.  The new AutoDock 
Vina package is able to perform docking experiments for hundreds of small molecules on a 
whole protein. There is the potential to identify other mode of actions or affects on other non-
target pathways. Blind docking, where the area of binding is not defined, has proven difficult in 
the past, but as technology advances it is becoming easier to do and produces more successful 
and reliable results. This not only provides information on whether the drug will bind but also 
where it may bind, which sometimes this can happen in more than one location on the protein. 
The potential now exists to test chemicals other than pharmaceuticals if their mode of action is 
known for example endocrine disrupting chemicals. 
According to the principles of green chemistry the functionality of a chemical should 
include the properties necessary for its application for fast, easy degradability after use 
(Kummerer, 2010; Khetan & Collins, 2007). One way to do this may be to develop tools which 
can predict a compounds degradation potential, lipophilicity, hydrolysis, persistence, 
bioaccumulation and toxicity properties before it is synthesized. This would mean a potential 
detrimental effect on the environment could be examined before extensive mammalian tests and 
manufacturing considerations begin. Boxall, (2004) suggests that environmental side effects 
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should be considered alongside mammalian toxicological side effects. Many pharmaceutical 
compounds never reach the market for reasons such as safety, efficacy, lack of market potential, 
difficulty in sourcing raw materials or lack of perceived profit. It is suggested that environmental 
considerations should also come into play. Low toxicity in humans is crucial for registration of 
pharmaceuticals, so could low toxicity towards non target organisms be considered as important 
as well? The bioinformatics and molecular docking work show that these tools could be useful in 
this respect by providing a first screen for predicting chronic toxicity effects on non target 
organisms. 
The advent of genomics in the drug development process with specific target definition 
means that bioinformatics and molecular docking packages are an important tool in the drug 
development process (Schoichet et al., 2002). For example the recent development of the anti 
viral drug for bird flu used this technology (Nguyen et al., 2009). The development of anticancer 
drugs is also an example of where molecular docking packages are being utilized (Mukherjee & 
Majumder, 2009). The bioinformatics work shows that these packages could also be used to 
predict toxicity of pharmaceuticals on aquatic organisms and aid and direct laboratory 
ecotoxicity tests. 
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This study identified several flaws in the current environmental risk assessment (see 
Sections 2, 3, 4). ERA is a key stage in the life cycle of the drug because it quantifies the amount 
of pharmaceutical that will be released into the environment (i.e. the exposure) and the effects 
that that pharmaceutical may have on the environment. In order to increase the ‘greenness’ of a 
pharmaceutical some of the limitations and gaps in the ERA need to be addressed. 
5.1 PECs  
One finding from the interviews (Section 3) indicates that post authorisation monitoring 
sales of a pharmaceutical should be addressed in the risk assessment. It is not precautionary to 
predict a compounds use and therefore likely environmental exposure concentrations prior to 
marketing and not establish the accuracy of the prediction subsequently. There needs to be a 
reassessment of exposure once actual consumption data is available say two or three years post 
market authorisation. The results of section 2 show that a lack of accurate data for consumption 
and clarity in the PEC calculation in the EMEA guidelines is hampering accurate assessment of 
exposure concentrations. The data that is collected currently on sales of pharmaceuticals should 
be more accurate and detailed to make PECs more realistic. Drug companies, pharmacies and the 
NHS should be encouraged to keep more detailed records of sales of drugs and the locations in 
which they are sold and prescribed. This data could then be fed into geographical information for 
exposure assessment and give indications of where ‘hot spots’ for specified drugs might occur. 
The results of the interview analysis support this recommendation (Section 4). At present there is 
no accurate indication of over the counter sales which must be taken into account when 
predicting exposure. This reassessment of exposure concentrations is also important when a drug 
comes off patent (see results of interview analysis section 3). This is because the market 
penetration factor of a drug may increase markedly when generics are produced because the drug 
price is likely to fall. Again an estimate of market increase because of loss of patent may not be 
entirely reliable, so it would be advisable to obtain accurate sales data and calculate exposure 
perhaps two or three years later. It may be necessary to recalculate the exposure of a drug every 
three years or so. This could be particularly important when new drugs that may have the same 
or similar MoA come onto the market because of changing markets affecting the use of older 
pharmaceuticals. New compounds that target similar metabolic pathways, however, may have 
additive or synergistic effects. This has been indicated in the bioinformatics and molecular 
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docking work for diclofenac and ibuprofen (Section 4). Bioinformatics databases and molecular 
docking could be useful tools when assessing likely additive and synergistic effects especially 
for older drugs where the MoA and target protein were not fully understood at the time of their 
registration. Bioinformatics and molecular docking package also may be useful when 
considering replacing or substituting a drug that has the same MoA or therapeutic action with 
one that has a better environmental profile.   
5.1.1 PEC Refinements 
One route to protecting the environment and considered important in green pharmacy is 
degradation during sewage treatment in order to reduce environmental exposure. The results 
from Section 2 show that not only is there is a large disparity in the effectiveness of different 
sewage treatment technologies in removing pharmaceuticals, but that the effectiveness of the 
same STP can vary substantially. It was also found (Section 2) that some drugs are highly 
resistant to most sewage treatment technologies e.g. carbamazepine. The interview analysis 
(Section 3) revealed that many pharmaceuticals do not pass the ready biodegradation study and 
therefore a rate constant cannot be calculated for STP removal. It is also known that log Kow is a 
poor indicator of sewage sludge adsorption because pharmaceuticals are generally ionisable 
compounds (Wells, 2006). This means that packages such as SimpleTreat recommended by the 
EMEA, which substantially rely on this data, are flawed. Another problem is that combined 
sewage overflows, storm events and misconnections mean that sewage can regularly enter water 
courses untreated. Given these factors and the lack of accurate figures it is not precautionary to 
refine a PEC for sewage treatment removal. The factors that increase sewage treatment 
degradation of compounds need to be examined in order to increase removal and reduce the 
exposure in the environment and promote green pharmacy. This, however, is not solely possible 
through ‘benign by design’, the sewage treatment process is also important. 
The results of Section 2 show that although concentrations of some pharmaceuticals are 
reduced after sewage treatment this does not occur consistently. The PEC and MEC analysis 
shows that when refinements are made to PECs for sewage treatment removal they may no 
longer provide conservative predictions.  
It would seem reasonable to take metabolism by the body into account when estimating 
exposure. However the results of this study indicate that when this type of data is used to refine a 
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PEC it is more likely to be an underestimate. Patients are wide ranging in their ability to 
metabolise some drugs (Carballa et al., 2008). It has been estimated that up to fifty percent of 
medicine is not consumed (Grass & Lalande, 2005) and may also enter sewage treatment without 
any removal or transformation by metabolism. These factors make refining PECs for excretion 
unprecautionary. Decreasing excretion rates of drugs in patients is seen as a potential route to 
green pharmacy. 
Due to the assumptions made in the PEC calculation for dilution, market penetration, 
wastewater production, even usage and distribution, PECs may not be precautionary especially in 
areas of high drug usage or low dilution (see Section 2). Refinements made to PECs for 
excretion and sewage treatment amplify the risks of obtaining an under estimate of 
environmental exposure.  
5.1.2 Exposure Modelling  
The findings of the interview engagement (Section 3) performed during this research 
indicated that modelling of environmental concentrations using computer packages and GIS was 
generally viewed favourably. The results of Section 2 also show that pharmaceutical 
concentrations can vary substantially and that a single blanket prediction of environmental 
concentration does not adequately reflect the real environmental situation. It was thought that 
with the right training and understanding of how exposure models work and acknowledgement 
of their limitations, that the accuracy of PECs could be improved substantially. The potential of 
producing a range of concentration data and a worst case scenario makes the applicability of 
exposure concentrations more useful for risk assessment. It was considered that the analytical 
chemistry shortfalls, for example difficult matrices  such as sewage and the extremely low 
detection limits required could be overcome by using models such as PhATE and GREAT-ER in 
conjunction with some environmental monitoring. Studies on the accuracy and potential of using 
these exposure models to predict environmental concentrations of pharmaceuticals have also 
been viewed very favourable in the literature (Johnson et al., 2007; Robinson et al., 2007; 
Cunningham et al., 2011). The utility of using computer models to estimate exposure could be 
beneficial in risk assessment. The incorporation of low flow data for geographical locations 
could help identify the ‘hot spot’ areas that perhaps are not fully protected by the current PEC 
calculation. Overall the limitations of the PEC calculation identified in Section 2 such as dilution 
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factor of 10 and assumption that drug usage is equal across time frames and geographical area 
could be reduced. The evidence gathered in the in depth expert knowledge holder interviews 
suggests that these models used in conjunction with measured concentrations are likely to help 
ensure validity of predicted environmental concentrations and better protect the environment. 
5.2 Metabolites  
The in depth knowledge holder interviews indicated that it would be more precautionary 
for pharmaceutical companies to consider pharmaceutical metabolites in more detail (Section 3). 
It is known that for some drugs active metabolites can be toxic. In some cases the parent 
compound undergoes extensive hydrolysis. This means that the parent compound may not be the 
compound that reaches the environment (see interview analysis Section 3) and that in some cases 
the metabolites are of paramount importance. For example the anti-viral pro-drug Tamiflu
®
 
shows increased toxicity in combination its active metabolite (Escher et al., 2010). Norfluoxetine, 
a key metabolite of fluoxetine is known to be as toxic as the parent compound (Nałecz-Jawecki, 
2007). Active metabolites with the same MoA as the parent compound should be considered 
during an ERA (Besse & Garric, 2010). The results of the data analysis performed in Section 2 
shows that there is a distinct data gap in the identification and ecotoxicological analysis of 
metabolites and transformation products of pharmaceuticals. The PEC analysis (Section 2) also 
highlights the lack of incorporation of metabolite data when considering exposure, especially if 
PECs are refined for human metabolism and excretion rates.  
In order to be precautionary pharmaceutical metabolites should not be released into the 
environment without any identification or ecotoxicity analysis. There is a potential that the 
transformation products formed after metabolism in the body and biodegradation during sewage 
treatment or in the environment may be more stable and therefore more persistent than the parent 
compound (Kummerer, 2009). At present a final stage of the ERA involves the identification of 
metabolites that form at levels of 10% or greater of the parent compound. It was suggested that 
key metabolites of a pharmaceutical, should be identified earlier on in risk assessment (see 
interview analysis Section 3) in order to fit into the paradigm of green pharmacy. It is potentially 
unrealistic to identify all the metabolites if the number is substantial or they are formed in such 
small quantities that they are insignificant.  
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The results of the molecular docking (Section 4) show that is possible to predict 
interactions between small molecules and proteins. This may be a way forward for screening 
metabolites for potential activity. Although the target proteins that a metabolite may interact with 
are unknown, it may be possible to do a more general screening of molecular docking to a range 
of proteins as the in silico capability increases. The interview analysis also found that QSARs 
may be useful to predict an increase in PBT through changes in structure in relation to the parent 
compound. Structural changes in pesticide metabolites/transformation products that increase 
toxicity and persistence have been identified (Neuwoehner et al., 2010). This knowledge could 
be applied to analysis of pharmaceutical metabolites. One of the potential problems with this 
solution is that if a new pharmaceutical is unlikely to have a PEC greater than 10 ngl
-1
 (Section 3) 
then it is also likely that an associated metabolite will be formed at concentrations lower than the 
parent compound and inevitably, will also have a PEC under 10 ngl
-1
. Metabolites, therefore, 
would not undergo the second phase of the risk assessment. 
 
5.3 The 10 ngl
-1 
action limit  
The findings of this research indicate that the 10 ngl
-1
 action limit may not be an 
appropriate trigger action limit for risk assessment of pharmaceuticals (Section 2 & 3). 
Pharmaceuticals differ from other chemical pollutants in that they are designed to have a specific 
biological effect. This fact means that having an arbitrary cut off at 10 ngl
-1
 could miss 
potentially toxic compounds. In order to be precautionary, the environmental impacts of a 
pharmaceutical should be fully investigated and this is not the case when no effects assessment is 
performed. Ideally each pharmaceutical should be considered in terms of action limit on a case 
by case basis. Pharmaceuticals that are carcinogenic, mutagenic or reproductively toxic may be 
highly potent at low concentrations. Given that the exposure prediction is simply an estimate 
(Section 2), actual measured concentrations could be above or below 10 ngl
-1
. The actual 
concentrations may vary depending on real market penetration and post patent protection. ‘Hot 
spot’ areas where the population of a specific location may have higher usage of drug e.g. more 
elderly populated areas are not reflected in PEC calculations and may have MECs above the 
trigger value. ‘Hot spots’ could also occur at certain times of year due to seasonal effects such as 
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increased usage of some drugs, or low flow surface water conditions. The use of the 10 ngl
-1
 
action limit has substantial limitations. 
 
5.4  Intelligent ecotoxicology 
Intelligent testing has been highlighted as the forward for ecotoxicity testing of 
pharmaceuticals by several authors (Winter et al., 2009; Boxall & Greenwood, 2010; 
Gunnarsson et al., 2008; Christen et al., 2010). The results of the interview analysis also echo 
this view (Section 3). The results of this research show that bioinformatics databases could be 
used to aid and direct intelligent testing (Section 4). The results of the interview analysis also 
indicate that the unwanted side effects in humans of pharmaceuticals should also be assessed as 
potential modes of action in non target organisms (Section 3). Bioinformatics databases could 
also be used in this context. It would be interesting to examine the gene sequence differences that 
led to the surprising sensitivity of Gyps vultures in comparison to other avian species. It is not 
impossible that such effects may be replicated in other systems. 
 
5.4.1 Chronic ecotoxicity tests end point and species selection  
 The effects assessment and engagement exercise with key players involved in the ERA of 
pharmaceuticals identified a distinct need for a more intelligent approach to ecotoxicology 
testing (Section 3). It is impossible to test all the species that might be exposed to a 
pharmaceutical using all conceivable chronic test end points. It is important to be intelligent in 
the approach for ERA. The bioinformatics work indicates that bioinformatics and molecular 
docking be a useful aid to ecotoxicology tests providing a technique to select potentially 
vulnerable species and direct choice chronic test end points. Molecular docking exercises here 
provide an inexpensive tool to predict drug interactions with non target organisms. Simple 
homologue mining exercises such as the ones performed as part of this research using databases 
such as BLAST and drug bank can be used to identify protein targets for MoA assessment and 
incorporation of potential drug mixture effects (Section 4). 
As the area of genomics increases the usefulness of bioinformatics to ecotoxicity work is 
also likely to increase. If you consider that there are a finite number of drug targets, and a limited 
number of species of fish that will be exposed (in UK rivers) it may ultimately be possible to 
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actually consider all the species that may be exposed and potentially select the most sensitive one. 
This avoids unnecessarily testing drugs on species that do not have the target receptor. Molecular 
docking exercises can also predict whether similar drug target receptors would actually interact 
with the drug. The AutoDock results in this study show that although D.pulex produces a similar 
COX 2 protein, important differences in the amino acid sequence produce differences in the 3D 
structure of the binding site. These differences prevent interactions with diclofenac and 
ibuprofen and may explain the lack of chronic toxicity reported in the literature.  
This kind of experiment may be more limited in respect to some organisms. The number 
of species of invertebrates that may be exposed could be substantial. The likelihood of these 
organisms having complete genomes sequenced is quite slim. However one can never obtain 
total scientific certainty but it is possible to reduce the uncertainty somewhat using 
bioinformatics and molecular docking techniques.  
5.4.2 Mixtures of pharmaceuticals 
One of the potentially serious failings of the current ERA is the lack of inclusion of 
mixture effects of pharmaceuticals which is the norm in aquatic systems (Section 2). The 
additive, synergistic or antagonistic effects of other pharmaceuticals that will be present in the 
environment need to be considered when calculating a PEC for a drug and when performing 
ecotoxicological tests. The MoA of each pharmaceutical should be considered in respect to other 
drugs already available that share that same MoA. Bioinformatics databases and molecular 
modelling such as these performed during this study (Section 4) could significantly increase the 
depth and breadth of knowledge in this area. Bioinformatics could help reduce some of the 
scientific uncertainty related to these issues without increasing animal tests or incurring 
enormous financial costs. Human medicine identifies the effects of combinations of drugs and 
this information could be important and useful for risk assessment. Pharmacovigilance monitors 
these effects and could be extended to environmental effects as well and termed 
pharmaecovigilance (Daughton & Ruhoy, 2008). 
5.4.3 Biomarkers and bioassays  
One of the findings of the key player engagement interviews was that a potential shortfall 
of ecotoxicity tests in general was the inherent differences between the laboratory and the field. 
The laboratory cannot replicate the vast amount of pressures and variables that are present in the 
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environment. One suggested solution for this was to monitor effects in the environment using 
bioassays and biomarkers (Section 3). Environmental toxicologists and regulators felt that 
sharing of test methods including bioassays from pharmaceutical companies would be extremely 
beneficial. The Environment Agency argues for the EMEA and MHRA to put in place a suitable 
system to make environmental information on human pharmaceuticals easily available and 
accessible to facilitate ERA (EA, 2003). More communication and transparency between 
environmental regulators and pharmaceutical companies is a key aspect of moving towards green 
pharmacy. Increasing communication between organisations can also help environmental 
regulators become aware of potential limitations. 
5.5 Retrospective environmental risk assessment 
The effects of pharmaceuticals which are not new to the market i.e. licensed prior to the 
current ERA and authorisation requirements must also be examined for effective environmental 
protection. The findings from the MEC data (Section 2) indicate that many ‘old’ medicines are 
present in the environmental at concentrations that require an environmental risk assessment and 
that chronic effects data for most of these pharmaceuticals is missing. The interviews revealed 
that regulators and academics believed that this was something that needed to be addressed 
(Section 3). A prioritisation method was seen as the best way forward with regard to this matter. 
The example put forward in Sweden (Agerstrand & Ruden, 2009) and suggestions by other 
authors (Besse & Garric, 2008; Kumar & Xagoraraki, 2010; Roos et al., 2012; Cooper et al., 
2008) for prioritisation procedures should be fully examined. The Water Framework Directive 
may provide a mechanism by which retrospective risk assessment and environmental monitoring 
of priority pharmaceuticals can be achieved (von der Ohe et al., 2011). The Water Framework 
Directive 2000/60/EC (WFD) requires “good chemical status” of water bodies in the EU by 2015. 
WFD contains a defined list of priority substances that can adversely affect the ecosystem. It puts 
emphasis on the precautionary principle stating that especially in identifying priority hazardous 
substances, any potential adverse effects of the product should be taken into account and should 
lead to scientific assessment of the risk (recital 11 & 44, WFD). Inclusion on the priority list is 
governed by toxic, persistent and bio accumulative characteristics. On this basis three 
pharmaceuticals have been suggested for inclusion by the German Environment Agency, 
carbamazepine, diclofenac and ibuprofen (Kampa et al., 2010) and recently it was announced 
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that diclofenac and EE2, two of the pharmaceuticals investigated in this study are to be added to 
this list (Europa, 2012). 
 
5.6 Sound science and reporting standards 
A crucial finding during this research was that there were substantial inadequacies in the 
literature reporting pharmaceutical concentrations in water bodies and effluent. These were 
sufficient to limit any contribution to monitoring and risk assessment. It was frequently the case 
that much environmental data e.g. flow rate etc needed to make PECs environmentally relevant 
were not included in papers (Section 2). Improvements in standards of reporting of 
environmental concentrations of pharmaceuticals are needed to enable regulators to use data for 
risk assessment and this falls to standards set by scientific journals. Monitoring campaigns are 
expensive and availability of good quality data from scientific publications could effectively feed 
into monitoring. Work needs to be undertaken to establish guidelines and standards for reporting 
exposure data in scientific journals. Communication between risk assessors, regulators, 
ecotoxicologists and academics is needed to determine the requirements and the information to 
be included when reporting environmental concentrations. Statistical analysis of data should be 
uniform across publications in order to be able to make comparisons. The data analysis 
undertaken here (Section 2) was significantly hampered by the lack of uniform statistical 
analysis or lack of key parameters such as flow rates, population sizes, sampling dates and 
sewage treatment employed. 
The interviews revealed that a lack of sound science and poor reporting standards were 
also a major problem with toxicological effects literature as well as concentration data related 
literature (Section 3). The pharmaceutical company interviewee said that as a company risk 
assessments (PECs, MECs & PNECs) were continually reviewed in the light of new data. 
However this data was often not of a standard that would lead to a revision in the figures.   
One of the limitations in presenting all the information relevant to monitoring and risk 
assessment in a publication are the journals content and word limits. As a consequence it would 
help to make access to raw data in supplementary sections or on line access permanently 
available. It was often impossible to retrieve raw data from authors if they had changed job or if 
the work was undertaken some time ago.  
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A standardisation in reporting standards and scientific procedures for effects and 
exposure data for pharmaceuticals is required to fulfil a green agenda for the whole life cycle of 
a drug. This would ensure an increase in knowledge on the exposure and effects of 
pharmaceuticals in the environment. A reduction in scientific uncertainty is an important aspect 
of risk management. There is also an opportunity to reduce animal testing of pharmaceuticals if 
ecotoxicological studies are only performed once in a correct and meaningful way with a full 
sharing of data.  
An improvement in the quality of ecotoxicological data and exposure concentration data 
would also be beneficial when assessing the successes of any mitigation practices that may be 
put into place to reduce environmental damage by pharmaceuticals. 
 
5.7  Mitigation 
  Ultimately there has to be a level at which the potential for serious environmental damage 
from a pharmaceutical outweighs the benefit to human health. If this not the case then what is the 
point of having an environmental risk assessment? Time, money and effort are wasted in 
conducting an environmental risk assessment if a medicine cannot be turned down in the event of 
a predicted high risk.  
A key finding from the interviews was the need for some sort of cost to the environment 
versus benefit to human health analysis to be brought into the risk assessment process if an 
environmental risk was perceived (Section 3). If the cost was considered too high then mitigation 
and risk management processes could be put in place. This could involve elements such as 
potential substitutions to more environmentally friendly drugs, some limitation to the amount of 
product that could be sold in each country or limitations on where drugs could be taken, e.g. 
hospitals. 
The problem with limiting sales of a drug that is required for human health is that it 
would be unethical and unfair to start making judgements about who should receive the 
medication and who should not. If a medication is authorised for market then everybody should 
be entitled to take it. This consideration leads to more pragmatic management approaches such 
as trying to reduce the therapeutic dose, the frequency of dose or the administration method (e.g. 
intravenous as opposed to tablet form). The question is have any pharmaceuticals failed the risk 
assessment since the 2006 EMEA guidelines were introduced? If not then potentially these 
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mitigation strategies in reality, may not be needed. Although perhaps unlikely it still does not 
preclude a new drug posing a high environmental risk that requires risk management and 
mitigation strategies. 
5.7.1 Substitutions 
One of the key failings or the ERA is the lack of mitigation measures that are available to 
reduce the exposure to the environment in light of a real or perceived risk.  One solution to this 
may be the approach taken in Sweden which is to substitute medicines that do the same job with 
more environmentally friendly ones where they exist (Agerstrand et al., 2009). This could also 
incorporate incentives for producing new drugs that have the same or improved therapeutic 
efficacy but have a better environmental profile.  
The other side of this approach is to make doctors and physicians and the public aware of 
the environmental impact of pharmaceuticals on labels, websites, leaflets and potentially 
advertisements and the media. Information could also be supplied on more environmentally 
sound drug choices. This is one of the more practical approaches to managing risk and green 
pharmacy that does not prevent medicine being available to those who need it but reduces 
environmental impacts. It is clearly an achievable goal as demonstrated in Sweden where a 
system for assessing the environmental effects of drugs as well as clinical needs has been 
successful (Vidaurre et al., 2010). 
5.7.2 Pharmaceutical return schemes 
Pharmaceutical return schemes are one of the most deliverable options to limit exposure 
in the environment. The system in place at present for advising and educating the public on the 
return of unused medicines to the pharmacy for disposal should be given higher prioritisation 
(Section 3). All of the key players, pharmaceutical companies, doctors, dentists, other 
prescribing physicians, pharmacies, regulators, water companies and the government should 
collaborate in addressing public awareness. Pharmaceutical labels and package inserts need to be 
clear and specific about the return of unused pharmaceuticals. The message needs to be 
unambiguous. Campaigns on television and newspapers would be beneficial to raise public 
awareness. Investigation into practical and safe pharmaceutical returns bins for example in GP 
surgeries and at pharmacies should be undertaken. There is no need at all for unnecessary 
pollution of the environment from unused medicines. It is unknown what proportion of 
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environmental burden comes from unused and expired drugs but if estimates that 50% of 
medicines are not taken are accurate then it could be substantial. Warnings to the pubic about the 
potential dangers to children and pets from accidental poisonings in the home could also remind 
people of the importance of returning them to a pharmacy for destruction. 
5.7.3  Prescription habits 
The results of the interviews (Section 3) indicated that improvements in prescription 
habits could be one way to reduce the environmental exposure to pharmaceuticals. New methods 
are beginning to be developed for a more intelligent approach to prescribing. Doctors and 
prescribing practitioners need to inform patients about potential side effects of medication before 
the patient picks up the prescription as this can account for a proportion of non compliance. The 
medical profession should ideally inform patients about returning unused medicines to 
pharmacies when changes are made in therapy.  
Overall the findings (Section 3) and the literature indicate that more could be done to 
incorporate the environmental significance of pharmaceuticals into training in the medical 
professions and that there should be dialogue between these professionals and other stakeholders.  
5.7.4 Sewage treatment plant improvements 
 Ultimately regardless of whether pharmaceuticals are consumed or disposed of via the 
drain, STPs are a key stage in the life cycle of pharmaceuticals. The findings of the data analysis 
on sewage treatment removal indicated wide ranging performances of STPs across different 
plants and within the same facility (Section 2). One obvious way to reduce environmental 
exposure to pharmaceuticals is to increase the capacity of STPs to remove these chemicals. The 
results of the interviews, however, suggested that this was one of the less favourable options for 
mitigation of the risk posed to the environment (Section 3). There is a key problem with 
improving STPs by increasing residence times or adding extra steps such as tertiary treatments 
e.g. granular activated carbon, ozone or membrane filters, in order to optimize removal of drugs. 
This is that different drugs achieve better removal with different treatments and that some drugs 
are resistant to most forms of sewage treatment such as carbamazepine (Section 2). This means 
that no matter what extra treatment is put in place there will always be some compounds that 
enter the environment unchanged.  
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One of the findings during this research was that water companies are wary of any extra 
burden from upgrading STPs in order to remove greater amounts of pharmaceuticals (Section 3). 
This was especially true in the light of the fact that apart from EE2, no actual or real detrimental 
effects of pharmaceuticals have been identified. The precipitous decline of amphibians for 
example has not been linked to drug residues. The financial implications of upgrading STPs are 
substantial and it was considered by the majority of interviewees that this was unacceptable 
without an actual problem being identified. Simply taking a precautionary approach was not 
justified (Section 3). The other highly relevant consideration aside from financial burden of 
sewage treatment improvements is that STP upgrades have substantial impact on energy use and 
emissions i.e. greenhouse gas emissions. Increases in energy use and carbon emissions outweigh 
any environmental impacts from pharmaceuticals.  
5. 8 Green pharmacy 
The results of this study highlight some of the scientific uncertainty surrounding the issue 
of human pharmaceuticals as pollutants of the aquatic environment. The concept of green 
pharmacy may be a potential way forward to reduce some of the scientific uncertainty and the 
risks to the environment.  
Green pharmacy should cover the entire life cycle of the drug from initial design and lead 
candidate selection to final monitoring in the environment post market authorisation (Kummerer 
et al., 2007; Daughton & Ruhoy, 2008; Daughton, 2003a & b). The consequences for the 
environment should be considered at each stage of the lifecycle of a pharmaceutical including the 
following: ‘benign by design’ approaches, PBT considerations at lead candidate stage; 
manufacture, risk assessment; excretion rates; and the pre existence of more or less 
environmentally sound drugs that already fill the therapeutic role, packaging, marketing and 
sales, prescription, dispensing, compliance, return schemes, disposal, sewage treatment, 
degradation during sewage treatment, degradation in the environment, potential remediation 
strategies.  
5.8.1 ‘Benign by Design’  
One way to reduce the exposure and risks to the environment is the benign by design 
approach. The idea is to consider the potential for PBT and ultimate degradation at the design 
stage of the drug development process. This is being considered for commercially available 
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chemicals (Boethling et al., 2007).The results of the data analysis in this study (Section 2) show 
that many pharmaceuticals are pollutants in many aquatic environments, have known detrimental 
effects but may also have potential unknown subtle chronic effects. The interview analysis 
(Section 3) revealed that many key players in the pharmaceutical industry and regulation believe 
that the risk assessment process needs to be moved to a much earlier stage in drug development. 
Pharmaceutical companies need to think about environmental stability earlier on in the process 
(Sumpter, 2010). Large pharmaceutical companies are now thinking along these lines (Lubick, 
2008). 
5.9 Hypothesis revisited 
 1) The environmental risk assessment (ERA) for human pharmaceuticals and use of 
predicted environmental concentrations is probably inadequate to protect the aquatic 
environment. The availability of good quality environmental monitoring data, however, is 
needed to fully address this hypothesis. 
 The work carried out on environmental concentrations and PECs of human 
pharmaceuticals (Section 2) and the expert knowledge holder interviews (Sections 3) suggest that 
the ERA for human pharmaceuticals could be improved to better protect the aquatic environment. 
This work has led to a set of recommendations (Section 5.10) for improvement in the ERA. 
2) Bioinformatics and molecular docking may be a potential tool to aid and direct the ERA of 
human pharmaceuticals through a focus on mode of action. 
 Bioinformatics and molecular docking was shown to be effective in predicting a 
toxicological effect by diclofenac and ibuprofen on non target aquatic organisms. This was 
substantiated by ecotoxicology data available in the literature (Section 4). The hypothesis that 
bioinformatics and molecular docking may be a valuable tool in ERA of human pharmaceuticals 
is accepted. 
5.10  Recommendations and suggestions for future research 
 In light of the findings in this work on the limitations of the current environmental risk 
assessment, the following recommendations are made to reduce the risks to the aquatic 
environment from human pharmaceuticals: 
 
248 
 
1) ERA should be performed earlier than currently in the drug development process 
with consideration of environmental impacts made at the lead candidate stage in the 
development of new pharmaceuticals. 
One of the major shortfalls identified with the current ERA is that a pharmaceutical 
cannot be refused for market authorisation even if an adverse environmental risk is identified. 
The results of the interview analysis (Section 3) lead to the conclusion that mitigation and risk 
limitation or management action is currently very limited for the reduction of risks to the 
environment. It would be prudent, therefore, to consider the environmental impact of 
pharmaceuticals at a much earlier stage in drug development, i.e. the drug candidate stage. The 
interview with the Environment Agency representatives revealed strong agreement for this and 
the pharmaceutical company manager revealed that this was a possibility for the future.  
2) ERAs should be performed post marketing and post patent expiry. 
The results of the data analysis (Section 2) show that environmental exposure to 
pharmaceuticals can fluctuate substantially in time and space. Environmental concentrations of 
pharmaceuticals are linked to usage which is variable over the life of a drug. The results of the 
PEC & MEC analysis show that pharmaceuticals can regularly exceed predictions. Currently, 
when the ERA is performed a default Fpen is used as an estimate of usage as the drug has yet to 
be marketed. If the drug is successful it is possible that consumption may be above original 
estimates. If an ERA were performed this would increase the PEC making post marketing ERAs 
important in environmental protection. The interview analysis revealed that drug sales may also 
increase once the patent has expired because of the development of generic drugs (Section 3). 
The bioinformatics work (Section 4) shows that many drugs such as NSAIDs target the same 
protein receptors potentially producing additive effects. When new drugs reach the market, it is 
recommended that consumption of existing drugs which target the same receptors should be 
incorporated into the PEC (See flow chart Section 4.4). 
3) Accurate and reliable data collection schemes should be established to determine 
consumption of pharmaceuticals for exposure assessments. 
Expert knowledge holders of environmental risks of human pharmaceuticals (Section 3) 
believed that environmental exposure too pharmaceuticals might be underestimated in regional 
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‘hot spots’. Presently the ERA assumes even consumption of a pharmaceutical over the whole 
country over the course of the year. It would be beneficial to identify where and at what times of 
year ‘hot spots’ may occur. Currently data for regional prescriptions of pharmaceuticals are not 
available. Accurate data for regional sales of over the counter medicines would also be valuable 
for exposure assessments because these drugs are often consumed in large quantities which can 
vary with the time of year e.g. antihistamines and analgesics. One reason for the sometimes 
orders of magnitude fluctuations in surface water concentrations of pharmaceuticals (Section 2) 
might be variations in usage. The inclusion of accurate sales data in the calculation of PECs 
would make them a more reliable prediction of environmental exposure.  
4) Refinements to PEC calculations should not be made without substantial, validated 
and accurate data. 
The results of the work carried out in Section 2 show that removal efficiencies of 
pharmaceuticals in STPs are highly varied. The results of the data analysis show that increases in 
concentration of pharmaceuticals after sewage treatment can occur as well as reducing 
concentration. Some pharmaceuticals such as carbamazepine are highly resistant to sewage 
treatment. The PEC and MEC analysis (Section 2) revealed that PECs were much more likely to 
be an underestimate when refinements were made for removal by STPs. The interview analysis 
also revealed that estimation of removal of pharmaceuticals by STPs was very difficult because 
they are often highly polar ionisable compounds (Section 3).  
The default values in the crude PEC calculation seem to be precautionary only when 
refinements for excretion and STP removal are not made. If allowances for these are applied then 
discrepancies, which are probably caused by underestimates of dilution and wastewater 
production, become apparent. 
5) Modelling of environmental exposures could be more informative than the current 
PEC calculation. 
The interviews performed in Section 3 show that expert knowledge holders believe that 
analytical chemistry techniques for measuring pharmaceuticals have some failings. The analysis 
also showed that there was scope for improving predictions of pharmaceutical exposure by 
including some computer modelling (Section 3). It was revealed that this type of tool can 
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increase knowledge about ‘hot spots’ due to higher consumption or low dilution may occur. This 
information could identify areas where monitoring campaigns may be required. Monitoring of 
pharmaceuticals is expensive and time consuming and making targeted monitoring essential.  
6) All new medicines should undergo ecotoxicological assessment prior to market 
authorisation regardless of the PEC. 
The work carried out in Section 3 revealed that expert knowledge holders were sceptical 
about the 10 ngl
-1
 action limit for ecotoxicological assessment. The reason for this primarily was 
that EE2 has effects at less than 10ngl
-1
. The data analysis performed in section 2 shows that 
many pharmaceuticals reach concentrations above this action limit. The work carried out in 
Sections 2 & 3 reveals that concentrations regularly fluctuate and that PECs can be inaccurate 
predictors of environmental loads especially if refinements are made to the PEC. It is 
recommended that some ecotoxicological assessment should be performed prior to market 
authorisation. This would help reduce uncertainties around unanticipated effects and better 
protect the environment. 
7) Ecotoxicological assessment of human medicines should include MoA information. 
The work carried out in Section 4 shows that human drug target receptors can be highly 
conserved in non target species and that there can be a similar MoA. The interviews with expert 
knowledge holders (Section 3) also revealed that traditional ecotoxicology tests may 
underestimate effect concentrations and should be revised to include MoA tests. 
8) Bioinformatics and molecular docking packages should be examined for their 
potential to aid and direct ecotoxicological tests for ERA of human pharmaceuticals. 
Including use of MoA information and selection of sensitive species. 
The work in Section 4 shows that bioinformatics databases and molecular docking tools 
can provide valuable information to help predict the effects of human pharmaceuticals in aquatic 
organisms. The flow chart in Section 4 indicates how these tools could be used to improve the 
ERA. These tools could be used cheaply to guide selection of sensitive organisms and chronic 
test end points in ecotoxicological tests.  
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9) The effects of mixtures of pharmaceuticals including those that may cause 
synergistic, antagonistic or additive effects need to be listed in ERAs and included in 
PEC and PNEC calculations. 
The results of the work carried out in Section 4 show how drugs of the same therapeutic class 
may target the same receptor protein and produce additive effects. The data analysis in section 2 
shows that the pharmaceuticals investigated occur as mixtures in surface waters in order to 
address these problems. PECs should be revised to include additive, synergistic or antagonistic 
effects of other drugs currently marketed (see proposed flow chart for ERA Section 4.4.10). 
10) A prioritisation strategy should be developed in order to conduct retrospective risk 
assessment for existing medicines. 
The interviews performed in Section 3 show that retrospective risk assessments of 
pharmaceuticals licensed prior to 2006 is thought to be necessary by many expert knowledge 
holders. The data analysis in section 2 also shows that the selected pharmaceuticals frequently 
occur in concentrations far exceeding 10 ngl
-1
 in surface waters. It is clearly not possible to 
conduct an ERA for all licensed medicines and it is proposed that a system for prioritisation such 
as that employed in Sweden would be the most pragmatic approach for retrospective risk 
assessment of existing medicines. 
11)  There should be a public education campaign in order to improve understanding of 
the correct disposal of medicines. Public education is crucial for the reduction of 
pollution by human pharmaceuticals. 
The work carried out in Section 3 revealed that expert knowledge holders believed that 
informing the public on the correct disposal of medicines would be one of the easiest ways to 
reduce environmental concentrations. Inappropriate disposal down sinks and toilets is a 
particular problem, especially in the context of the variable performance of STPs in 
pharmaceutical removal. It was found that this was something that was currently not being 
performed successfully in the UK and that doctors, pharmacists and the media needed to take 
action. Government information campaigns might be valuable in this regard.  
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12) Mitigation strategies for pharmaceuticals that may pose a significant risk to the 
environment should be developed. 
The work carried out in this thesis leads to the conclusion that one of the major flaws in 
the ERA is a lack of any strategy for mitigation of environmental risk. Currently pharmaceuticals 
cannot be refused market authorisation even if they pose a substantial environmental risk. This 
results in a lack of incentive to investigate precautionary management and renders the 
identification of risks somewhat pointless. Human health must take priority but in a world where 
population and age expectancy is increasing so will the environmental burden caused by 
pharmaceuticals. It may be useful to build in, as a significant stage in drug design, consideration 
of ways to limit environmental risk. 
13)  Research is needed to develop a set of reporting standards for environmental 
exposure data articles in peer reviewed scientific journals useful to regulators, risk 
assessors and policy makers. 
The work carried out in Section 2 shows that currently reporting standards in the peer 
reviewed literature are too poor to perform meaningful meta analysis of pharmaceutical 
concentrations. The increasing need for science to help inform policy and the current fiscal 
climate mean that it is paramount that expensive and time consuming research is made usable to 
environmental regulators and risk assessors. This has led to the development of a list of proposed 
reporting standards that could be used by researchers and peer reviewed journals to improve the 
quality of the publication of environmental concentration data (Section 2.4.7).  
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